WO2014198594A1 - Novel compounds for the treatment of cancer - Google Patents

Novel compounds for the treatment of cancer Download PDF

Info

Publication number
WO2014198594A1
WO2014198594A1 PCT/EP2014/061530 EP2014061530W WO2014198594A1 WO 2014198594 A1 WO2014198594 A1 WO 2014198594A1 EP 2014061530 W EP2014061530 W EP 2014061530W WO 2014198594 A1 WO2014198594 A1 WO 2014198594A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
group
alkoxy
phenyl
halo
Prior art date
Application number
PCT/EP2014/061530
Other languages
French (fr)
Inventor
Volker Schulze
Hartmut Schirok
Dirk Kosemund
Hans Briem
Benjamin Bader
Ulf Bömer
Antje Margret Wengner
Gerhard Siemeister
Philip Lienau
Detlef STÖCKIGT
Ulrich LÜCKING
Andreas Schall
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50897594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2014198594(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CN201480032697.9A priority Critical patent/CN105246891A/en
Priority to AU2014280395A priority patent/AU2014280395A1/en
Priority to US14/896,450 priority patent/US20160207928A1/en
Priority to CA2914668A priority patent/CA2914668A1/en
Priority to EP14728921.9A priority patent/EP3008061A1/en
Priority to EA201501175A priority patent/EA201501175A1/en
Priority to MA38655A priority patent/MA38655A1/en
Priority to BR112015030774A priority patent/BR112015030774A2/en
Priority to MX2015017011A priority patent/MX2015017011A/en
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Priority to SG11201509351UA priority patent/SG11201509351UA/en
Priority to JP2016518921A priority patent/JP2016521737A/en
Priority to KR1020157034736A priority patent/KR20160019426A/en
Priority to AP2015008905A priority patent/AP2015008905A0/en
Priority to TN2015000542A priority patent/TN2015000542A1/en
Publication of WO2014198594A1 publication Critical patent/WO2014198594A1/en
Priority to IL242546A priority patent/IL242546A0/en
Priority to PH12015502747A priority patent/PH12015502747A1/en
Priority to CR20150653A priority patent/CR20150653A/en
Priority to CUP2015000175A priority patent/CU20150175A7/en
Priority to HK16107837.4A priority patent/HK1219737A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the present invention relates to novel compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
  • the present invention relates to chemical compounds that inhibit Mps-1 (Monopolar Spindle 1 ) kinase (also known as Tyrosine Threonine Kinase, TTK).
  • Mps-1 is a dual specificity Ser/Thr kinase which plays a key role in the activation of the mitotic checkpoint (also known as spindle checkpoint, spindle assembly checkpoint) thereby ensuring proper chromosome segregation during mitosis [Abrieu A et ai, Cell, 2001 , 106, 83-93]. Every dividing cell has to ensure equal separation of the replicated chromosomes into the two daughter cells.
  • chromosomes Upon entry into mitosis, chromosomes are attached at their kinetochores to the microtubules of the spindle apparatus.
  • the mitotic checkpoint is a surveillance mechanism that is active as long as unattached kinetochores are present and prevents mitotic cells from entering anaphase and thereby completing cell division with unattached chromosomes [Suijkerbuijk SJ and Kops GJ, Biochemica et Biophysica Acta, 2008, 1786, 24- 31 ; Musacchio A and Salmon ED, Nat Rev Mol Cell Biol., 2007, 8, 379-93]. Once all kinetochores are attached in a correct amphitelic, i.e.
  • the mitotic checkpoint consists of complex network of a number of essential proteins, including members of the MAD (mitotic arrest deficient, MAD 1 -3) and Bub (Budding uninhibited by benzimidazole, Bub 1 -3) families, the motor protein CENP-E, Mps-1 kinase as well as other components, many of these being over-expressed in proliferating cells (e.g. cancer cells) and tissues [Yuan B et al., Clinical Cancer Research, 2006, 12, 405-10].
  • Mps-1 kinase activity in mitotic checkpoint signalling has been shown by shRNA-silencing, chemical genetics as well as chemical inhibitors of Mps-1 kinase [Jelluma N et al. , PLos ONE, 2008, 3, e2415; Jones MH et al. , Current Biology, 2005, 15, 160-65; Dorer RK et al. , Current Biology, 2005, 15, 1070-76; Schmidt M et al. , EMBO Reports, 2005, 6, 866-72].
  • mitotic checkpoint abrogation through pharmacological inhibition of Mps-1 kinase or other components of the mitotic checkpoint represents a new approach for the treatment of proliferative disorders including solid tumours such as carcinomas and sarcomas and leukaemias and lymphoid malignancies or other disorders associated with uncontrolled cellular proliferation.
  • WO 2009/024824 A1 discloses 2-Anilinopurin-8-ones as inhibitors of Mps-1 for the treatment of proliferate disorders.
  • WO 2010/124826 A1 discloses substituted imidazoquinoxaline compounds as inhibitors of Mps-1 kinase.
  • WO 201 1 /026579 A1 discloses substituted aminoquinoxalines as Mps-1 inhibitors.
  • WO201 1 /157688(A1 ), WO201 1 /063908(A1 ), WO201 1 /064328(A1 ), WO201 1063907(A1 ) and WO2012/143329(A1 ) disclose substituted triazolopyridine compounds as inhibitors of Mps-1 kinase.
  • said compounds of the present invention have surprisingly been found to effectively inhibit Mps-1 kinase and may therefore be used for the treatment or prophylaxis of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses or diseases which are accompanied with uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses, particularly in which the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses is mediated by Mps-1 kinase, such as, for example, haemotological tumours, solid tumours, and/or metastases thereof, e.g.
  • leukaemias and myelodysplasia syndrome malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.
  • the present invention covers com ounds of general formula (I) : in which :
  • A is selected from:
  • R 1 represents a phenyl- group
  • G -Ce-alkyl- group represents a hydrogen atom or a group selected from phenyl-, pyridyl-; said group being substituted, one or more times, identically or differently, with a substituent selected from :
  • R 2 represents a group selected from:
  • * indicates the point of attachment of said group with the rest of the molecule; represents a 4- to 6-membered heterocyclic ring; which is optionally substituted, one or more times, identically or differently, with halo-, -CN , -OH, nitro-, CrC&-alkyl-, halo-Ci -C&-alkyl-, G -Ce-alkoxy-, halo-Ci -C&-alkoxy-, hydroxy-Ci -C&-alkyl-,
  • R 8 (CH 2 ) n (CHOH)(CH 2 )p-0-, R 8 -(Ci -C 6 -alkoxy-Ci -C 6 -alkyl)-,
  • R 7 represents a hydrogen atom, a Ci -C&-alkyl-, or C3-C 6 -cycloalkyl- group ; or
  • R 8 represents a hydrogen atom, a CrC&-alkyl- or C3-C 6 -cycloalkyl- group
  • R 9 represents a Ci -C&-alkyl- or C3-C&-cycloalkyl- group ;
  • q represents an integer of 0, 1 , 2 or 3 ;
  • t represents an integer of 0, 1 or 2 ; or a stereoisomer, a tautomer, an N -oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.
  • the present invention further relates to methods of preparing compounds of general formula (I), to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
  • halogen atom halo- or Hal-
  • fluorine chlorine, bromine or iodine atom, preferably a fluorine, chlorine or bromine atom.
  • CrGo-alkyl is to be understood as preferably meaning a linear or branched, saturated, monovalent hydrocarbon group having 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, e.g. a methyl, ethyl, propyl, butyl, pentyl, hexyl, iso-propyl, iso-butyl, sec-butyl, tert-butyl, iso-pentyl, 2-methylbutyl, 1 -methylbutyl, 1 -ethylpropyl, 1 ,2-dimethylpropyl, neo-pentyl, 1 , 1 -dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1 -methylpentyl, 2-ethylbutyl, 1 -ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1 ,
  • said group has 1 , 2, 3, 4, 5 or 6 carbon atoms ("Ci-C 6 -alkyl”), more particularly, said group has 1 , 2, 3 or 4 carbon atoms (“Ci-C4-alkyl”), e.g. a methyl, ethyl, propyl, butyl, iso-propyl, iso-butyl, sec-butyl, tert-butyl group; even more particularly 1 , 2 or 3 carbon atoms (“CrC3-alkyl”), e.g. a methyl, ethyl, n-propyl- or iso-propyl group.
  • Ci-Cio-alkylene is to be understood as preferably meaning a linear or branched, saturated, bivalent hydrocarbon group having 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, e.g. a methylene, ethylene, n-propylene, n-butylene, n-pentylene, 2-methylbutylene, n-hexylene, 3-methylpentylene group, or an isomer thereof.
  • said group is linear and has 2, 3, 4 or 5 carbon atoms (“C 2 -Cs-alkylene”), e.g.
  • C3-C4-alkylene an ethylene, n-propylene, n-butylene, n- pentylene group, more particularly 3 or 4 carbon atoms
  • C3-C4-alkylene e.g. an n-propylene or n-butylene group.
  • halo-G-Ce-alkyl is to be understood as preferably meaning a linear or branched, saturated, monovalent hydrocarbon group in which the term "CrCe-alkyl” is defined supra, and in which one or more hydrogen atoms is replaced by a halogen atom, in identically or differently, i.e. one halogen atom being independent from another. Particularly, said halogen atom is F.
  • Said halo-Ci-C&-alkyl group is, for example, -CF 3 , -CHF 2 , -CH 2 F, -CF 2 CF 3 , or -CH 2 CF 3 .
  • hydroxy-d-Ce-alkyl- is to be understood as preferably meaning a linear or branched, saturated, monovalent hydrocarbon group in which the term "d-Ce-alkyl-" is defined supra, and in which one or more of the hydrogen atoms is replaced by a hydroxy group with the proviso that not more than one hydrogen atom attached to a single carbon atom is being replaced.
  • Said hydroxy-CrC 6 -alkyl- group is, for example, -CH 2 OH, -CH 2 CH 2 -OH, -C(OH)H-CH 3 , or -C(OH)H-CH 2 OH.
  • G-Ce-alkoxy is to be understood as preferably meaning a linear or branched, saturated, monovalent, hydrocarbon group of formula -0-(G-C6- alkyl), in which the term "d-Ce-alkyl” is defined supra, e.g. a methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, tert-butoxy, sec-butoxy, pentoxy, iso-pentoxy, or n-hexoxy group, or an isomer thereof.
  • halo-d-Ce-alkoxy is to be understood as preferably meaning a linear or branched, saturated, monovalent Ci-C&-alkoxy group, as defined supra, in which one or more of the hydrogen atoms is replaced, in identically or differently, by a halogen atom.
  • said halogen atom is F.
  • Said halo-d-Ce-alkoxy group is, for example, -OCF 3 , -OCHF 2 , -OCH 2 F, -OCF 2 CF 3 , or -OCH 2 CF 3 .
  • Ci-C 6 -alkoxy-CrC 6 -alkyl is to be understood as preferably meaning a linear or branched, saturated, monovalent CrC&-alkyl group, as defined supra, in which one or more of the hydrogen atoms is replaced, in identically or differently, by a Ci-C&-alkoxy group, as defined supra, e.g.
  • halo-Ci-C6-alkoxy-CrC6-alkyl is to be understood as preferably meaning a linear or branched, saturated, monovalent O-Ce-alkoxy-G-Ce-alkyl group, as defined supra, in which one or more of the hydrogen atoms is replaced, in identically or differently, by a halogen atom.
  • said halogen atom is F.
  • Said halo-G-Ce-alkoxy-G-Ce-alkyl group is, for example, -CH 2 CH 2 OCF 3 , -CH 2 CH 2 OCHF 2 , -CH 2 CH 2 OCH 2 F, -CH 2 CH 2 OCF 2 CF 3 , or -CH 2 CH 2 OCH 2 CF 3 .
  • C 2 -Cio-alkenyl is to be understood as preferably meaning a linear or branched, monovalent hydrocarbon group, which contains one or more double bonds, and which has 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, particularly 2, 3, 4, 5 or 6 carbon atoms ("C 2 -C6-alkenyl”), more particularly 2 or 3 carbon atoms (“C 2 -C 3 -alkenyl”), it being understood that in the case in which said alkenyl group contains more than one double bond, then said double bonds may be isolated from, or conjugated with, each other.
  • Said alkenyl group is, for example, a vinyl, allyl, (£)-2-methylvinyl, (Z)-2-methylvinyl, homoallyl, (E)-but-2-enyl, (Z)-but-2-enyl, (f)-but- l -enyl, (Z)-but- l -enyl, pent-4-enyl, (E)-pent-3-enyl, (Z)-pent-3-enyl, (E)-pent-2-enyl, (Z)-pent-2-enyl, (f)-pent- l -enyl, (Z)-pent- l -enyl, hex-5-enyl, (f)-hex-4-enyl, (Z)-hex-4-enyl, (f)-hex-3-enyl, (Z)-hex-3-enyl, (f)-hex-2-enyl, (Z)-he
  • C 2 -Cio-alkynyl is to be understood as preferably meaning a linear or branched, monovalent hydrocarbon group which contains one or more triple bonds, and which contains 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, particularly 2, 3, 4, 5 or 6 carbon atoms ("C 2 -C 6 -alkynyl”), more particularly 2 or 3 carbon atoms ("C 2 -C3-alkynyl").
  • Said C 2 -Cio-alkynyl group is, for example, ethynyl, prop-1 -ynyl, prop-2-ynyl, but-1 -ynyl, but-2-ynyl, but-3-ynyl, pent-1 -ynyl, pent-2-ynyl, pent-3-ynyl, pent-4-ynyl, hex-1 -ynyl, hex-2-ynyl, hex-3-ynyl, hex-4-ynyl, hex-5-ynyl, 1 -methylprop-2-ynyl, 2-methylbut-3-ynyl, 1 -methylbut-3-ynyl, 1 -methylbut-2-ynyl, 3-methylbut-1 -ynyl,
  • alkynyl group is ethynyl, prop- 1 -ynyl, or prop-2-ynyl.
  • C3-Cio-cycloalkyl is to be understood as meaning a saturated, monovalent, mono-, or bicyclic hydrocarbon ring which contains 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms ("C3-Cio-cycloalkyl").
  • Said C3-Go-cycloalkyl group is for example, a monocyclic hydrocarbon ring, e.g. a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl or cyclodecyl, or a bicyclic hydrocarbon ring, e.g. a perhydropentalenylene or decalin ring.
  • said ring contains 3, 4, 5 or 6 carbon atoms ("C3-C6-cycloalkyl").
  • C3-C6-cycloalkyloxy refers to a (C3-C&-cycloalkyl)-0- group in which "C3-C&-cycloalkyl" is as defined herein. Examples include, but are not limited to, cyclopropanoxy and cyclobutanoxy.
  • C -Cio-cycloalkenyl is to be understood as preferably meaning a non-aromatic, monovalent, mono-, or bicyclic hydrocarbon ring which contains 4, 5, 6, 7, 8, 9 or 10 carbon atoms and one, two, three or four double bonds, in conjugation or not, as the size of said cycloalkenyl ring allows.
  • Said C 4 -Cio-cycloalkenyl group is for example, a monocyclic hydrocarbon ring, e.g. a cyclobutenyl, cyclopentenyl, or cyclohexenyl or a bicyclic hydrocarbon, e.g.
  • Cs-Cs-cycloalkenyloxy refers to a (Cs-Cs-cycloalkenylJ-O- group in which "C5-C8-cycloalkenyl" is as defined herein.
  • R a represents a hydrogen atom or a Ci-C 6 -alkyl- group ; it being possible for said heterocycloalkyl group to be attached to the rest of the molecule via any one of the carbon atoms or, if present, the nitrogen atom.
  • said 3- to 10-membered heterocycloalkyl can contain 2, 3, 4, or 5 carbon atoms, and one or more of the above-mentioned heteroatom-containing groups (a "3- to 6-membered heterocycloalkyl"), more particularly said heterocycloalkyl can contain 4 or 5 carbon atoms, and one or more of the above-mentioned heteroatom-containing groups (a "5- to 6-membered heterocycloalkyl").
  • said heterocycloalkyl can be a 4-membered ring, such as an azetidinyl, oxetanyl, or a 5-membered ring, such as tetrahydrofuranyl, dioxolinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, or a 6-membered ring, such as tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, or trithianyl, or a 7-membered ring, such as a diazepanyl ring, for example.
  • 4-membered ring such as an azetidinyl, oxetanyl, or a 5-membered ring, such as tetrahydrofuranyl, dioxolinyl, pyrrolidinyl, imidazolidinyl, pyrazolid
  • Said heterocycloalkyl can be bicyclic, such as, without being limited thereto, a
  • 5.5- membered ring e.g. a hexahydrocyclopenta[c]pyrrol-2(1 H)-yl ring, or a
  • Said heterocycloalkyl can be spirocyclic, such as, without being limited thereto, e.g. a 2-oxa-6-azaspiro[3.3]heptane ring or a 2-oxa-6- azaspiro[3.4]octane ring or a 2-oxa-7-azaspiro[4.4]nonane ring.
  • the term "4- to 10-membered heterocycloalkenyl” is to be understood as meaning an non-aromatic, unsaturated, monovalent, mono- or bicyclic hydrocarbon ring which contains 3, 4, 5, 6, 7, 8 or 9 carbon atoms, and one or more heteroatom-containing groups selected from:
  • R a represents a hydrogen atom or a Ci-C&-alkyl- group ; it being possible for said heterocycloalkenyl group to be attached to the rest of the molecule via any one of the carbon atoms or, if present, the nitrogen atom.
  • heterocycloalkenyl are e.g.
  • 4H-pyranyl 2H-pyranyl, 3H-diazirinyl, 2,5-dihydro-1 H-pyrrolyl, [1 ,3]dioxolyl, 4H-[1 ,3,4]thiadiazinyl, 2,5-dihydrofuranyl, 2,3-dihydrofuranyl, 2,5-dihydrothiophenyl, 2,3-dihydrothiophenyl, 4,5-dihydrooxazolyl, or 4H-[1 ,4]thiazinyl group.
  • aryl is to be understood as preferably meaning a monovalent, aromatic or partially aromatic, mono-, or bi- or tricyclic hydrocarbon ring having 6, 7, 8, 9, 10, 1 1 , 12, 13 or 14 carbon atoms (a "C&-Ci4-aryl” group), particularly a ring having 6 carbon atoms (a "Ce-aryl” group), e.g. a phenyl group; or a biphenyl group, or a ring having 9 carbon atoms (a "Cg-aryl” group), e.g. an indanyl or indenyl group, or a ring having 10 carbon atoms (a "Cio-aryl” group), e.g.
  • heteroaryl is understood as preferably meaning a monovalent, monocyclic, bicyclic or tricyclic aromatic ring system having 5, 6, 7, 8, 9, 10, 11 , 12, 13 or 14 ring atoms (a "5- to 14-membered heteroaryl” group), particularly 5 or 6 or 9 or 10 atoms, and which contains at least one heteroatom which may be identical or different, said heteroatom being such as oxygen, nitrogen or sulfur, and in addition in each case can be benzocondensed.
  • heteroaryl is selected from thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, thia-4H-pyrazolyl etc., and benzo derivatives thereof, such as, for example, benzofuranyl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, benzotriazolyl, indazolyl, indolyl, isoindolyl, etc.; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, etc., and benzo derivatives thereof, such as, for example, quinolinyl, quinazolinyl, isoquinolinyl, etc.;
  • d-d as used throughout this text, e.g. in the context of the definition of "d-d-alkyl", “Ci-C 6 -haloalkyl", “C C 6 -alkoxy”, or “CrC6-haloalkoxy” is to be understood as meaning an alkyl group having a finite number of carbon atoms of 1 to 6, i.e. 1 , 2, 3, 4, 5, or 6 carbon atoms. It is to be understood further that said term “Ci-C6” is to be interpreted as any sub-range comprised therein, e.g.
  • d-d C 2 -d , C 3 -C 4 , Ci-C 2 , C1-C3 , Ci-C 4 , C1-C5 ; particularly C1-C2 , C C 3 , Ci-C , C1-C5, d-d; more particularly d-C 4 ; in the case of "d-Ce-haloalkyl" or "Ci-C6-haloalkoxy" even more particularly Ci-C 2 .
  • d-Ce as used throughout this text, e.g.
  • C 2 -C6-alkenyl and "C 2 -C6-alkynyl”
  • C 2 -C6-alkynyl is to be understood as meaning an alkenyl group or an alkynyl group having a finite number of carbon atoms of 2 to 6, i.e. 2, 3, 4, 5, or 6 carbon atoms.
  • said term "C 2 -C6” is to be interpreted as any sub-range comprised therein, e.g. G-Ce , C3-C5 , C3-C4 , C 2 -C 3 , C 2 -C 4 , C 2 -Cs ; particularly C 2 -C 3 .
  • C 3 -C& as used throughout this text, e.g. in the context of the definition of "C 3 -C&-cycloalkyl”, is to be understood as meaning a cycloalkyl group having a finite number of carbon atoms of 3 to 6, i.e. 3, 4, 5 or 6 carbon atoms. It is to be understood further that said term “CrCe” is to be interpreted as any sub-range comprised therein, e.g. C 3 -C& , C 4 -Cs , C 3 -C5 , C 3 -C 4 , C 4 -C&, C5-C& ; particularly C 3 -C&.
  • substituted means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom ' s normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • optionally substituted means optional substitution with the specified groups, radicals or moieties.
  • a leaving group refers to an atom or a group of atoms that is displaced in a chemical reaction as stable species taking with it the bonding electrons.
  • a leaving group is selected from the group comprising: halo, in particular chloro, bromo or iodo, methanesulfonyloxy, p-toluenesulfonyloxy, trifluoromethanesulfonyloxy,
  • protecting group is a protective group attached to a nitrogen in intermediates used for the preparation of compounds of the general formula I. Such groups are introduced e.g. by chemical modification of the respective amino group in order to obtain chemoselectivity in a subsequent chemical reaction. Protective groups for amino groups are descibed for example in T.W. Greene and P.G.M.
  • said groups can be selected from substituted sulfonyl groups, such as mesyl-, tosyl- or phenylsulfonyl-, acyl groups such as benzoyl, acetyl or tetrahydropyranoyl-, or carbamate based groups, such as tert. -butoxycarbonyl (Boc), or can include silicon, as in e.g. 2-(trimethylsilyl)ethoxymethyl (SEM).
  • the term "one or more”, e.g. in the definition of the substituents of the compounds of the general formulae of the present invention is understood as meaning "one, two, three, four or five, particularly one, two, three or four, more particularly one, two or three, even more particularly one or two".
  • the invention also includes all suitable isotopic variations of a compound of the invention.
  • An isotopic variation of a compound of the invention is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually or predominantly found in nature.
  • isotopes that can be incorporated into a compound of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine, chlorine, bromine and iodine, such as 2 H (deuterium), 3 H (tritium), 11 C, 13 C, 14 C, 1 N, 17 0, 18 0, 32 P, 33 P, 33 S, 34 S, 3 S, 36 S, 18 F, 36 Cl, 82 Br, 123 l, 124 l, 129 l and 131 1, respectively.
  • Certain isotopic variations of a compound of the invention for example, those in which one or more radioactive isotopes such as 3 H or 14 C are incorporated, are useful in drug and/or substrate tissue distribution studies.
  • Tritiated and carbon-14, i.e. , 14 C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements and hence may be preferred in some circumstances.
  • isotopic variations of a compound of the invention can generally be prepared by conventional procedures known by a person skilled in the art such as by the illustrative methods or by the preparations described in the examples hereafter using appropriate isotopic variations of suitable reagents.
  • stable compound or “ stable structure” is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • the compounds of this invention may contain one or more asymmetric centre, depending upon the location and nature of the various substituents desired.
  • Asymmetric carbon atoms may be present in the (R) or (S) configuration, resulting in racemic mixtures in the case of a single asymmetric centre, and diastereomeric mixtures in the case of multiple asymmetric centres.
  • asymmetry may also be present due to restricted rotation about a given bond, for example, the central bond adjoining two substituted aromatic rings of the specified compounds.
  • the compounds of the present invention may contain sulphur atoms which are asymmetric, such as an asymmetric sulphoxide or sulphoximine group, of structure:
  • Preferred compounds are those which produce the more desirable biological activity.
  • Separated, pure or partially purified isomers and stereoisomers or racemic or diastereomeric mixtures of the compounds of this invention are also included within the scope of the present invention.
  • the purification and the separation of such materials can be accomplished by standard techniques known in the art.
  • Pure stereoisomers can be obtained by resolution of racemic mixtures according to conventional processes, for example, by the formation of diastereoisomeric salts using an optically active acid or base or formation of covalent diastereomers.
  • appropriate acids are tartaric, diacetyltartaric, ditoluoyltartaric and camphorsulfonic acid.
  • Mixtures of diastereoisomers can be separated into their individual diastereomers on the basis of their physical and/or chemical differences by methods known in the art, for example, by chromatography or fractional crystallisation.
  • the optically active bases or acids are then liberated from the separated diastereomeric salts.
  • a different process for separation of optical isomers involves the use of chiral chromatography ⁇ e.g. , chiral HPLC columns), with or without conventional derivatisation, optimally chosen to maximise the separation of the enantiomers.
  • Suitable chiral HPLC columns are manufactured by Daicel, e.g. , Chiracel OD and Chiracel OJ among many others, all routinely selectable.
  • Enzymatic separations, with or without derivatisation are also useful.
  • the optically active compounds of this invention can likewise be obtained by chiral syntheses utilizing optically active starting materials.
  • the present invention includes all possible stereoisomers of the compounds of the present invention as single stereoisomers, or as any mixture of said stereoisomers, e.g. (/?) or (S) isomers, or (£) or (Z) isomers, in any ratio.
  • Isolation of a single stereoisomer, e.g. a single enantiomer or a single diastereomer, of a compound of the present invention may be achieved by any suitable state of the art method, such as chromatography, especially chiral chromatography, for example.
  • the compounds of the present invention may exist as tautomers.
  • any compound of the present invention which contains a pyrazole moiety as a heteroaryl group for example can exist as a 1 H tautomer, or a 2H tautomer, or even a mixture in any amount of the two tautomers, or a triazole moiety for example can exist as a 1 H tautomer, a 2H tautomer, or a 4H tautomer, or even a mixture in any amount of said 1 H, 2H and 4H tautomers, namely :
  • the present invention includes all possible tautomers of the compounds of the present invention as single tautomers, or as any mixture of said tautomers, in any ratio.
  • the compounds of the present invention can exist as N -oxides, which are defined in that at least one nitrogen of the compounds of the present invention is oxidised.
  • the present invention includes all such possible N-oxides.
  • the present invention also relates to useful forms of the compounds as disclosed herein, such as metabolites, hydrates, solvates, salts, in particular pharmaceutically acceptable salts, and co-precipitates.
  • the compounds of the present invention can exist as a hydrate, or as a solvate, wherein the compounds of the present invention contain polar solvents, in particular water, methanol or ethanol for example as structural element of the crystal lattice of the compounds.
  • polar solvents in particular water, methanol or ethanol for example as structural element of the crystal lattice of the compounds.
  • the amount of polar solvents, in particular water may exist in a stoichiometric or non-stoichiometric ratio.
  • stoichiometric solvates e.g. a hydrate, hemi-, (semi-), mono-, sesqui-, di-, tri-, tetra-, penta- etc. solvates or hydrates, respectively, are possible.
  • the present invention includes all such hydrates or solvates.
  • the compounds of the present invention can exist in free form, e.g. as a free base, or as a free acid, or as a zwitterion, or can exist in the form of a salt.
  • Said salt may be any salt, either an organic or inorganic addition salt, particularly any pharmaceutically acceptable organic or inorganic addition salt, customarily used in pharmacy.
  • pharmaceutically acceptable salt refers to a relatively non-toxic, inorganic or organic acid addition salt of a compound of the present invention. For example, see S. M. Berge, et al. "Pharmaceutical Salts," J. Pharm. Sci. 1977, 66, 1 -19.
  • a suitable pharmaceutically acceptable salt of the compounds of the present invention may be, for example, an acid-addition salt of a compound of the present invention bearing a nitrogen atom, in a chain or in a ring, for example, which is sufficiently basic, such as an acid-addition salt with an inorganic acid, such as hydrochloric, hydrobromic, hydroiodic, sulfuric, bisulfuric, phosphoric, or nitric acid, for example, or with an organic acid, such as formic, acetic, acetoacetic, pyruvic, trifluoroacetic, propionic, butyric, hexanoic, heptanoic, undecanoic, lauric, benzoic, salicylic, 2-(4-hydroxybenzoyl)-benzoic, camphoric, cinnamic, cyclopentanepropionic, digluconic, 3-hydroxy-2-naphthoic, nicotinic, pamoic, pectinic
  • an alkali metal salt for example a sodium or potassium salt
  • an alkaline earth metal salt for example a calcium or magnesium salt
  • an ammonium salt or a salt with an organic base which affords a physiologically acceptable cation, for example a salt with N-methyl-glucamine, dimethyl-glucamine, ethyl-glucamine, lysine, dicyclohexylamine, 1 ,6-hexadiamine, ethanolamine, glucosamine, sarcosine, serinol, tris-hydroxy-methyl-aminomethane, aminopropandiol, sovak-base, 1 -amino-2,3,4-butantriol, or with a quarternary ammonium salt, such as tetramethylammonium, tetraethylammonium, tetra(n-propyl)ammonium, tetra
  • acid addition salts of the claimed compounds may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods.
  • alkali and alkaline earth metal salts of acidic compounds of the invention are prepared by reacting the compounds of the invention with the appropriate base via a variety of known methods.
  • the present invention includes all possible salts of the compounds of the present invention as single salts, or as any mixture of said salts, in any ratio.
  • the present invention includes all possible crystalline forms, or polymorphs, of the compounds of the present invention, either as single polymorphs, or as a mixture of more than one polymorphs, in any ratio.
  • the present invention covers compounds of general formula (I) : in which :
  • A is selected from:
  • * represents the point of attachment to the nitrogen atom and ** represents the point of attachment to the R 1 group; represents a phenyl- group
  • Ci-C&-alkyl- group which is optionally substituted, one or more times, identically or differently, with a Ci-C&-alkyl- group ; represents a hydrogen atom or a group selected from phenyl-, pyridyl-; said group being substituted, one or more times, identically or differently, with a substituent selected from :
  • * indicates the point of attachment of said group with the rest of the molecule; represents a 4- to 6-membered heterocyclic ring; which is optionally substituted, one or more times, identically or differently, with halo-, -CN, -OH, nitro-, Ci-C&-alkyl-, halo-G-Ce-alkyl-, Ci-C&-alkoxy-,
  • R 8 (CH 2 )n(CHOH)(CH 2 ) p -0-, R 8 -(Ci-C 6 -alkoxy-Ci-C 6 -alkyl)-,
  • R 7 represents a hydrogen atom, a G-C6-alkyl-, or C 3 -C 6 -cycloalkyl- group ;
  • R 8 represents a hydrogen atom, a d-Ca-alkyl- or C3-C&-cycloalkyl- group ;
  • R 9 represents a Ci -C&-alkyl- or C3-C&-cycloalkyl- group ;
  • q represents an integer of 0, 1 , 2 or 3 ;
  • t represents an integer of 0, 1 or 2 ; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.
  • the invention relates to compounds of formula (I), wherein :
  • A represents:
  • A represents:
  • the invention relates to compounds of formula (I), wherein :
  • the invention relates to compounds of formula (I), wherein :
  • A represents:
  • the invention relates to compounds of formula (I), wherein :
  • A represents:
  • the invention relates to compounds of formula (I), wherein :
  • A represents:
  • the invention relates to compounds of formula (I), wherein :
  • the invention relates to compounds of formula (I), wherein :
  • R 1 represents a phenyl group
  • Ci-C&-alkyl- group which is optionally substituted, one or more times, identically or differently, with a Ci-C&-alkyl- group.
  • the invention relates to compounds of formula (I), wherein :
  • R 1 represents a phenyl group
  • the invention relates to compounds of formula (I), wherein :
  • R 1 represents
  • R 10 represents a group selected from: Ci-C3-alkyl-, hydroxy-CrC3-alkyl-, N(H)(R 8 )-CrC 3 -alkyl-; and
  • R 6a represents a group
  • the invention relates to compounds of formula (I), wherein :
  • R 1 represents
  • the invention relates to compounds of formula (I), wherein :
  • R 2 represents a phenyl group or a pyridyl group
  • the invention relates to compounds of formula (I), wherein :
  • R 2 represents a phenyl group - which is substituted, one or more times, identically or differently, with a substituent selected from :
  • the invention relates to compounds of formula (I), wherein :
  • R 2 represents a phenyl group
  • the invention relates to compounds of formula (I), wherein :
  • R 2 represents
  • the invention relates to compounds formula (I), wherein :
  • R a represents a group selected from:
  • R ! 5b represents a hydrogen atom or a group selected from:
  • R ! 5c represents halo, preferably fluoro
  • the invention relates to compounds of formula (I), wherein : R 2 represents
  • R ! 5a represents a group selected from: Ci-C4-alkoxy-, halo-Ci-C4-alkoxy-, CrC4-alkyl ;
  • the invention relates to compounds of formula (I ), wherein :
  • R a represents a group selected from:
  • R b represents a hydrogen atom or a group selected from:
  • the invention relates to compounds of formula (I), wherein :
  • R 2 represents a group selected from:
  • the invention relates to compounds of formula (I), wherein :
  • R 2 re resents a group selected from:
  • R 2 represents
  • the invention relates to compounds of formula (I), wherein R 2 represents:
  • the invention relates to compounds of formula I), wherein R 2 is selected from:
  • the invention relates to compounds of formula I), wherein R 2 is selected from:
  • the invention relates to compounds of formula (I), wherein R 2 represents:
  • the invention relates to compounds of formula I), wherein R 2 represents a group selected from:
  • the invention relates to compounds of formula (I), wherein B represents a 5- to 6-membered heterocyclic ring; which is optionally, one or more times, identically or differently, substituted with Ci-C 3 -alkyl-, halo-Ci-C 3 -alkyl-.
  • the invention relates to compounds of formula (I), wherein B represents a 5- to 6-membered heterocyclic ring.
  • the invention relates to compounds of formula (I), wherein B represents a 5-membered heterocyclic ring.
  • the invention relates to compounds of formula (I), wherein C represents a 5- to 6-membered heterocyclic ring; which is optionally substituted, one or more times, identically or differently, with halo-, -CN, -OH, Ci-C 3 -alkyl-, halo-d-C 3 -alkyl-, Ci-C 3 -alkoxy-,
  • the invention relates to compounds of formula (I), wherein C represents a 5- to 6-membered heterocyclic ring; which is optionally, one or more times, identically or differently, substituted with CrC 3 -alkyl-, halo-Ci-C 3 -alkyl-.
  • the invention relates to compounds of formula (I), wherein C represents a 5- to 6-membered heterocyclic ring.
  • the invention relates to compounds of formula (I), wherein C represents a 5-membered heterocyclic ring. In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
  • R a represents a group selected from:
  • R 8 -S( 0) 2 -, (C 3 -C 6 -cycloalkyl)-(CH 2 ) n -0-.
  • R a is selected from:
  • R a is selected from:
  • cyclopropyl-O- cyclopropyl-CH 2 -0-, CH 3 -0-CH 2 CH 2 -0-, CHF 2 -0-, CF 3 -0-,
  • the invention relates to compounds of formula (I), wherein :
  • R a represents a Ci-C6-alkoxy- group.
  • the invention relates to compounds of formula (I), wherein :
  • R a represents a Ci-C 3 -alkoxy- group.
  • the invention relates to compounds of formula (I), wherein :
  • R 5a represents a halo-G-C6-alkoxy- group.
  • the invention relates to compounds of formula (I), wherein :
  • R a represents a halo-CrC3-alkoxy- group.
  • the invention relates to compounds of formula (I), wherein :
  • R a represents a (C3-C 6 -cycloalkyl)-(CH 2 ) n -0- group.
  • the preferred halogen atom is F.
  • the invention relates to compounds of formula (I), supra, wherein R represents a group selected from:
  • the invention relates to compounds of formula (I), supra, wherein R 5 represents a group selected from:
  • the invention relates to compounds of formula (I), supra, wherein R 5 represents a group:
  • the invention relates to compounds of formula (I), supra, wherein R b represents a group:
  • the invention relates to compounds of formula (I), supra, wherein R b represents a hydrogen atom.
  • the invention relates to compounds of formula (I), supra, wherein R b represents a group:
  • the invention relates to compounds of formula (I), wherein wherein R c represents halo . In another preferred embodiment, the invention relates to compounds of formula (I), wherein wherein R c represents fluoro .
  • R 6 represents a group selected from :
  • the invention relates to compounds of formula (I), wherein :
  • R 6 represents -(CH 2 ) q -(C3-C6-cycloalkyl) ;
  • the invention relates to compounds of formula (I), wherein :
  • R 6 represents -(CH 2 ) q -aryl
  • the invention relates to compounds of formula (I), wherein :
  • R 6 represents a group selected from :
  • the invention relates to compounds of formula (I), wherein :
  • R 6 represents -(CH 2 ) q -(C3-C6-cycloalkyl) ;
  • the invention relates to compounds of formula (I), wherein :
  • R 6 represents -(CH 2 ) q -aryl
  • the invention relates to compounds of formula (I), wherein :
  • R 6 represents CrC 6 -alkyl, -(CH 2 ) q -(C3-C6-cycloalkyl) or-(CH 2 ) q -aryl ;
  • said group being optionally substituted, one or more times, identically or differently, with halo-.
  • the invention relates to compounds of formula (I), supra, wherein R 6 represents a group selected from:
  • the invention relates to compounds of formula I), supra, wherein R 6 represents a group selected from:
  • the invention relates to compounds of formula I ), supra, wherein R 6 represents a group:
  • the invention relates to compounds of formula I ), supra, wherein R 6 represents a group:
  • the invention relates to compounds of formula (I ), wherein :
  • R 7 represents a hydrogen atom, a Ci-C&-alkyl-, or C3-C 6 -cycloalkyl- group.
  • R 7 represents a hydrogen atom or a Ci-C&-alkyl- group. More preferably, R 7 represents a hydrogen atom.
  • the invention relates to compounds formula (I), wherein :
  • the invention relates to compounds of formula (I), wherein :
  • R 8 represents a hydrogen atom or a CrC&-alkyl- group.
  • R 8 represents a d-Ce-alkyl- group
  • the invention relates to compounds formula (I), wherein :
  • R 9 represents a Ci-C&-alkyl- group.
  • the invention relates to compounds of formula (I), wherein :
  • the invention relates to compounds of formula (I), wherein :
  • the invention relates to compounds of formula (I), wherein :
  • the invention relates to compounds of formula (I), wherein :
  • the invention relates to compounds of formula (I), wherein Q 1 represents CH and Q 2 represents CH.
  • the invention relates to compounds of formula (I), wherein :
  • the invention relates to compounds of formula (I), wherein :
  • q represents an integer of 1 or 2.
  • q is 1.
  • the invention relates to compounds of formula (I), wherein :
  • t represents an integer of 1 or 2.
  • t 1
  • R 1 represents a phenyl- group
  • R z represents a hydrogen atom or a phenyl- group; said phenyl- group being substituted, one or more times, identically or differently, with a substituent selected from :
  • R 2 represents:
  • * indicates the point of attachment of said group with the rest of the molecule; represents a 5- to 6-membered heterocyclic ring; which is optionally, one or more times, identically or differently, substituted with
  • Ci -C 3 -alkyl-, halo-Ci -C 3 -alkyl-. represents a group selected from:
  • halo-Ci -C&-alkoxy- represents a group selected from :
  • t represents an integer of 1 ; or a stereoisomer, a tautomer, an N -oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.
  • the invention relates to compounds of formula (I):
  • R 1 represents a phenyl- group - which is substituted, one or more times, identically or differently, with a substituent selected from :
  • Ci-C&-alkyl- group which is optionally substituted, one or more times, identically or differently, with a Ci-C&-alkyl- group ;
  • R 2 represents a hydrogen atom or a phenyl- group; said phenyl- group being substituted, one or more times, identically or differently, with a substituent selected from :
  • R 2 represents:
  • B represents a 5- to 6-membered heterocyclic ring; which is optionally, one or more times, identically or differently, substituted with
  • Ci-C 3 -alkyl-, halo-Ci-C 3 -alkyl-. represents a group selected from: halo-, CrC6-alkyl-, halo-Ci -C&-alkyl-, Ci -C&-alkoxy-,
  • R 6 represents a group selected from :
  • q represents an integer of 1 ;
  • t represents an integer of 1 ; or a stereoisomer, a tautomer, an N -oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.
  • the invention relates to compounds of formula (I ): in which : represents
  • * represents the point of attachment to the nitrogen atom and * * represents the point of attachment to the R 1 group; represents a phenyl- group
  • R 2 represents
  • * indicates the point of attachment of said group with the rest of the molecule; represents a 4- to 6-membered heterocyclic ring; which is optionally substituted, one or more times, identically or differently, with halo-, -CN, -OH, nitro-, Ci -C&-alkyl-, halo-d-Ce-alkyl-, Ci -C&-alkoxy-, halo-G -C&-alkoxy- , hydroxy-G -Ce-alkyl- ,
  • R 8 (CH 2 ) n (CHOH)(CH 2 )p-0-, R 8 -(Ci -C 6 -alkoxy-Ci -C 6 -alkyl)-,
  • R 7 represents a hydrogen atom, a Ci-C&-alkyl-, or C3-C&-cycloalkyl- group ;
  • R 8 represents a hydrogen atom, a Ci-C&-alkyl- or C3-C&-cycloalkyl- group ;
  • R 9 represents a d-Ce-alkyl- group ;
  • q represents an integer of 1 ;
  • t represents an integer of 0, 1 or 2 ; or a stereoisomer, a tautomer, an N -oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.
  • the invention relates to compounds of formula (I):
  • * represents the point of attachment to the nitrogen atom and * * represents the point of attachment to the R 1 group;
  • * indicates the point of attachment of said group with the rest of the molecule; represents a phenyl group which is substituted, one or more times, identically or differently, with a substituent selected from :
  • * indicates the point of attachment of said group with the rest of the molecule; represents a CrC3-alkoxy- or a halo-Ci -C3-alkoxy-group;
  • R' 6a represents a group
  • * indicates the point of attachment of said group with the rest of the molecule ; wherein said group is optionally substituted, one or more times, identically or differently, with a halogen atom or a methyl- group;
  • R 7 represents a hydrogen atom, a CrC&-alkyl-, or C3-C&-cycloalkyl- group ;
  • R 8 represents a hydrogen atom, a CrC&-alkyl- or C3-Ce-cycloalkyl- group ; represents a Ci -C&-alkyl- group ;
  • R 10 represents a group selected from: G-C3-alkyl-, hydroxy-Ci-C3-alkyl-,
  • the invention relates to compounds formula (I):
  • A represents
  • * indicates the point of attachment of said group with the rest of the molecule; represents a group selected from:
  • * indicates the point of attachment of said group with the rest of the molecule; or a stereoisomer, a tautomer, an N -oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.
  • the present invention covers compounds of general formula (I) which are disclosed in the Example section of this text, infra.
  • the invention relates to a stereoisomer, a tautomer, an N- oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same, of any of the compounds of formula (I).
  • the present invention covers methods of preparing compounds of the present invention, said methods comprising the steps as described in the Experimental Section herein.
  • This invention also relates to pharmaceutical compositions containing one or more compounds of the present invention. These compositions can be utilised to achieve the desired pharmacological effect by administration to a patient in need thereof.
  • a patient for the purpose of this invention, is a mammal, including a human, in need of treatment for the particular condition or disease. Therefore, the present invention includes pharmaceutical compositions that are comprised of a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound, or salt thereof, of the present invention.
  • a pharmaceutically acceptable carrier is preferably a carrier that is relatively non-toxic and innocuous to a patient at concentrations consistent with effective activity of the active ingredient so that any side effects ascribable to the carrier do not vitiate the beneficial effects of the active ingredient.
  • a pharmaceutically effective amount of compound is preferably that amount which produces a result or exerts an influence on the particular condition being treated.
  • the compounds of the present invention can be administered with pharmaceutically-acceptable carriers well known in the art using any effective conventional dosage unit forms, including immediate, slow and timed release preparations, orally, parenterally, topically, nasally, ophthalmically, optically, sublingually, rectally, vaginally, and the like.
  • the compounds of this invention can be administered as the sole pharmaceutical agent or in combination with one or more other pharmaceutical agents where the combination causes no unacceptable adverse effects.
  • the present invention relates also to such combinations.
  • the compounds of this invention can be combined with known anti-hyper- proliferative or other indication agents, and the like, as well as with admixtures and combinations thereof.
  • Other indication agents include, but are not limited to, anti-angiogenic agents, mitotic inhibitors, alkylating agents, anti-metabolites, DNA-intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzyme inhibitors, toposisomerase inhibitors, biological response modifiers, or anti-hormones.
  • Preferred additional pharmaceutical agents are: 131 1-chTNT, abarelix, abiraterone, aclarubicin, aldesleukin, alemtuzumab, alitretinoin, altretamine, aminoglutethimide, amrubicin, amsacrine, anastrozole, arglabin, arsenic trioxide, asparaginase, azacitidine, basiliximab, BAY 80-6946, BAY 1000394, BAY 86-9766 (RDEA 1 19), belotecan, bendamustine, bevacizumab, bexarotene, bicalutamide, bisantrene, bleomycin, bortezomib, buserelin, busulfan, cabazitaxel, calcium folinate, calcium levofolinate, capecitabine, carboplatin, carmofur, carmustine, catumaxomab, celecoxib, celmole
  • Optional anti-hyper-proliferative agents which can be added to the composition include but are not limited to compounds listed on the cancer chemotherapy drug regimens in the 11 th Edition of the Merck Index, (1996), which is hereby incorporated by reference, such as asparaginase, bleomycin, carboplatin, carmustine, chlorambucil, cisplatin, colaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, doxorubicin (adriamycine), epirubicin, etoposide, 5-fluorouracil, hexamethylmelamine, hydroxyurea, ifosfamide, irinotecan, leucovorin, lomustine, mechlorethamine, 6-mercaptopurine, mesna, methotrexate, mitomycin C, mitoxantrone, prednisolone, prednisone
  • anti-hyper-proliferative agents suitable for use with the composition of the invention include but are not limited to those compounds acknowledged to be used in the treatment of neoplastic diseases in Goodman and Gilman's The Pharmacological Basis of Therapeutics (Ninth Edition), editor Molinoff et a/. , publ.
  • anti-hyper-proliferative agents suitable for use with the composition of the invention include but are not limited to other anti-cancer agents such as epothilone and its derivatives, irinotecan, raloxifen and topotecan.
  • the compounds of the invention may also be administered in combination with protein therapeutics.
  • protein therapeutics suitable for the treatment of cancer or other angiogenic disorders and for use with the compositions of the invention include, but are not limited to, an interferon (e.g., interferon .alpha., .beta. , or .gamma.
  • supraagonistic monoclonal antibodies Tuebingen, TRP-1 protein vaccine, Colostrinin, anti-FAP antibody, YH-16, gemtuzumab, infliximab, cetuximab, trastuzumab, denileukin diftitox, rituximab, thymosin alpha 1 , bevacizumab, mecasermin, mecasermin rinfabate, oprelvekin, natalizumab, rhMBL, MFE-CP1 + ZD-2767-P, ABT-828, ErbB2-specific immunotoxin, SGN-35, MT-103, rinfabate, AS-1402, B43-genistein, L-19 based radioimmunotherapeutics, AC-9301 , NY-ESO-1 vaccine, IMC-1C11 , CT-322, rhCCIO, r(m)CRP, MORAb-009, expcumine,
  • Monoclonal antibodies useful as the protein therapeutic include, but are not limited to, muromonab-CD3, abciximab, edrecolomab, daclizumab, gentuzumab, alemtuzumab, ibritumomab, cetuximab, bevicizumab, efalizumab, adalimumab, omalizumab, muromomab-CD3, rituximab, daclizumab, trastuzumab, palivizumab, basiliximab, and infliximab.
  • cytotoxic and/or cytostatic agents in combination with a compound or composition of the present invention will serve to:
  • the present invention covers a compound of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, as described and defined herein, for use in the treatment or prophylaxis of a disease, as mentioned supra.
  • Another particular aspect of the present invention is therefore the use of a compound of general formula (I), described supra, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, for the prophylaxis or treatment of a disease.
  • Another particular aspect of the present invention is therefore the use of a compound of general formula (I) described supra for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.
  • the diseases referred to in the two preceding paragraphs are diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses, or diseases which are accompanied with uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses, particularly in which the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses is mediated by Mps-1 , such as, for example, haematological tumours, solid tumours, and/or metastases thereof, e.g.
  • leukaemias and myelodysplastic syndrome including leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.
  • inappropriate within the context of the present invention, in particular in the context of "inappropriate cellular immune responses, or inappropriate cellular inflammatory responses", as used herein, is to be understood as preferably meaning a response which is less than, or greater than normal, and which is associated with, responsible for, or results in, the pathology of said diseases.
  • the use is in the treatment or prophylaxis of diseases, wherein the diseases are haemotological tumours, solid tumours and/or metastases thereof.
  • the present invention relates to a method for using the compounds of the present invention and compositions thereof, to treat mammalian hyper- proliferative disorders.
  • Compounds can be utilized to inhibit, block, reduce, decrease, etc. , cell proliferation and/or cell division, and/or produce apoptosis.
  • This method comprises administering to a mammal in need thereof, including a human, an amount of a compound of this invention, or a pharmaceutically acceptable salt, isomer, polymorph, metabolite, hydrate, solvate or ester thereof ; etc. which is effective to treat the disorder.
  • Hyper- proliferative disorders include but are not limited, e.g., psoriasis, keloids, and other hyperplasias affecting the skin, benign prostate hyperplasia (BPH), solid tumors, such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases.
  • BPH benign prostate hyperplasia
  • solid tumors such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases.
  • Those disorders also include lymphomas, sarcomas, and leukemias.
  • breast cancer examples include, but are not limited to invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ.
  • cancers of the respiratory tract include, but are not limited to small-cell and non-small-cell lung carcinoma, as well as bronchial adenoma and pleuropulmonary blastoma.
  • brain cancers include, but are not limited to brain stem and hypophtalmic glioma, cerebellar and cerebral astrocytoma, medulloblastoma, ependymoma, as well as neuroectodermal and pineal tumor.
  • Tumors of the male reproductive organs include, but are not limited to prostate and testicular cancer.
  • Tumors of the female reproductive organs include, but are not limited to endometrial, cervical, ovarian, vaginal, and vulvar cancer, as well as sarcoma of the uterus.
  • Tumors of the digestive tract include, but are not limited to anal, colon, colorectal, esophageal, gallbladder, gastric, pancreatic, rectal, small- intestine, and salivary gland cancers.
  • Tumors of the urinary tract include, but are not limited to bladder, penile, kidney, renal pelvis, ureter, urethral and human papillary renal cancers.
  • Eye cancers include, but are not limited to intraocular melanoma and retinoblastoma.
  • liver cancers include, but are not limited to hepatocellular carcinoma (liver cell carcinomas with or without fibrolamellar variant), cholangiocarcinoma (intrahepatic bile duct carcinoma), and mixed hepatocellular cholangiocarcinoma.
  • Skin cancers include, but are not limited to squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, and non-melanoma skin cancer.
  • Head-and-neck cancers include, but are not limited to laryngeal, hypopharyngeal, nasopharyngeal, oropharyngeal cancer, lip and oral cavity cancer and squamous cell.
  • Lymphomas include, but are not limited to AIDS- related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Burkitt lymphoma, Hodgkin's disease, and lymphoma of the central nervous system.
  • Sarcomas include, but are not limited to sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma.
  • Leukemias include, but are not limited to acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia. These disorders have been well characterized in humans, but also exist with a similar etiology in other mammals, and can be treated by administering pharmaceutical compositions of the present invention.
  • treating or “treatment” as stated throughout this document is used conventionally, e.g., the management or care of a subject for the purpose of combating, alleviating, reducing, relieving, improving the condition of, etc., of a disease or disorder, such as a carcinoma.
  • the present invention also provides methods for the treatment of disorders associated with aberrant mitogen extracellular kinase activity, including, but not limited to stroke, heart failure, hepatomegaly, cardiomegaly, diabetes, Alzheimer's disease, cystic fibrosis, symptoms of xenograft rejections, septic shock or asthma.
  • Effective amounts of compounds of the present invention can be used to treat such disorders, including those diseases (e.g. , cancer) mentioned in the Background section above. Nonetheless, such cancers and other diseases can be treated with compounds of the present invention, regardless of the mechanism of action and/or the relationship between the kinase and the disorder.
  • aberrant kinase activity or "aberrant tyrosine kinase activity, " includes any abnormal expression or activity of the gene encoding the kinase or of the polypeptide it encodes. Examples of such aberrant activity, include, but are not limited to, over-expression of the gene or polypeptide ; gene amplification ; mutations which produce constitutively-active or hyperactive kinase activity ; gene mutations, deletions, substitutions, additions, etc.
  • the present invention also provides for methods of inhibiting a kinase activity, especially of mitogen extracellular kinase, comprising administering an effective amount of a compound of the present invention, including salts, polymorphs, metabolites, hydrates, solvates thereof, and diastereoisomeric forms thereof.
  • Kinase activity can be inhibited in cells (e.g. , in vitro), or in the cells of a mammalian subject, especially a human patient in need of treatment.
  • dichloromethane adduct chloro[2-(dicyclohexylphosphino)-3,6-dimethoxy-2 ' -4 ' -6 ' -
  • NMR peak forms are stated as they appear in the spectra, possible higher order effects have not been considered.
  • A, R 1 , and R 2 are as defined for the compounds of general formula (I), supra, and Y represents a leaving group, such as a halogen atom or a trifluoromethylsulphonyloxy or nonafluorobutylsulphonyloxy group for example, and Z represents a suitable functional group via which the R 1 of the R 1 -Z compound can be coupled, by a coupling reaction, onto the Y-bearing carbon atom of a compound (4), thereby replacing said Y with said R 1 moiety.
  • Y represents a leaving group, such as a halogen atom or a trifluoromethylsulphonyloxy or nonafluorobutylsulphonyloxy group for example
  • Z represents a suitable functional group via which the R 1 of the R 1 -Z compound can be coupled, by a coupling reaction, onto the Y-bearing carbon atom of a compound (4), thereby replacing said Y with said R 1 moiety.
  • Reagents of the general structure R 1a -Z and R 1 -Z can for example be aryl boronic acids or aryl boronic esters. Many such reagents of the general structures R 1a -Z and R 1 -Z are also commercially available. Reagents of the general structures R 1a -Z and R 1 -Z can be prepared from aryl halides [see for example K. L. Billingslay, T. E. Barde, S. L Buchwald, Angew. Chem. 2007, 1 19, 5455 or T.Graening, sympatheticen aus der Chemie, Jan 2009, 57, 34] . R 1a can be converted to R 1 in one or several steps.
  • R 1a can be a protected phenyl-amine, especially -phenyl-NH-Boc, or a phenyl-carboxylic acid, [-phenyl-C(0)OH] or a -phenyl-carboxylic acid ester [ phenyl-C(0)0- alkyl] .
  • R 1a is a phenyl group to which an -NH 2 substituent is bound
  • Intermediates of general formula (3) can be converted to intermediates of general formula (4) by reaction with suitable aryl compounds R 2 -Y, preferably aryl bromides, or aryl iodides or for example aryl trifluoromethylsulphonates or aryl nonafluorobutylsulphonates in the presence of a suitable base, such as, for example NaOtBu or caesium carbonate or potassium phosphate, and a suitable catalyst/ ligand system, such as for example Pd 2 (dba) 3 /rac-BINAP, Pd 2 dba 3 /X- Phos, Pd 2 dba 3 /tBu-X-Phos, Pd 2 dba 3 /Brett-Phos, Pd-X-Phos-pre-cat/X-Phos, Pd- tBu-X-Phos-pre-cat/tBu-X-Phos, Pd-Brett-Phos-pre-cat/ Brett-Phos
  • intermediates of general formula (3) can be converted to intermediates of general formula (4) by reaction with suitable phenyl or pyridyl compounds R 2 -Y, preferably phenyl chlorides, and more preferably 2- chloro-pyridines or 6-chloro-pyridines in the presence of a suitable base, such as, for example sodium hydride in a suitable solvent such as THF, DMF, DME, or NMP, preferably THF or NMP or mixtures of these solvents at temperatures ranging from room temperature to the 200° C, preferably 130 °C in a microwave vessel.
  • suitable base such as, for example sodium hydride
  • a suitable solvent such as THF, DMF, DME, or NMP, preferably THF or NMP or mixtures of these solvents at temperatures ranging from room temperature to the 200° C, preferably 130 °C in a microwave vessel.
  • Intermediates of general formula (4) can be converted to compounds of general formula (I) by reaction with a suitable reagent, like for example a boronic acid derivative in the presence of a suitable catalyst system, like for example Pd(OAc) 2 and P(oTol) 3 , or PdCl 2 (PPh 3 ) 2 and PPh 3 and a suitable base, like for example aqueous potassium carbonate in a suitable solvent, like for example THF, DME, ethanol or 1 -propanol or mixtures of these solvents at temperatures ranging from room temperature to 200° C, preferably the boiling point of the used solvent.
  • a suitable reagent like for example a boronic acid derivative in the presence of a suitable catalyst system, like for example Pd(OAc) 2 and P(oTol) 3 , or PdCl 2 (PPh 3 ) 2 and PPh 3 and a suitable base, like for example aqueous potassium carbonate in a suitable solvent, like for example THF, DME,
  • intermediates of general formula (3) can be reacted with a suitable reagent, like for example a boronic acid derivative in the presence of a suitable catalyst system, like for example Pd(OAc) 2 and P(oTol) 3 , or PdCl 2 (PPh 3 ) 2 and PPh 3 and a suitable base, like for example aqueous potassium carbonate in a suitable solvent, like for example THF, DME, ethanol or 1 -propanol or mixtures of these solvents at temperatures ranging from room temperature to 200° C, preferably the boiling point of the used solvent to furnish intermediates of the general formula (5).
  • a suitable reagent like for example a boronic acid derivative in the presence of a suitable catalyst system, like for example Pd(OAc) 2 and P(oTol) 3 , or PdCl 2 (PPh 3 ) 2 and PPh 3 and a suitable base, like for example aqueous potassium carbonate in a suitable solvent, like for example THF, DME,
  • Intermediates of general formula (5) can be converted to compounds of general formula (I) by reaction with suitable phenyl or pyridyl compounds R 2 -Y, preferably bromides, iodides, trifluoromethylsulphonates or nonafluorobutylsulphonates in the presence of a suitable base, such as, for example NaOtBu or caesium carbonate or potassium phosphate, and a suitable catalyst/ ligand system, such as for example Pd 2 (dba)3/rac-BINAP, Pd 2 dba 3 /X- Phos, Pd 2 dba 3 /tBu-X-Phos, Pd 2 dba 3 /Brett-Phos, Pd-X-Phos-pre-cat/X-Phos, Pd- tBu-X-Phos-pre-cat/tBu-X-Phos, Pd-Brett-Phos-pre-cat/Brett-Phos in a suitable solvent
  • Intermediates of general formula (6) can then be converted to intermediates of general formula (7) by a coupling reaction as described supra for synthesis of intermediates of general formula (4), thereby forming a bond between NH and said R 2 moiety.
  • Intermediates of general formula (7) can then be converted to compounds of general formula (I) by one or more further transformations. These can be modifications such as cleavage of protecting groups, reduction or oxidation of functional groups, halogenation, metallation, substitution or other reactions known to the person skilled in the art, for example the formation of an amide bond, the formation of a urea, or the formation of a sulfonamide, thereby converting R 1a to said R 1 moiety.
  • intermediates of general formula (6) can be converted to intermediates of general formula (5) by one or more further transformations.
  • These can be modifications such as cleavage of protecting groups, reduction or oxidation of functional groups, halogenation, metallation, substitution or other reactions known to the person skilled in the art, for example the formation of an amide bond, the formation of a urea, or the formation of a sulphonamide, thereby converting R 1a to said R 1 moiety.
  • the compounds and intermediates produced according to the methods of the invention may require purification. Purification of organic compounds is well known to the person skilled in the art and there may be several ways of purifying the same compound. In some cases, no purification may be necessary. In some cases, the compounds may be purified by crystallisation. In some cases, impurities may be stirred out using a suitable solvent. In some cases, the compounds may be purified by chromatography, particularly flash chromatography, using for example pre-packed silica gel cartridges, e.g.
  • Separtis such as Isolute® Flash silica gel (silica gel chromatography) or Isolute® Flash NH2 silica gel (aminophase-silica-gel chromatography) in combination with a suitable chromatographic system such as a Flashmaster II (Separtis) or an Isolera system (Biotage) and eluents such as, for example, gradients of hexane/ethyl acetate or DCM/methanol.
  • a suitable chromatographic system such as a Flashmaster II (Separtis) or an Isolera system (Biotage)
  • eluents such as, for example, gradients of hexane/ethyl acetate or DCM/methanol.
  • the compounds may be purified by preparative HPLC using, for example, a Waters autopurifier equipped with a diode array detector and/or on-line electrospray ionisation mass spectrometer in combination with a suitable pre-packed reverse phase column and eluants such as, for example, gradients of water and acetonitrile which may contain additives such as trifluoroacetic acid, formic acid or aqueous ammonia.
  • a Waters autopurifier equipped with a diode array detector and/or on-line electrospray ionisation mass spectrometer in combination with a suitable pre-packed reverse phase column and eluants such as, for example, gradients of water and acetonitrile which may contain additives such as trifluoroacetic acid, formic acid or aqueous ammonia.
  • Names of compounds were generated using ACD/Name Batch ver. 12.00 or ACD/Name Batch ver. 12.01 .
  • Names of compounds in table format were generated using ACD/Name Batch ver. 12.00.
  • Method 6 Instrument Waters Acquity UPLC-MS SQD; Column: Acquity UPLC BEH C18 1.7 50x2.1 mm; eluent A: water + 0.2% vol. ammonia (32%), eluent B: acetonitrile; gradient: 0-1.6 min 1 -99% B, 1.6-2.0 min 99% B; flow 0.8 mL/min; temperature: 60 °C; injection: 2 ⁇ ; DAD scan: 210-400 nm; ELSD.
  • Ethoxycarbonyl isothiocyanate (9.12 g) was added to a stirred solution of 6- bromopyridazin-3-amine (11 g) in dioxane (113 mL). The mixture was stirred for 16 h at r.t. A white solid precipitated. Hexane (110 mL) was added and the white solid was collected by filtration to give 16.6 g of the title compound.
  • Ethoxycarbonyl isothiocyanate (49.7 g) was added to a stirred solution of 5- bromopyrazin-2-amine (60.0 g) in dioxane (600 ml_). The mixture was stirred for 48 h at r.t. A white solid precipitated. The white solid was collected by filtration to give 78.5 g of the title compound.
  • a white solid was collected by filtration, was washed with ethyl acetate and dried in vacuum to give 18.3 g of a solid.
  • the solid was twice recrystallized from refluxing ethyl acetate (350 mL; 300 mL).
  • a white solid was collected by filtration, was washed with ethyl acetate and dried in vacuum to give 10.51 g of a solid.
  • the crude product was used without further purification.
  • Ethoxycarbonyl isothiocyanate (11.1 g) was added to a stirred solution of 2- amino-4-chloropyridine (10.1 g) in dioxane (100 mL). The mixture was stirred for 2h at r.t. A white solid precipitated. Hexane (25 mL) was added and the white solid was collected by filtration to give 8.0 g of the title compound. The solution was concentrated in vacuum and the residue was recrystallized from ethyl acetate to give further 8.5 g of the title compound.
  • Int12.01 was prepared as described by David W. Robertson et al. in European Journal of Medicinal Chemistry, 1986, 21 , p223-229.
  • Int12.01 can also be prepared in a similar way as described below:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

The present invention relates to novel compounds showing an inhibitory effect on Mps-1 kinase, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

Description

Novel compounds for the treatment of cancer
The present invention relates to novel compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
BACKGROUND OF THE INVENTION
The present invention relates to chemical compounds that inhibit Mps-1 (Monopolar Spindle 1 ) kinase (also known as Tyrosine Threonine Kinase, TTK). Mps-1 is a dual specificity Ser/Thr kinase which plays a key role in the activation of the mitotic checkpoint (also known as spindle checkpoint, spindle assembly checkpoint) thereby ensuring proper chromosome segregation during mitosis [Abrieu A et ai, Cell, 2001 , 106, 83-93]. Every dividing cell has to ensure equal separation of the replicated chromosomes into the two daughter cells. Upon entry into mitosis, chromosomes are attached at their kinetochores to the microtubules of the spindle apparatus. The mitotic checkpoint is a surveillance mechanism that is active as long as unattached kinetochores are present and prevents mitotic cells from entering anaphase and thereby completing cell division with unattached chromosomes [Suijkerbuijk SJ and Kops GJ, Biochemica et Biophysica Acta, 2008, 1786, 24- 31 ; Musacchio A and Salmon ED, Nat Rev Mol Cell Biol., 2007, 8, 379-93]. Once all kinetochores are attached in a correct amphitelic, i.e. bipolar, fashion with the mitotic spindle, the checkpoint is satisfied and the cell enters anaphase and proceeds through mitosis. The mitotic checkpoint consists of complex network of a number of essential proteins, including members of the MAD (mitotic arrest deficient, MAD 1 -3) and Bub (Budding uninhibited by benzimidazole, Bub 1 -3) families, the motor protein CENP-E, Mps-1 kinase as well as other components, many of these being over-expressed in proliferating cells (e.g. cancer cells) and tissues [Yuan B et al., Clinical Cancer Research, 2006, 12, 405-10]. The essential role of Mps-1 kinase activity in mitotic checkpoint signalling has been shown by shRNA-silencing, chemical genetics as well as chemical inhibitors of Mps-1 kinase [Jelluma N et al. , PLos ONE, 2008, 3, e2415; Jones MH et al. , Current Biology, 2005, 15, 160-65; Dorer RK et al. , Current Biology, 2005, 15, 1070-76; Schmidt M et al. , EMBO Reports, 2005, 6, 866-72].
There is ample evidence linking reduced but incomplete mitotic checkpoint function with aneuploidy and tumorigenesis [Weaver BA and Cleveland DW, Cancer Research, 2007, 67, 10103-5; King RW, Biochimica et Biophysica Acta, 2008, 1786, 4-14]. In contrast, complete inhibition of the mitotic checkpoint has been recognised to result in severe chromosome missegregation and induction of apoptosis in tumour cells [Kops GJ et al. , Nature Reviews Cancer, 2005, 5, 773-85; Schmidt M and Medema RH, Cell Cycle, 2006, 5, 159-63; Schmidt M and Bastians H, Drug Resistance Updates, 2007, 10, 162-81].
Therefore, mitotic checkpoint abrogation through pharmacological inhibition of Mps-1 kinase or other components of the mitotic checkpoint represents a new approach for the treatment of proliferative disorders including solid tumours such as carcinomas and sarcomas and leukaemias and lymphoid malignancies or other disorders associated with uncontrolled cellular proliferation.
Different compounds have been disclosed in prior art which show an inhibitory effect on Mps-1 kinase:
WO 2009/024824 A1 discloses 2-Anilinopurin-8-ones as inhibitors of Mps-1 for the treatment of proliferate disorders. WO 2010/124826 A1 discloses substituted imidazoquinoxaline compounds as inhibitors of Mps-1 kinase. WO 201 1 /026579 A1 discloses substituted aminoquinoxalines as Mps-1 inhibitors.
WO201 1 /157688(A1 ), WO201 1 /063908(A1 ), WO201 1 /064328(A1 ), WO201 1063907(A1 ) and WO2012/143329(A1 ) disclose substituted triazolopyridine compounds as inhibitors of Mps-1 kinase.
However, the state of the art described above does not describe the compounds of general formula (I) of the present invention, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same, as described and defined herein, and as hereinafter referred to as "compounds of the present invention", or their pharmacological activity. It has now been found, and this constitutes the basis of the present invention, that said compounds of the present invention have surprising and advantageous properties.
In particular, said compounds of the present invention have surprisingly been found to effectively inhibit Mps-1 kinase and may therefore be used for the treatment or prophylaxis of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses or diseases which are accompanied with uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses, particularly in which the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses is mediated by Mps-1 kinase, such as, for example, haemotological tumours, solid tumours, and/or metastases thereof, e.g. leukaemias and myelodysplasia syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.
SUMMARY of the INVENTION
The present invention covers com ounds of general formula (I) :
Figure imgf000005_0001
in which :
A is selected from:
Figure imgf000005_0002
wherein * represents the point of attachment to the nitrogen atom and ** represents the point of attachment to the R1 group;
R1 represents a phenyl- group
- which is substituted, one or more times, identically or differently, with a substituent selected from :
-OH, -N(H)C(=0)R6, -N(R7)C(=0)R6, -N(H)C(=0)NR6R7,
-N(R7)C(=0)NR6R7, -NH2, -NR6R7, -C(=0)N(H)R6, -C(=0)NR6R7;
and - which is optionally substituted, one or more times, identically or differently, with a G -Ce-alkyl- group ; represents a hydrogen atom or a group selected from phenyl-, pyridyl-; said group being substituted, one or more times, identically or differently, with a substituent selected from :
halo-, hydroxy-, cyano-, nitro-, G -Ce-alkyl-,
halo-CrCe-alkyl-, CrC6-alkoxy-, halo-Ci -C&-alkoxy-,
hydroxy-d-Ce-alkyl-, d-Ce-alkoxy-CrCe-alkyl-,
halo-Ci -C6-alkoxy-Ci -C6-alkyl-,
R9-, R9- (CrC6-alkyl)-, R9- (CH2)n(CHOH ) (CH2)m- , R9- (C C6-alkoxy)-,
R9- (CH2)n(CHOH ) (CH2)p-0-, R9- (Ci -C6-alkoxy-Ci -C6-alkyl)-,
R9- (Ci -C6-alkoxy-Ci -C6-alkyl)-0-, -0- (CH2)n-C(=0)NR9R7, R9-0-, -C(=0)R9, -C(=0)0-R9, -OC(=0)-R9, -N(H )C(=0)R9, -N(R7)C(=0)R9, -N(H )C(=0)NR9R7, -N(R7)C(=0)NR9R7, -NR9R7, -C(=0)N(H)R9, -C(=0)NR9R7, R9-S-, R9-S(=0)-, R9-S(=0)2-, -N(H)S(=0)R9, -N(R7)S(=0)R9, -S(=0)N(H)R9, -S(=0)NR9R7, -N(H)S(=0)2R9, -N(R7)S(=0)2R9, -S(=0)2N(H)R9, -S(=0)2NR9R7,
-S(=0)(=NR9)R7, -S(=0)(=NR7)R9 or -N=S(=0)(R9)R7 ; or
R2 represents a group selected from:
wherein * indicates the point of attachment of said group with the rest of the molecule; represents a 4- to 6-membered heterocyclic ring; which is optionally substituted, one or more times, identically or differently, with halo-, -CN , -OH, nitro-, CrC&-alkyl-, halo-Ci -C&-alkyl-, G -Ce-alkoxy-, halo-Ci -C&-alkoxy-, hydroxy-Ci -C&-alkyl-,
CrCe-alkoxy-CrCe-alkyl-, halo-Ci -Ce-alkoxy-d-Ce-alkyl-,
R8- (CrC6-alkoxy)-, R8-0-, -N R8R7, R8-S- , R8-S(=0)-, R8-S(=0)2-,
(C3-C6-cycloalkyl)- (CH2)n-0-; represents a 4- to 6-membered heterocyclic ring; which is optionally substituted, one or more times, identically or differently, with halo-, -CN , -OH, nitro-, Ci -C&-alkyl-, halo-Ci -C&-alkyl-, CrC&-alkoxy-, halo-Ci -C&-alkoxy-, hydroxy-CrC&-alkyl-,
CrCe-alkoxy-d-Ce-alkyl-, halo-Ci -C6-alkoxy-CrC6-alkyl-,
R8- (CrC6-alkoxy)-, R8-0-, -NR8R7, R8-S- , R8-S(=0)-, R8-S(=0)2-,
(C3-C6-cycloalkyl)- (CH2)n-0-; each R5a
independently represents a group selected from:
halo-, cyano-, nitro-, CrC&-alkyl-, halo-CrC6-alkyl-, Ci -C&-alkoxy-, halo-d-Ce-alkoxy-, hydroxy-O -Ce-alkyl-, CrCe-alkoxy-CrCe-alkyl-, halo-Ci -C6-alkoxy-Ci -C6-alkyl-, R8- (Ci -C6-alkoxy)-, R8-0-, -NR8R7, R8-S-, R8-S(=0)-, R8-S(=0)2-, (C3-C6-cycloalkyl)- (CH2)n-0-; represents a group selected from :
Ci -C&-alkyl-, C3-C&-cycloalkyl-, 3- to 10-membered heterocycloalkyl-, aryl-, heteroaryl-, - (CH2)q- (C3-C6-cycloalkyl) , - (CH2)q-heteroaryl,
- (CH2)q-(3- to 10-membered heterocycloalkyl), - (CH2)q-aryl ;
said group being optionally substituted, one or more times, identically or differently, with a substituent selected from :
halo-, hydroxy-, cyano-, nitro-, CrC&-alkyl-, halo-Ci -C&-alkyl-, d-Ce-alkoxy-, halo-d-Ce-alkoxy-, hydroxy-CrC&-alkyl-,
CrCe-alkoxy-CrCe-alkyl-, halo-CrCe-alkoxy-CrCe-alkyl-, R8-(CrC6-alkyl)-, R8-(CH2)n(CHOH)(CH2)m-, R8-(d-C6-alkoxy)-,
R8-(CH2)n(CHOH)(CH2)p-0-, R8-(Ci -C6-alkoxy-Ci -C6-alkyl)-,
R8-(Ci -C6-alkoxy-Ci -C6-alkyl)-0-, aryl-, R8-0-, -C(=0)R8, -C(=0)0-R8, -OC(=0)-R8, -N(H )C(=0)R8, -N(R7)C(=0)R8, -N(H )C(=0)NR8R7,
-N(R7)C(=0)NR8R7, -NR8R7 , -C(=0)N(H)R8, -C(=0)NR8R7, R8-S-, R8-S(=0)-,
R8-S(=0)2-, -N(H)S(=0)R8, -N(R7)S(=0)R8, -S(=0)N(H)R8, -S(=0)NR8R7, -N(H)S(=0)2R8, -N(R7)S(=0)2R8, -S(=0)2N(H)R8, -S(=0)2NR8R7,
-S(=0)(=NR8)R7,-S(=0)(=NR7)R8, -N=S(=0)(R8)R7 ; R7 represents a hydrogen atom, a Ci -C&-alkyl-, or C3-C6-cycloalkyl- group ; or
R6 and R7,
together with the nitrogen atom to which they are attached,
represent a 3- to 10-membered heterocycloalkyl- group ;
R8 represents a hydrogen atom, a CrC&-alkyl- or C3-C6-cycloalkyl- group ; R9 represents a Ci -C&-alkyl- or C3-C&-cycloalkyl- group ;
or
R9 and R7,
together with the nitrogen atom to which they are attached,
represent a 3- to 10-membered heterocycloalkyl- group;
which is optionally substituted with a halogen atom; n, m, p
represent, independently from each other, an integer of 0, 1 , 2, 3, 4, or 5 ;
q represents an integer of 0, 1 , 2 or 3 ; and
t represents an integer of 0, 1 or 2 ; or a stereoisomer, a tautomer, an N -oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.
The present invention further relates to methods of preparing compounds of general formula (I), to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
DETAILED DESCRIPTION of the INVENTION
The terms as mentioned in the present text have preferably the following meanings : The term "halogen atom", "halo-" or "Hal-" is to be understood as meaning a fluorine, chlorine, bromine or iodine atom, preferably a fluorine, chlorine or bromine atom.
The term "CrGo-alkyl" is to be understood as preferably meaning a linear or branched, saturated, monovalent hydrocarbon group having 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, e.g. a methyl, ethyl, propyl, butyl, pentyl, hexyl, iso-propyl, iso-butyl, sec-butyl, tert-butyl, iso-pentyl, 2-methylbutyl, 1 -methylbutyl, 1 -ethylpropyl, 1 ,2-dimethylpropyl, neo-pentyl, 1 , 1 -dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1 -methylpentyl, 2-ethylbutyl, 1 -ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1 , 1 -dimethylbutyl, 2,3-dimethylbutyl, 1 ,3-dimethylbutyl, or 1 ,2-dimethylbutyl group, or an isomer thereof. Particularly, said group has 1 , 2, 3, 4, 5 or 6 carbon atoms ("Ci-C6-alkyl"), more particularly, said group has 1 , 2, 3 or 4 carbon atoms ("Ci-C4-alkyl"), e.g. a methyl, ethyl, propyl, butyl, iso-propyl, iso-butyl, sec-butyl, tert-butyl group; even more particularly 1 , 2 or 3 carbon atoms ("CrC3-alkyl"), e.g. a methyl, ethyl, n-propyl- or iso-propyl group.
The term "Ci-Cio-alkylene" is to be understood as preferably meaning a linear or branched, saturated, bivalent hydrocarbon group having 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, e.g. a methylene, ethylene, n-propylene, n-butylene, n-pentylene, 2-methylbutylene, n-hexylene, 3-methylpentylene group, or an isomer thereof. Particularly, said group is linear and has 2, 3, 4 or 5 carbon atoms ("C2-Cs-alkylene"), e.g. an ethylene, n-propylene, n-butylene, n- pentylene group, more particularly 3 or 4 carbon atoms ("C3-C4-alkylene"), e.g. an n-propylene or n-butylene group.
The term "halo-G-Ce-alkyl" is to be understood as preferably meaning a linear or branched, saturated, monovalent hydrocarbon group in which the term "CrCe-alkyl" is defined supra, and in which one or more hydrogen atoms is replaced by a halogen atom, in identically or differently, i.e. one halogen atom being independent from another. Particularly, said halogen atom is F. Said halo-Ci-C&-alkyl group is, for example, -CF3, -CHF2, -CH2F, -CF2CF3, or -CH2CF3.
The term "hydroxy-d-Ce-alkyl-" is to be understood as preferably meaning a linear or branched, saturated, monovalent hydrocarbon group in which the term "d-Ce-alkyl-" is defined supra, and in which one or more of the hydrogen atoms is replaced by a hydroxy group with the proviso that not more than one hydrogen atom attached to a single carbon atom is being replaced. Said hydroxy-CrC6-alkyl- group is, for example, -CH2OH, -CH2CH2-OH, -C(OH)H-CH3, or -C(OH)H-CH2OH.
The term "G-Ce-alkoxy" is to be understood as preferably meaning a linear or branched, saturated, monovalent, hydrocarbon group of formula -0-(G-C6- alkyl), in which the term "d-Ce-alkyl" is defined supra, e.g. a methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, tert-butoxy, sec-butoxy, pentoxy, iso-pentoxy, or n-hexoxy group, or an isomer thereof. The term "halo-d-Ce-alkoxy" is to be understood as preferably meaning a linear or branched, saturated, monovalent Ci-C&-alkoxy group, as defined supra, in which one or more of the hydrogen atoms is replaced, in identically or differently, by a halogen atom. Particularly, said halogen atom is F. Said halo-d-Ce-alkoxy group is, for example, -OCF3, -OCHF2, -OCH2F, -OCF2CF3, or -OCH2CF3.
The term "Ci-C6-alkoxy-CrC6-alkyl" is to be understood as preferably meaning a linear or branched, saturated, monovalent CrC&-alkyl group, as defined supra, in which one or more of the hydrogen atoms is replaced, in identically or differently, by a Ci-C&-alkoxy group, as defined supra, e.g. methoxyalkyl, ethoxyalkyl, propyloxyalkyl, iso-propoxyalkyl, butoxyalkyl, iso-butoxyalkyl, tert-butoxyalkyl, sec-butoxyalkyl, pentyloxyalkyl, iso-pentyloxyalkyl, hexyloxyalkyl group, or an isomer thereof. The term "halo-Ci-C6-alkoxy-CrC6-alkyl" is to be understood as preferably meaning a linear or branched, saturated, monovalent O-Ce-alkoxy-G-Ce-alkyl group, as defined supra, in which one or more of the hydrogen atoms is replaced, in identically or differently, by a halogen atom. Particularly, said halogen atom is F. Said halo-G-Ce-alkoxy-G-Ce-alkyl group is, for example, -CH2CH2OCF3, -CH2CH2OCHF2, -CH2CH2OCH2F, -CH2CH2OCF2CF3, or -CH2CH2OCH2CF3.
The term "C2-Cio-alkenyl" is to be understood as preferably meaning a linear or branched, monovalent hydrocarbon group, which contains one or more double bonds, and which has 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, particularly 2, 3, 4, 5 or 6 carbon atoms ("C2-C6-alkenyl"), more particularly 2 or 3 carbon atoms ("C2-C3-alkenyl"), it being understood that in the case in which said alkenyl group contains more than one double bond, then said double bonds may be isolated from, or conjugated with, each other. Said alkenyl group is, for example, a vinyl, allyl, (£)-2-methylvinyl, (Z)-2-methylvinyl, homoallyl, (E)-but-2-enyl, (Z)-but-2-enyl, (f)-but- l -enyl, (Z)-but- l -enyl, pent-4-enyl, (E)-pent-3-enyl, (Z)-pent-3-enyl, (E)-pent-2-enyl, (Z)-pent-2-enyl, (f)-pent- l -enyl, (Z)-pent- l -enyl, hex-5-enyl, (f)-hex-4-enyl, (Z)-hex-4-enyl, (f)-hex-3-enyl, (Z)-hex-3-enyl, (f)-hex-2-enyl, (Z)-hex-2-enyl, (f)-hex- l -enyl, (Z)-hex- l -enyl, /so-propenyl, 2-methylprop-2-enyl, 1 -methylprop-2-enyl,
2- methylprop-1 -enyl, (f )-1 -methylprop-1 -enyl, (Z)-1 -methylprop-1 -enyl,
3- methylbut-3-enyl, 2-methylbut-3-enyl, 1 -methylbut-3-enyl, 3-methylbut-2-enyl, (f)-2-methylbut-2-enyl, (Z)-2-methylbut-2-enyl, (E)-1 -methylbut-2-enyl, (Z)-1 -methylbut-2-enyl, (E)-3-methylbut-1 -enyl, (Z)-3-methylbut-1 -enyl, (£)-2-methylbut-1 -enyl, (Z)-2-methylbut-1 -enyl, (f )-1 -methylbut-1 -enyl, (Z)-1 -methylbut-1 -enyl, 1 ,1 -dimethylprop-2-enyl, 1 -ethylprop-1 -enyl, 1 -propylvinyl, 1 -isopropylvinyl, 4-methylpent-4-enyl, 3-methylpent-4-enyl, 2-methylpent-4-enyl, 1 -methylpent-4-enyl, 4-methylpent-3-enyl, (f)-3-methylpent-3-enyl, (Z)-3-methylpent-3-enyl, (f )-2-methylpent-3-enyl, (Z)-2-methylpent-3-enyl, (f )-1 -methylpent-3-enyl, (Z)-1 -methylpent-3-enyl, (f )-4-methylpent-2-enyl, (Z)-4-methylpent-2-enyl, (f)-3-methylpent-2-enyl, (Z)-3-methylpent-2-enyl, (E)-2-methylpent-2-enyl, (Z)-2-methylpent-2-enyl, (E)-1 -methylpent-2-enyl, (Z)-1 -methylpent-2-enyl, (f)-4-methylpent-1 -enyl, (Z)-4-methylpent-1 -enyl, (f)-3-methylpent-1 -enyl, (Z)-3-methylpent-1 -enyl, (f )-2-methylpent-1 -enyl, (Z)-2-methylpent-1 -enyl, (f )-1 -methylpent-1 -enyl, (Z)-1 -methylpent-1 -enyl, 3-ethylbut-3-enyl, 2-ethylbut-3-enyl, 1 -ethylbut-3-enyl, (E)-3-ethylbut-2-enyl,
(Z)-3-ethylbut-2-enyl, (f)-2-ethylbut-2-enyl, (Z)-2-ethylbut-2-enyl, (f)-1 -ethylbut-2-enyl, (Z)-1 -ethylbut-2-enyl, (E)-3-ethylbut-1 -enyl, (Z)-3-ethylbut-1 -enyl, 2-ethylbut-1 -enyl, (E)-1 -ethylbut-1 -enyl,
(Z)-1 -ethylbut-1 -enyl, 2-propylprop-2-enyl, 1 -propylprop-2-enyl,
2-isopropylprop-2-enyl, 1 -isopropylprop-2-enyl, (f )-2-propylprop-1 -enyl, (Z)-2-propylprop-1 -enyl, (f )-1 -propylprop-1 -enyl, (Z)-1 -propylprop-1 -enyl, (f)-2-isopropylprop-1 -enyl, (Z)-2-isopropylprop-1 -enyl, (f )-1 -isopropylprop-1 -enyl, (Z)-1 -isopropylprop-1 -enyl,
(f )-3,3-dimethylprop-1 -enyl, (Z)-3,3-dimethylprop-1 -enyl,
1 -(1 , 1 -dimethylethyl)ethenyl, buta-1 ,3-dienyl, penta-1 ,4-dienyl, hexa-1 ,5-dienyl, or methylhexadienyl group. Particularly, said group is vinyl or allyl.
The term "C2-Cio-alkynyl" is to be understood as preferably meaning a linear or branched, monovalent hydrocarbon group which contains one or more triple bonds, and which contains 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, particularly 2, 3, 4, 5 or 6 carbon atoms ("C2-C6-alkynyl"), more particularly 2 or 3 carbon atoms ("C2-C3-alkynyl"). Said C2-Cio-alkynyl group is, for example, ethynyl, prop-1 -ynyl, prop-2-ynyl, but-1 -ynyl, but-2-ynyl, but-3-ynyl, pent-1 -ynyl, pent-2-ynyl, pent-3-ynyl, pent-4-ynyl, hex-1 -ynyl, hex-2-ynyl, hex-3-ynyl, hex-4-ynyl, hex-5-ynyl, 1 -methylprop-2-ynyl, 2-methylbut-3-ynyl, 1 -methylbut-3-ynyl, 1 -methylbut-2-ynyl, 3-methylbut-1 -ynyl,
1 -ethylprop-2-ynyl, 3-methylpent-4-ynyl, 2-methylpent-4-ynyl, 1 -methyl- pent-4-ynyl, 2-methylpent-3-ynyl, 1 -methylpent-3-ynyl, 4-methylpent-2-ynyl,
1 - methylpent-2-ynyl, 4-methylpent-1 -ynyl, 3-methylpent-1 -ynyl,
2- ethylbut-3-ynyl, 1 -ethylbut-3-ynyl, 1 -ethylbut-2-ynyl, 1 -propylprop-2-ynyl, 1 -isopropylprop-2-ynyl, 2,2-dimethylbut-3-ynyl, 1 , 1 -dimethylbut-3-ynyl, 1 , 1 -dimethylbut-2-ynyl, or 3,3-dimethylbut-1 -ynyl group. Particularly, said alkynyl group is ethynyl, prop- 1 -ynyl, or prop-2-ynyl.
The term "C3-Cio-cycloalkyl" is to be understood as meaning a saturated, monovalent, mono-, or bicyclic hydrocarbon ring which contains 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms ("C3-Cio-cycloalkyl"). Said C3-Go-cycloalkyl group is for example, a monocyclic hydrocarbon ring, e.g. a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl or cyclodecyl, or a bicyclic hydrocarbon ring, e.g. a perhydropentalenylene or decalin ring. Particularly, said ring contains 3, 4, 5 or 6 carbon atoms ("C3-C6-cycloalkyl").
The term "C3-C6-cycloalkyloxy" refers to a (C3-C&-cycloalkyl)-0- group in which "C3-C&-cycloalkyl" is as defined herein. Examples include, but are not limited to, cyclopropanoxy and cyclobutanoxy.
The term "C -Cio-cycloalkenyl" is to be understood as preferably meaning a non-aromatic, monovalent, mono-, or bicyclic hydrocarbon ring which contains 4, 5, 6, 7, 8, 9 or 10 carbon atoms and one, two, three or four double bonds, in conjugation or not, as the size of said cycloalkenyl ring allows. Said C4-Cio-cycloalkenyl group is for example, a monocyclic hydrocarbon ring, e.g. a cyclobutenyl, cyclopentenyl, or cyclohexenyl or a bicyclic hydrocarbon, e.g.
Figure imgf000014_0001
The term "Cs-Cs-cycloalkenyloxy" refers to a (Cs-Cs-cycloalkenylJ-O- group in which "C5-C8-cycloalkenyl" is as defined herein.
The term "3- to 10-membered heterocycloalkyl", is to be understood as meaning a saturated, monovalent, mono- or bicyclic hydrocarbon ring which contains 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, and one or more heteroatom-containing groups selected from: -C(=0)-, -0-, -S-, -S(=0)-,
-S(=0)2-, -N(Ra)-, in which Ra represents a hydrogen atom or a Ci-C6-alkyl- group ; it being possible for said heterocycloalkyl group to be attached to the rest of the molecule via any one of the carbon atoms or, if present, the nitrogen atom.
Particularly, said 3- to 10-membered heterocycloalkyl can contain 2, 3, 4, or 5 carbon atoms, and one or more of the above-mentioned heteroatom-containing groups (a "3- to 6-membered heterocycloalkyl"), more particularly said heterocycloalkyl can contain 4 or 5 carbon atoms, and one or more of the above-mentioned heteroatom-containing groups (a "5- to 6-membered heterocycloalkyl"). Particularly, without being limited thereto, said heterocycloalkyl can be a 4-membered ring, such as an azetidinyl, oxetanyl, or a 5-membered ring, such as tetrahydrofuranyl, dioxolinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, or a 6-membered ring, such as tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, or trithianyl, or a 7-membered ring, such as a diazepanyl ring, for example.
Said heterocycloalkyl can be bicyclic, such as, without being limited thereto, a
5.5- membered ring, e.g. a hexahydrocyclopenta[c]pyrrol-2(1 H)-yl ring, or a
5.6- membered bicyclic ring, e.g. a hexahydropyrrolo[1 ,2-a]pyrazin-2(1 H)-yl ring.
Said heterocycloalkyl can be spirocyclic, such as, without being limited thereto, e.g. a 2-oxa-6-azaspiro[3.3]heptane ring or a 2-oxa-6- azaspiro[3.4]octane ring or a 2-oxa-7-azaspiro[4.4]nonane ring. The term "4- to 10-membered heterocycloalkenyl", is to be understood as meaning an non-aromatic, unsaturated, monovalent, mono- or bicyclic hydrocarbon ring which contains 3, 4, 5, 6, 7, 8 or 9 carbon atoms, and one or more heteroatom-containing groups selected from:
-C(=0)-, -0-, -S-, -S(=0)-, -S(=0)2-, -N(Ra)-, in which Ra represents a hydrogen atom or a Ci-C&-alkyl- group ; it being possible for said heterocycloalkenyl group to be attached to the rest of the molecule via any one of the carbon atoms or, if present, the nitrogen atom. Examples of said heterocycloalkenyl are e.g. 4H-pyranyl, 2H-pyranyl, 3H-diazirinyl, 2,5-dihydro-1 H-pyrrolyl, [1 ,3]dioxolyl, 4H-[1 ,3,4]thiadiazinyl, 2,5-dihydrofuranyl, 2,3-dihydrofuranyl, 2,5-dihydrothiophenyl, 2,3-dihydrothiophenyl, 4,5-dihydrooxazolyl, or 4H-[1 ,4]thiazinyl group.
The term "heterocyclic ring", as used in the term "4-, 5- or 6- membered heterocyclic ring", or "4- to 6-membered heterocyclic ring" or "4- to 5- membered heterocyclic ring", for example, as used in the definition of compounds of general formula (I) as defined herein, is to be understood as meaning a saturated, partially unsaturated or aromatic monocyclic hydrocarbon ring which contains 1 , 2, 3, 4 or 5 carbon atoms, and one or more heteroatom-containing groups selected from -C(=0)-, -0-, -S-, -S(=0)-,
-S(=0)z-, =N-,-N(H)-, -N(R")-, wherein R" represents a d-C6-alkyl, C3-C6- cycloalkyl, -C(=0)-(Ci-C6-alkyl) or -C(=0)-(Ci-C6-cycloalkyl) group.
The term "aryl" is to be understood as preferably meaning a monovalent, aromatic or partially aromatic, mono-, or bi- or tricyclic hydrocarbon ring having 6, 7, 8, 9, 10, 1 1 , 12, 13 or 14 carbon atoms (a "C&-Ci4-aryl" group), particularly a ring having 6 carbon atoms (a "Ce-aryl" group), e.g. a phenyl group; or a biphenyl group, or a ring having 9 carbon atoms (a "Cg-aryl" group), e.g. an indanyl or indenyl group, or a ring having 10 carbon atoms (a "Cio-aryl" group), e.g. a tetralinyl, dihydronaphthyl, or naphthyl group, or a ring having 13 carbon atoms, (a "Ci3-aryl" group), e.g. a fluorenyl group, or a ring having
14 carbon atoms, (a "Ci4-aryl" group), e.g. an anthranyl group. Preferably, the aryl group is a phenyl group. The term "heteroaryl" is understood as preferably meaning a monovalent, monocyclic, bicyclic or tricyclic aromatic ring system having 5, 6, 7, 8, 9, 10, 11 , 12, 13 or 14 ring atoms (a "5- to 14-membered heteroaryl" group), particularly 5 or 6 or 9 or 10 atoms, and which contains at least one heteroatom which may be identical or different, said heteroatom being such as oxygen, nitrogen or sulfur, and in addition in each case can be benzocondensed. Particularly, heteroaryl is selected from thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, thia-4H-pyrazolyl etc., and benzo derivatives thereof, such as, for example, benzofuranyl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, benzotriazolyl, indazolyl, indolyl, isoindolyl, etc.; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, etc., and benzo derivatives thereof, such as, for example, quinolinyl, quinazolinyl, isoquinolinyl, etc.; or azocinyl, indolizinyl, purinyl, etc. , and benzo derivatives thereof; or cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthpyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, xanthenyl, or oxepinyl, etc..
The term "d-d", as used throughout this text, e.g. in the context of the definition of "d-d-alkyl", "Ci-C6-haloalkyl", "C C6-alkoxy", or "CrC6-haloalkoxy" is to be understood as meaning an alkyl group having a finite number of carbon atoms of 1 to 6, i.e. 1 , 2, 3, 4, 5, or 6 carbon atoms. It is to be understood further that said term "Ci-C6" is to be interpreted as any sub-range comprised therein, e.g. d-d , C2-d , C3-C4, Ci-C2, C1-C3 , Ci-C4, C1-C5 ; particularly C1-C2 , C C3 , Ci-C , C1-C5, d-d; more particularly d-C4 ; in the case of "d-Ce-haloalkyl" or "Ci-C6-haloalkoxy" even more particularly Ci-C2. Similarly, as used herein, the term "d-Ce", as used throughout this text, e.g. in the context of the definitions of "C2-C6-alkenyl" and "C2-C6-alkynyl", is to be understood as meaning an alkenyl group or an alkynyl group having a finite number of carbon atoms of 2 to 6, i.e. 2, 3, 4, 5, or 6 carbon atoms. It is to be understood further that said term "C2-C6" is to be interpreted as any sub-range comprised therein, e.g. G-Ce , C3-C5 , C3-C4 , C2-C3 , C2-C4 , C2-Cs ; particularly C2-C3. Further, as used herein, the term "C3-C&", as used throughout this text, e.g. in the context of the definition of "C3-C&-cycloalkyl", is to be understood as meaning a cycloalkyl group having a finite number of carbon atoms of 3 to 6, i.e. 3, 4, 5 or 6 carbon atoms. It is to be understood further that said term "CrCe" is to be interpreted as any sub-range comprised therein, e.g. C3-C& , C4-Cs , C3-C5 , C3-C4 , C4-C&, C5-C& ; particularly C3-C&.
The term "substituted" means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
The term "optionally substituted" means optional substitution with the specified groups, radicals or moieties.
As used herein, the term "leaving group" refers to an atom or a group of atoms that is displaced in a chemical reaction as stable species taking with it the bonding electrons. Preferably, a leaving group is selected from the group comprising: halo, in particular chloro, bromo or iodo, methanesulfonyloxy, p-toluenesulfonyloxy, trifluoromethanesulfonyloxy,
nonafluorobutanesulfonyloxy, (4-bromo-benzene)sulfonyloxy, (4-nitro- benzene)sulfonyloxy, (2-nitro-benzene)-sulfonyloxy, (4-isopropyl- benzene)sulfonyloxy, (2,4,6-tri-isopropyl-benzene)-sulfonyloxy,
(2,4,6-trimethyl-benzene)sulfonyloxy, (4-tertbutyl-benzene)sulfonyloxy, benzenesulfonyloxy, and (4-methoxy-benzene)sulfonyloxy.
As used herein, the term "protective group" is a protective group attached to a nitrogen in intermediates used for the preparation of compounds of the general formula I. Such groups are introduced e.g. by chemical modification of the respective amino group in order to obtain chemoselectivity in a subsequent chemical reaction. Protective groups for amino groups are descibed for example in T.W. Greene and P.G.M. Wuts in Protective Groups in Organic Synthesis, 3rd edition, Wiley 1999; more specifically, said groups can be selected from substituted sulfonyl groups, such as mesyl-, tosyl- or phenylsulfonyl-, acyl groups such as benzoyl, acetyl or tetrahydropyranoyl-, or carbamate based groups, such as tert. -butoxycarbonyl (Boc), or can include silicon, as in e.g. 2-(trimethylsilyl)ethoxymethyl (SEM). As used herein, the term "one or more", e.g. in the definition of the substituents of the compounds of the general formulae of the present invention, is understood as meaning "one, two, three, four or five, particularly one, two, three or four, more particularly one, two or three, even more particularly one or two".
The invention also includes all suitable isotopic variations of a compound of the invention. An isotopic variation of a compound of the invention is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually or predominantly found in nature. Examples of isotopes that can be incorporated into a compound of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine, chlorine, bromine and iodine, such as 2H (deuterium), 3H (tritium), 11C, 13C, 14C, 1 N, 170, 180, 32P, 33P, 33S, 34S, 3 S, 36S, 18F, 36Cl, 82Br, 123l, 124l, 129l and 1311, respectively. Certain isotopic variations of a compound of the invention, for example, those in which one or more radioactive isotopes such as 3H or 14C are incorporated, are useful in drug and/or substrate tissue distribution studies. Tritiated and carbon-14, i.e. , 14C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements and hence may be preferred in some circumstances. Isotopic variations of a compound of the invention can generally be prepared by conventional procedures known by a person skilled in the art such as by the illustrative methods or by the preparations described in the examples hereafter using appropriate isotopic variations of suitable reagents.
Where the plural form of the word compounds, salts, polymorphs, hydrates, solvates and the like, is used herein, this is taken to mean also a single compound, salt, polymorph, isomer, hydrate, solvate or the like.
By "stable compound' or "stable structure" is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
The compounds of this invention may contain one or more asymmetric centre, depending upon the location and nature of the various substituents desired. Asymmetric carbon atoms may be present in the (R) or (S) configuration, resulting in racemic mixtures in the case of a single asymmetric centre, and diastereomeric mixtures in the case of multiple asymmetric centres. In certain instances, asymmetry may also be present due to restricted rotation about a given bond, for example, the central bond adjoining two substituted aromatic rings of the specified compounds.
The compounds of the present invention may contain sulphur atoms which are asymmetric, such as an asymmetric sulphoxide or sulphoximine group, of structure:
Figure imgf000021_0001
for example, in which * indicates atoms to which the rest of the molecule can be bound. Substituents on a ring may also be present in either cis or trans form. It is intended that all such configurations (including enantiomers and diastereomers), are included within the scope of the present invention.
Preferred compounds are those which produce the more desirable biological activity. Separated, pure or partially purified isomers and stereoisomers or racemic or diastereomeric mixtures of the compounds of this invention are also included within the scope of the present invention. The purification and the separation of such materials can be accomplished by standard techniques known in the art.
Pure stereoisomers can be obtained by resolution of racemic mixtures according to conventional processes, for example, by the formation of diastereoisomeric salts using an optically active acid or base or formation of covalent diastereomers. Examples of appropriate acids are tartaric, diacetyltartaric, ditoluoyltartaric and camphorsulfonic acid. Mixtures of diastereoisomers can be separated into their individual diastereomers on the basis of their physical and/or chemical differences by methods known in the art, for example, by chromatography or fractional crystallisation. The optically active bases or acids are then liberated from the separated diastereomeric salts. A different process for separation of optical isomers involves the use of chiral chromatography {e.g. , chiral HPLC columns), with or without conventional derivatisation, optimally chosen to maximise the separation of the enantiomers. Suitable chiral HPLC columns are manufactured by Daicel, e.g. , Chiracel OD and Chiracel OJ among many others, all routinely selectable. Enzymatic separations, with or without derivatisation, are also useful. The optically active compounds of this invention can likewise be obtained by chiral syntheses utilizing optically active starting materials.
In order to limit different types of isomers from each other reference is made to lUPAC Rules Section E (Pure Appl Chem 45, 1 1 -30, 1976). The present invention includes all possible stereoisomers of the compounds of the present invention as single stereoisomers, or as any mixture of said stereoisomers, e.g. (/?) or (S) isomers, or (£) or (Z) isomers, in any ratio. Isolation of a single stereoisomer, e.g. a single enantiomer or a single diastereomer, of a compound of the present invention may be achieved by any suitable state of the art method, such as chromatography, especially chiral chromatography, for example.
Further, the compounds of the present invention may exist as tautomers. For example, any compound of the present invention which contains a pyrazole moiety as a heteroaryl group for example can exist as a 1 H tautomer, or a 2H tautomer, or even a mixture in any amount of the two tautomers, or a triazole moiety for example can exist as a 1 H tautomer, a 2H tautomer, or a 4H tautomer, or even a mixture in any amount of said 1 H, 2H and 4H tautomers, namely :
Figure imgf000023_0001
1 H-tautomer 2H-tautomer 4H-tautomei
The present invention includes all possible tautomers of the compounds of the present invention as single tautomers, or as any mixture of said tautomers, in any ratio.
Further, the compounds of the present invention can exist as N -oxides, which are defined in that at least one nitrogen of the compounds of the present invention is oxidised. The present invention includes all such possible N-oxides.
The present invention also relates to useful forms of the compounds as disclosed herein, such as metabolites, hydrates, solvates, salts, in particular pharmaceutically acceptable salts, and co-precipitates.
The compounds of the present invention can exist as a hydrate, or as a solvate, wherein the compounds of the present invention contain polar solvents, in particular water, methanol or ethanol for example as structural element of the crystal lattice of the compounds. The amount of polar solvents, in particular water, may exist in a stoichiometric or non-stoichiometric ratio. In the case of stoichiometric solvates, e.g. a hydrate, hemi-, (semi-), mono-, sesqui-, di-, tri-, tetra-, penta- etc. solvates or hydrates, respectively, are possible. The present invention includes all such hydrates or solvates.
Further, the compounds of the present invention can exist in free form, e.g. as a free base, or as a free acid, or as a zwitterion, or can exist in the form of a salt. Said salt may be any salt, either an organic or inorganic addition salt, particularly any pharmaceutically acceptable organic or inorganic addition salt, customarily used in pharmacy. The term "pharmaceutically acceptable salt" refers to a relatively non-toxic, inorganic or organic acid addition salt of a compound of the present invention. For example, see S. M. Berge, et al. "Pharmaceutical Salts," J. Pharm. Sci. 1977, 66, 1 -19.
A suitable pharmaceutically acceptable salt of the compounds of the present invention may be, for example, an acid-addition salt of a compound of the present invention bearing a nitrogen atom, in a chain or in a ring, for example, which is sufficiently basic, such as an acid-addition salt with an inorganic acid, such as hydrochloric, hydrobromic, hydroiodic, sulfuric, bisulfuric, phosphoric, or nitric acid, for example, or with an organic acid, such as formic, acetic, acetoacetic, pyruvic, trifluoroacetic, propionic, butyric, hexanoic, heptanoic, undecanoic, lauric, benzoic, salicylic, 2-(4-hydroxybenzoyl)-benzoic, camphoric, cinnamic, cyclopentanepropionic, digluconic, 3-hydroxy-2-naphthoic, nicotinic, pamoic, pectinic, persulfuric, 3-phenylpropionic, picric, pivalic, 2-hydroxyethanesulfonate, itaconic, sulfamic, trifluoromethanesulfonic, dodecylsulfuric, ethansulfonic, benzenesulfonic, para-toluenesulfonic, methansulfonic, 2-naphthalenesulfonic, naphthalinedisulfonic, camphorsulfonic acid, citric, tartaric, stearic, lactic, oxalic, malonic, succinic, malic, adipic, alginic, maleic, fumaric, D-gluconic, mandelic, ascorbic, glucoheptanoic, glycerophosphoric, aspartic, sulfosalicylic, hemisulfuric, or thiocyanic acid, for example.
Further, another suitably pharmaceutically acceptable salt of a compound of the present invention which is sufficiently acidic, is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically acceptable cation, for example a salt with N-methyl-glucamine, dimethyl-glucamine, ethyl-glucamine, lysine, dicyclohexylamine, 1 ,6-hexadiamine, ethanolamine, glucosamine, sarcosine, serinol, tris-hydroxy-methyl-aminomethane, aminopropandiol, sovak-base, 1 -amino-2,3,4-butantriol, or with a quarternary ammonium salt, such as tetramethylammonium, tetraethylammonium, tetra(n-propyl)ammonium, tetra (n-butyl)ammonium, or A/-benzyl- N,N,N-trimethylammonium. Those skilled in the art will further recognise that acid addition salts of the claimed compounds may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods. Alternatively, alkali and alkaline earth metal salts of acidic compounds of the invention are prepared by reacting the compounds of the invention with the appropriate base via a variety of known methods.
The present invention includes all possible salts of the compounds of the present invention as single salts, or as any mixture of said salts, in any ratio.
Furthermore, the present invention includes all possible crystalline forms, or polymorphs, of the compounds of the present invention, either as single polymorphs, or as a mixture of more than one polymorphs, in any ratio.
In accordance with a first aspect, the present invention covers compounds of general formula (I) :
Figure imgf000025_0001
in which :
A is selected from:
Figure imgf000025_0002
Figure imgf000026_0001
wherein * represents the point of attachment to the nitrogen atom and ** represents the point of attachment to the R1 group; represents a phenyl- group
- which is substituted, one or more times, identically or differently, wil a substituent selected from :
-OH, -N(H)C(=0)R6, -N(R7)C(=0)R6, -N(H)C(=0)NR6R7,
-N(R7)C(=0)NR6R7, -NH2, -NR6R7, -C(=0)N(H)R6, -C(=0)NR6R7;
and
- which is optionally substituted, one or more times, identically or differently, with a Ci-C&-alkyl- group ; represents a hydrogen atom or a group selected from phenyl-, pyridyl-; said group being substituted, one or more times, identically or differently, with a substituent selected from :
halo-, hydroxy-, cyano-, nitro-, Ci-C&-alkyl-,
halo-Ci-C&-alkyl-, Ci-C&-alkoxy-, halo-Ci-C6-alkoxy-,
hydroxy-d-Ce-alkyl-, CrCe-alkoxy-d-Ce-alkyl-,
halo-CrCe-alkoxy-CrCe-alkyl-,
R9-, R9-(CrC6-alkyl)-, R9-(CH2)n(CHOH)(CH2)m-, R9-(d-C6-alkoxy)-, R9-(CH2)n(CHOH)(CH2)p-0-, R9-(Ci-C6-alkoxy-Ci-C6-alkyl)-,
R9-(Ci-C6-alkoxy-Ci-C6-alkyl)-0-, -0-(CH2)n-C(=0)NR9R7, R9-0-, -C(=0)R9, -C(=0)0-R9, -OC(=0)-R9, -N(H)C(=0)R9, -N(R7)C(=0)R9, -N(H)C(=0)NR9R7, -N(R7)C(=0)NR9R7, -NR9R7, -C(=0)N(H)R9, -C(=0)NR9R7, R9-S-, R9-S(=0)-, R9-S(=0)2-, -N(H)S(=0)R9, -N(R7)S(=0)R9, -S(=0)N(H)R9, -S(=0)NR9R7, -N(H)S(=0)2R9, -N(R7)S(=0)2R9, -S(=0)2N(H)R9, -S(=0)2NR9R7, -S(=0)(=NR9)R7, -S(=0)(=NR7)R9 or -N=S(=0)(R9)R7 ;
re resents a group selected from
Figure imgf000027_0001
wherein * indicates the point of attachment of said group with the rest of the molecule; represents a 4- to 6-membered heterocyclic ring; which is optionally substituted, one or more times, identically or differently, with halo-, -CN, -OH, nitro-, Ci-C&-alkyl-, halo-G-Ce-alkyl-, Ci-C&-alkoxy-,
halo-Ci -Ce-alkoxy- , hydroxy-G -C&-alkyl- ,
CrCe-alkoxy-d-Ce-alkyl-, halo-Ci-C6-alkoxy-Ci-C&-alkyl-,
R8-(CrC6-alkoxy)-, R8-0-, -NR8R7, R8-S-, R8-S(=0)-, R8-S(=0)2-,
(C3-C6-cycloalkyl)-(CH2)n-0-; represents a 4- to 6-membered heterocyclic ring; which is optionally substituted, one or more times, identically or differently, with halo-, -CN, -OH, nitro-, Ci-C6-alkyl-, halo-Ci-C&-alkyl-, G-Ce-alkoxy-,
halo-CrCe-alkoxy-, hydroxy-G-Ce-alkyl-,
CrCe-alkoxy-CrCe-alkyl-, halo-Ci-C6-alkoxy-Ci-C6-alkyl-,
R8-(CrC6-alkoxy)-, R8-0-, -NR8R7, R8-S-, R8-S(=0)-, R8-S(=0)2-,
(C3-C6-cycloalkyl)-(CH2)n-0-; each R5a
independently represents a group selected from:
halo-, cyano-, nitro-, Ci-C&-alkyl-, halo-Ci-C&-alkyl-, Ci-C&-alkoxy-, halo-CrCe-alkoxy-, hydroxy-G-Ce-alkyl-, CrCe-alkoxy-d-Ce-alkyl-, halo-Ci-C6-alkoxy-Ci-C6-alkyl-, R8-(Ci-C6-alkoxy)-, R8-0-, -NR8R7, R8-S-, R8-S(=0)-, R8-S(=0)2-, (C3-C6-cycloalkyl)-(CH2)n-0-; represents a group selected from :
Ci-C&-alkyl-, C3-C&-cycloalkyl-, 3- to 10-membered heterocycloalkyl-, aryl-, heteroaryl-, -(CH2)q-(C3-C6-cycloalkyl),-(CH2)q-heteroaryl,
-(CH2)q-(3- to 10-membered heterocycloalkyl), -(CHz)q-aryl ;
said group being optionally substituted, one or more times, identically or differently, with a substituent selected from :
halo-, hydroxy-, cyano-, nitro-, CrC6-alkyl-, halo-Ci-C&-alkyl-,
CrC6-alkoxy-, halo-G-Ce-alkoxy-, hydroxy-Ci-C6-alkyl-,
CrCe-alkoxy-d-Ce-alkyl-, halo-Ci-C6-alkoxy-CrC6-alkyl-,
R8-(CrC6-alkyl)-, R8-(CH2)n(CHOH)(CH2)m-, R8-(C C6-alkoxy)-,
R8-(CH2)n(CHOH)(CH2)p-0-, R8-(Ci-C6-alkoxy-Ci-C6-alkyl)-,
R8-(Ci-C6-alkoxy-Ci-C6-alkyl)-0-, aryl-, R8-0-, -C(=0)R8, -C(=0)0-R8, -OC(=0)-R8, -N(H)C(=0)R8, -N(R7)C(=0)R8, -N(H)C(=0)NR8R7,
-N(R7)C(=0)NR8R7, -NR8R7 , -C(=0)N(H)R8, -C(=0)NR8R7, R8-S-, R8-S(=0)-, R8-S(=0)2-, -N(H)S(=0)R8, -N(R7)S(=0)R8, -S(=0)N(H)R8, -S(=0)NR8R7, -N(H)S(=0)2R8, -N(R7)S(=0)2R8, -S(=0)2N(H)R8, -S(=0)2NR8R7,
-S(=0)(=NR8)R7,-S(=0)(=NR7)R8, -N=S(=0)(R8)R7 ;
R7 represents a hydrogen atom, a G-C6-alkyl-, or C3-C6-cycloalkyl- group ; or
6 and R7,
together with the nitrogen atom to which they are attached, represent a 3- to 10-membered heterocycloalkyl- group ; R8 represents a hydrogen atom, a d-Ca-alkyl- or C3-C&-cycloalkyl- group ;
R9 represents a Ci -C&-alkyl- or C3-C&-cycloalkyl- group ;
or
R9 and R7,
together with the nitrogen atom to which they are attached,
represent a 3- to 10-membered heterocycloalkyl- group;
which is optionally substituted with a halogen atom, preferably with fluoro; n, m, p
represent, independently from each other, an integer of 0, 1 , 2, 3, 4, or 5 ;
q represents an integer of 0, 1 , 2 or 3 ;
and
t represents an integer of 0, 1 or 2 ; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.
In a preferred embodiment, the invention relates to compounds of formula (I), wherein :
A represents:
Figure imgf000029_0001
wherein * represents the point of attachment to the nitrogen atom and
** represents the point of attachment to the R1 group. In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
A represents:
Figure imgf000030_0001
wherein * represents the point of attachment to the nitrogen atom and ** represents the point of attachment to the R1 group.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
A re resents:
Figure imgf000030_0002
wherein * represents the point of attachment to the nitrogen atom and ** represents the point of attachment to the R1 group. In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
A represents:
Figure imgf000030_0003
wherein * represents the point of attachment to the nitrogen atom and ** represents the point of attachment to the R group.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
A represents:
Figure imgf000031_0001
wherein * represents the point of attachment to the nitrogen atom and ** represents the point of attachment to the R1 group.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
A represents:
Figure imgf000031_0002
wherein * represents the point of attachment to the nitrogen atom and ** represents the point of attachment to the R1 group.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
A re resents:
Figure imgf000031_0003
wherein * represents the point of attachment to the nitrogen atom and ** represents the point of attachment to the R1 group.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
R1 represents a phenyl group
- which is substituted, one or more times, identically or differently, with a substituent selected from : -OH, -N(H)C(=0)R6, -NH2, -C(=0)N(H)R6;
and
- which is optionally substituted, one or more times, identically or differently, with a Ci-C&-alkyl- group.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
R1 represents a phenyl group
- which is substituted, one or more times, identically or differently, with a substituent selected from :
-N(H)C(=0)R6, -C(=0)N(H)R6.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
R1 represents
Figure imgf000032_0001
wherein * indicates the point of attachment of said group with the rest of the molecule;
R10 represents a group selected from: Ci-C3-alkyl-, hydroxy-CrC3-alkyl-, N(H)(R8)-CrC3-alkyl-; and
R6a represents a
Figure imgf000032_0002
group ;
wherein * indicates the point of attachment of said group with the rest of the molecule ;
wherein said group is optionally substituted, one or more times, identically or differently, with a halogen atom or a methyl- group. In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
R1 represents
Figure imgf000033_0001
wherein * indicates the point of attachment of said group with the rest of the molecule.
In a preferred embodiment, the invention relates to compounds of formula (I), wherein :
R2 represents a phenyl group or a pyridyl group
- which is substituted, one or more times, identically or differently, with a substituent selected from :
halo-, hydroxy-, cyano-, nitro-, CrC&-alkyl-,
halo-d-Ce-alkyl-, G-Ce-alkoxy-, halo-d-Ce-alkoxy-,
hydroxy-d-Ce-alkyl-, G-Ce-alkoxy-G-Ce-alkyl-,
halo-Ci-C6-alkoxy-CrC6-alkyl-,
-C(=0)R9, -C(=0)0-R9, -OC(=0)-R9, -N(H)C(=0)R9, -N(R7)C(=0)R9,
-N(H)C(=0)NR9R7, -N(R7)C(=0)NR9R7, -NR9R7, -C(=0)N(H)R9, -C(=0)NR9R7, R9-S-, R9-S(=0)-, R9-S(=0)2-, -N(H)S(=0)R9, -N(R7)S(=0)R9, -S(=0)N(H)R9,
-S(=0)NR9R7, -N(H)S(=0)2R9, -N(R7)S(=0)2R9, -S(=0)2N(H)R9, -S(=0)2NR9R7, -S(=0)(=NR9)R7, -S(=0)(=NR7)R9 or -N=S(=0)(R )R7.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
R2 represents a phenyl group - which is substituted, one or more times, identically or differently, with a substituent selected from :
halo-, hydroxy-, cyano-, nitro-, Ci-C&-alkyl-,
halo-Ci-C&-alkyl-, Ci-C&-alkoxy-, halo-Ci-C&-alkoxy-,
hydroxy-CrC6-alkyl-, CrCe-alkoxy-d-Ce-alkyl-,
halo-Ci-C6-alkoxy-CrC6-alkyl-,
-C(=0)R9, -C(=0)0-R9, -OC(=0)-R9, -N(H)C(=0)R9, -N(R7)C(=0)R9,
-N(H)C(=0)NR9R7, -N(R7)C(=0)NR9R7, -NR9R7, -C(=0)N(H)R9, -C(=0)NR9R7, R9-S-, R9-S(=0)-, R9-S(=0)2-, -N(H)S(=0)R9, -N(R7)S(=0)R9, -S(=0)N(H)R9, -S(=0)NR9R7, -N(H)S(=0)2R9, -N(R7)S(=0)2R9, -S(=0)2N(H)R9, -S(=0)2NR9R7,
-S(=0)(=NR9)R7, -S(=0)(=NR7)R9 or -N=S(=0)(R9)R7.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
R2 represents a phenyl group
- which is substituted, one or more times, identically or differently, with a substituent selected from :
halo-, cyano-, C C&-alkoxy-, hydroxy-G-Ce-alkyl-, -NR9R7, -C(=0)NR9R7, R9-S(=0)2-.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
R2 represents
Figure imgf000034_0001
wherein * indicates the point of attachment of said group with the rest of the molecule;
represents a group selected from: CrC4-alkoxy-, halo-Ci-C4-alkoxy-, CrC4-alkyl ;
represents a group selected from: -C(=0)N(H)R9, -C(=0)NR9R7,
-NR9R7, R9-S(=0)2- ;
represents CH or N;
represents CH or N;
with the proviso that Q1 represents CH if Q2 represents N, and Q2 represents CH if Q.1 represents N.
In another preferred embodiment, the invention relates to compounds formula (I), wherein :
Figure imgf000035_0001
wherein * indicates the point of attachment of said group with of the molecule;
R a represents a group selected from:
CrC4-alkoxy-, preferably methoxy, -CN;
R! 5b represents a hydrogen atom or a group selected from:
-NR9R7, -C(=0)NR9R7, R7-S(=0)2-, hydroxy-d-C6-alkyl- ;
R! 5c represents halo, preferably fluoro;
represents CH or N;
represents CH or N;
with the proviso that Q1 represents CH if Q2 represents N, and Q2 represents CH if Q1 represents N.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein : R2 represents
Figure imgf000036_0001
wherein * indicates the point of attachment of said group with the rest of the molecule;
R! 5a represents a group selected from: Ci-C4-alkoxy-, halo-Ci-C4-alkoxy-, CrC4-alkyl ;
R' 5b represents a group selected from: -C(=0)N(H)R9, -C(=0)NR9R7,
-NR9R7, R9-S(=0)2- .
In another preferred embodiment, the invention relates to compounds of formula (I ), wherein :
Figure imgf000036_0002
wherein * indicates the point of attachment of said group with the rest of the molecule;
R a represents a group selected from:
CrC4-alkoxy-, preferably methoxy, -CN;
R b represents a hydrogen atom or a group selected from:
-NR9R7, -C(=0)NR9R7, R7-S(=0)2-, hydroxy-Ci-C6-alkyl- ; R c represents halo, preferably fluoro. In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
R2 represents a group selected from:
Figure imgf000037_0001
wherein * indicates the point of attachment of said group with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
R2 re resents a group selected from:
Figure imgf000037_0002
wherein * indicates the point of attachment of said group with the rest of the molecule. In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
R2 represents
Figure imgf000037_0003
wherein * indicates the point of attachment of said group with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein R2 represents:
Figure imgf000038_0001
wherein * indicates the point of attachment of said group with the rest of the molecule. In another preferred embodiment, the invention relates to compounds of formula I), wherein R2 is selected from:
Figure imgf000038_0002
wherein * indicates the point of attachment of said groups with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula I), wherein R2 is selected from:
Figure imgf000039_0001
wherein * indicates the point of attachment of said groups with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula I), wherein R2 is selected from:
Figure imgf000039_0002
wherein * indicates the point of attachment of said groups with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein R2 represents:
Figure imgf000040_0001
wherein * indicates the point of attachment of said groups with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula I), wherein R2 represents a group selected from:
Figure imgf000040_0002
wherein * indicates the point of attachment of said group with the rest of the molecule. In another preferred embodiment, the invention relates to compounds of formula (I), wherein B represents a 5- to 6-membered heterocyclic ring; which is optionally, one or more times, identically or differently, substituted with Ci-C3-alkyl-, halo-Ci-C3-alkyl-.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein B represents a 5- to 6-membered heterocyclic ring.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein B represents a 5-membered heterocyclic ring.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein C represents a 5- to 6-membered heterocyclic ring; which is optionally substituted, one or more times, identically or differently, with halo-, -CN, -OH, Ci-C3-alkyl-, halo-d-C3-alkyl-, Ci-C3-alkoxy-,
halo-CrC3-alkoxy-, hydroxy-G-C3-alkyl-,
Ci-C3-alkoxy-Ci-C3-alkyl-, halo-Ci-C3-alkoxy-Ci-C3-alkyl-, R8-(Ci-C3-alkoxy)-, R8-0-, -NR8R7, R8-S-, R8-S(=0)-, R8-S(=0)2-, (C3-C6-cycloalkyl)-(CH2)n-0-. In another preferred embodiment, the invention relates to compounds of formula (I), wherein C represents a 5- to 6-membered heterocyclic ring; which is optionally, one or more times, identically or differently, substituted with CrC3-alkyl-, halo-Ci-C3-alkyl-. In another preferred embodiment, the invention relates to compounds of formula (I), wherein C represents a 5- to 6-membered heterocyclic ring.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein C represents a 5-membered heterocyclic ring. In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
t = 1 ; and
R a represents a group selected from:
halo-, Ci-C6-alkyl-,CrC6-alkoxy-, halo-d-Ce-alkoxy-,
hydroxy-Ci-C&-alkyl-, CrC6-alkoxy-Ci-C6-alkyl-,
halo-CrCe-alkoxy-d-Ce-alkyl-, R8-(Ci-C6-alkoxy)-, R8-0-, R8-S-,
R8-S(=0)2-, (C3-C6-cycloalkyl)-(CH2)n-0-.
Preferably, R a is selected from:
halo-, CrC&-alkyl-, d-Ce-alkoxy-, halo-Ci-C&-alkoxy-,
Ci-C6-alkoxy-Ci-C6-alkyl-,
(C3-C6-cycloalkyl)-(CH2)n-0-.
More preferably, R a is selected from:
F-, methyl-, methoxy-, ethoxy-, n-propoxy-, iso-propoxy-,
cyclopropyl-O-, cyclopropyl-CH2-0-, CH3-0-CH2CH2-0-, CHF2-0-, CF3-0-,
CF3CH2-0-.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
t = 1 ; and
R a represents a Ci-C6-alkoxy- group.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
t = 1 ; and
R a represents a Ci-C3-alkoxy- group.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
t = 1 ; and R5a represents a halo-G-C6-alkoxy- group.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
t = 1 ; and
R a represents a halo-CrC3-alkoxy- group.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
t = 1 ; and
R a represents a (C3-C6-cycloalkyl)-(CH2)n-0- group.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein t = 1 , and R a represents a group selected from: CrC3-alkoxy-, halo-Ci-C3-alkoxy-, Ci-C3-alkyl-.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein t = 1 , and R5a represents a group selected from: CrC2-alkoxy-, halo-Ci-C2-alkoxy-, G-C2-alkyl-.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein t = 1 , and R a represents a group selected from: CrC3-alkoxy-, halo-G-C3-alkoxy-. In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein t = 1 , and R a represents a group selected from: CrC2-alkoxy-, halo-G-C2-alkoxy-.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein t = 1 , and R a represents a methoxy- or ethoxy- group which is optionally substituted, one or more times, identically or differently, with a halogen atom. The preferred halogen atom is F.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein t = 1 , and R5a represents a group selected from: methoxy-, ethoxy-, F3C-CH2-O-.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein t = 1 , and R5a represents a group selected from: methoxy-, F3C-CH2-O-.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein t = 1 , and R5a represents methoxy-. In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein t = 1 , and R a represents F3C-CH2-O-.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R represents a group selected from:
-C(=0)N(H)R9, -C(=0)NR9R7, -NR9R7, R9-S(=0)2- .
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R5 represents a group selected from:
-C(=0)N(H)R9, -C(=0)NR9R7 .
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R5 represents a group:
-NR9R7 . In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R b represents a group:
R9-S(=0)z- . In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R represents a hydrogen atom or a group selected from:
-NR9R7, -C(=0)NR9R7, R7-S(=0)2-, hydroxy-Ci -C6-alkyl- . In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R b represents a hydrogen atom.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R b represents a group:
hydroxy-d-Ce-alkyl- .
In another preferred embodiment, the invention relates to compounds of formula (I), wherein wherein R c represents halo . In another preferred embodiment, the invention relates to compounds of formula (I), wherein wherein R c represents fluoro .
R6 represents a group selected from :
C3-C6-cycloalkyl-, -(CH2)q-(C3-C6-cycloalkyl),
-(CH2)q-(3- to 10-membered heterocycloalkyl), -(CH2)q-aryl, or
-(CH2)q-heteroaryl ;
said group being optionally substituted, one or more times, identically or differently, with a substituent selected from :
halo-, CrCe-alkyl-, halo-G-Ce-alkyl-, d-Ce-alkoxy-, halo-d-Ce-alkoxy-. In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
R6 represents -(CH2)q-(C3-C6-cycloalkyl) ;
said group being optionally substituted, one or more times, identically or differently, with a substituent selected from :
halo-, CrCa-alkyl-, halo-Ci -C&-alkyl-, Ci -C&-alkoxy-, halo-d-Ce-alkoxy-.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
R6 represents -(CH2)q-aryl ;
said group being optionally substituted, one or more times, identically or differently, with a substituent selected from :
halo-, CrC6-alkyl-, halo-d-Ce-alkyl-, Ci -Ce-alkoxy-, halo-d-Ce-alkoxy-. In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
R6 represents a group selected from :
-(CH2)q-(C3-C6-cycloalkyl), -(CH2)q-aryl ;
said group being optionally substituted, one or more times, identically or differently, with a substituent selected from :
halo-, Ci -C&-alkyl-.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
R6 represents -(CH2)q-(C3-C6-cycloalkyl) ;
said group being optionally substituted, one or more times, identically or differently, with a substituent selected from :
halo-, Ci -C&-alkyl-. In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
R6 represents -(CH2)q-aryl ;
said group being optionally substituted, one or more times, identically or differently, with a substituent selected from :
halo-, CrC6-alkyl-.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
R6 represents CrC6-alkyl, -(CH2)q-(C3-C6-cycloalkyl) or-(CH2)q-aryl ;
said group being optionally substituted, one or more times, identically or differently, with halo-.
In another preferred embodiment, the invention relates to compounds of formula (I), supra, wherein R6 represents a group selected from:
Figure imgf000047_0001
wherein * indicates the point of attachment of said group with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula I), supra, wherein R6 represents a group selected from:
Figure imgf000047_0002
wherein * indicates the point of attachment of said group with the rest of the molecule. In another preferred embodiment, the invention relates to compounds of formula I ), supra, wherein R6 represents a group:
Figure imgf000048_0001
wherein * indicates the point of attachment of said group with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula I ), supra, wherein R6 represents a group:
Figure imgf000048_0002
wherein * indicates the point of attachment of said group with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula I ), supra, wherein R6 represents a group:
Figure imgf000048_0003
wherein * indicates the point of attachment of said group with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula (I ), wherein :
R7 represents a hydrogen atom, a Ci-C&-alkyl-, or C3-C6-cycloalkyl- group. Preferably, R7 represents a hydrogen atom or a Ci-C&-alkyl- group. More preferably, R7 represents a hydrogen atom.
In another preferred embodiment, the invention relates to compounds formula (I), wherein :
R6 and R7,
together with the nitrogen atom to which they are attached,
represent a 3- to 10-membered heterocycloalkyl- group. In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
R8 represents a hydrogen atom or a CrC&-alkyl- group.
Preferably, R8 represents a d-Ce-alkyl- group
In another preferred embodiment, the invention relates to compounds formula (I), wherein :
R9 represents a Ci-C&-alkyl- group.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
R9 and R7,
together with the nitrogen atom to which they are attached,
represent a 3- to 10-membered heterocycloalkyl- group
which is optionally substituted with a halogen atom, preferably with fluoro.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
R9 and R7,
together with the nitrogen atom to which they are attached, represent a group selected from:
Figure imgf000050_0001
wherein * indicates the point of attachment of said group with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
R9 and R7,
together with the nitrogen atom to which they are attached,
represent a group selected from:
Figure imgf000050_0002
wherein * indicates the point of attachment of said group with the rest of the molecule.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
R9 and R7,
together with the nitrogen atom to which they are attached,
represent a group selected from:
Figure imgf000051_0001
wherein * indicates the point of attachment of said group with the rest of the molecule. In another preferred embodiment, the invention relates to compounds of formula (I), wherein Q1 represents CH and Q2 represents CH.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
n, m, p
represent, independently from each other, an integer of 0, 1 , 2 or 3.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
q represents an integer of 1 or 2.
Preferably, q is 1.
In another preferred embodiment, the invention relates to compounds of formula (I), wherein :
t represents an integer of 1 or 2.
Preferably, t represents 1.
It is to be understood that the present invention relates also to any combination of the preferred embodiments described above.
Some examples of combinations are given hereinafter. However, the invention is not limited to these combinations. In a preferred embodiment, the invention relates to compounds of formula (I):
Figure imgf000052_0001
(I)
which :
is selected from:
Figure imgf000052_0002
wherein * represents the point of attachment to the nitrogen atom and ** represents the point of attachment to the R1 group;
R1 represents a phenyl- group
- which is substituted, one or more times, identically or differently, with a substituent selected from :
-OH, -N(H)C(=0)R6, -NHz, -C(=0)N(H)R6 ;
and
- which is optionally substituted, one or more times, identically or differently, with a Ci-C&-alkyl- group ; Rz represents a hydrogen atom or a phenyl- group; said phenyl- group being substituted, one or more times, identically or differently, with a substituent selected from :
halo-, cyano-, Ci-C&-alkyl-,
halo-d-Ce-alkyl-, CrC6-alkoxy-, halo-Ci-C&-alkoxy-, hydroxy-CrC6-alkyl-, Ci -Ce-alkoxy-CrCe-alkyl-,
halo-Ci -C6-alkoxy-Ci -C6-alkyl-,
-NR9R7, -C(=0)NR9R7, R9-S(=0)2- ; or
R2 represents:
Figure imgf000053_0001
wherein * indicates the point of attachment of said group with the rest of the molecule; represents a 5- to 6-membered heterocyclic ring; which is optionally, one or more times, identically or differently, substituted with
Ci -C3-alkyl-, halo-Ci -C3-alkyl-. represents a group selected from:
halo-, Ci -C&-alkyl-, halo-Ci -C&-alkyl-, Ci -C&-alkoxy-,
halo-Ci -C&-alkoxy-; represents a group selected from :
Ci -C&-alkyl-, C3-C&-cycloalkyl-,
-(CH2)q- (C3-C6-cycloalkyl), -(CH2)q-aryl ;
said group being optionally substituted, one or more times, identically or differently, with a substituent selected from :
fluoro- ; and R7,
together with the nitrogen atom to which they are attached, represent a 3- to 10-membered heterocycloalkyl- group; q represents an integer of 1 ; and
t represents an integer of 1 ; or a stereoisomer, a tautomer, an N -oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.
In another preferred embodiment, the invention relates to compounds of formula (I):
Figure imgf000054_0001
is selected from
Figure imgf000054_0002
wherein * represents the point of attachment to the nitrogen atom and ** represents the point of attachment to the R1 group;
R1 represents a phenyl- group - which is substituted, one or more times, identically or differently, with a substituent selected from :
-OH, -N(H)C(=0)R6, -NH2, -C(=0)N(H)R6 ;
and
- which is optionally substituted, one or more times, identically or differently, with a Ci-C&-alkyl- group ;
R2 represents a hydrogen atom or a phenyl- group; said phenyl- group being substituted, one or more times, identically or differently, with a substituent selected from :
halo-, cyano-, Ci-C&-alkyl-,
halo-CrC6-alkyl-, Ci-C&-alkoxy-, halo-Ci-C6-alkoxy-,
hydroxy-CrC6-alkyl-, CrCe-alkoxy-CrCe-alkyl-,
halo-CrCe-alkoxy-CrCe-alkyl-,
-NR9R7, -C(=0)NR9R7, R9-S(=0)2- ; or
R2 represents:
Figure imgf000055_0001
wherein * indicates the point of attachment of said group with the rest of the molecule;
B represents a 5- to 6-membered heterocyclic ring; which is optionally, one or more times, identically or differently, substituted with
Ci-C3-alkyl-, halo-Ci-C3-alkyl-. represents a group selected from: halo-, CrC6-alkyl-, halo-Ci -C&-alkyl-, Ci -C&-alkoxy-,
halo-Ci -C&-alkoxy-;
R6 represents a group selected from :
Ci -C&-alkyl-, C3-C&-cycloalkyl-,
-(CH2)q-(C3-C6-cycloalkyl), -(CH2)q-aryl ;
said group being optionally substituted, one or more times, identically or differently, with a substituent selected from :
fluoro-, methyl- ;
R9 and R7,
together with the nitrogen atom to which they are attached,
represent a 3- to 10-membered heterocycloalkyl- group; q represents an integer of 1 ; and
t represents an integer of 1 ; or a stereoisomer, a tautomer, an N -oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.
In another preferred embodiment, the invention relates to compounds of formula (I ):
Figure imgf000056_0001
in which : represents
Figure imgf000057_0001
wherein * represents the point of attachment to the nitrogen atom and ** represents the point of attachment to the R1 group; represents a phenyl- group
- which is substituted one time with a substituent selected from :
-N(H)C(=0)R6, -C(=0)N(H)R6 ; represents a phenyl- group ; said phenyl- group being substituted, one or more times, identically or differently, with a substituent selected from : halo-, hydroxy-, Ci-C&-alkyl-,
halo-CrCe-alkyl-, G-Ce-alkoxy-, halo-G-Ce-alkoxy-,
hydroxy-Ci-C&-alkyl-, CrCe-alkoxy-d-Ce-alkyl-,
halo-Ci-C6-alkoxy-CrC6-alkyl-,
-NR9R7, -C(=0)N(H)R9, -C(=0)NR9R7, R9-S-, R9-S(=0)-, R9-S(=0)2-,
-N(H)S(=0)R9, -N(R7)S(=0)R9, -S(=0)N(H)R9, -S(=0)NR9R7,
-N(H)S(=0)2R9, -N(R7)S(=0)2R9, -S(=0)2N(H)R9, -S(=0)2NR9R7,
-S(=0)(=NR9)R7, -S(=0)(=NR7)R9 or -N=S(=0)(R9)R7 ; or
R2 represents
Figure imgf000057_0002
wherein * indicates the point of attachment of said group with the rest of the molecule; represents a 4- to 6-membered heterocyclic ring; which is optionally substituted, one or more times, identically or differently, with halo-, -CN, -OH, nitro-, Ci -C&-alkyl-, halo-d-Ce-alkyl-, Ci -C&-alkoxy-, halo-G -C&-alkoxy- , hydroxy-G -Ce-alkyl- ,
CrCe-alkoxy-d-Ce-alkyl-, halo-G -C6-alkoxy-CrC6-alkyl-,
R8-(CrC6-alkoxy)-, R8-0-, -NR8R7, R8-S- , R8-S(=0)-, R8-S(=0)2-,
(C3-C6-cycloalkyl)-(CH2)n-0-;
independently represents a group selected from:
halo-, nitro-, G -Ce-alkyl-, halo-Ci -C&-alkyl-, G -Ce-alkoxy-,
halo-Ci -C&-alkoxy-, hydroxy-Ci -C&-alkyl-, CrC6-alkoxy-Ci -C6-alkyl-, halo-Ci -C6-alkoxy-Ci -C6-alkyl-, R8-(Ci -C6-alkoxy)-, R8-0-, -NR8R7, R8-S-, R8-S(=0)-, R8-S(=0)2-, (C3-C6-cycloalkyl)-(CH2)n-0-; represents a group selected from :
CrCe-alkyl-, CrCe-cycloalkyl-, 3- to 10-membered heterocycloalkyl-, aryl-, heteroaryl-, -(CH2)q-(C3-C6-cycloalkyl) , -(CH2)q-heteroaryl, -(CH2)q-(3- to 10-membered heterocycloalkyl), -(CH2)q-aryl ;
said group being optionally substituted, one or more times, identically or differently, with a substituent selected from :
halo-, hydroxy-, cyano-, nitro-, Ci -C&-alkyl-, halo-Ci -C&-alkyl-,
Ci -C&-alkoxy-, halo-G -Ce-alkoxy-, hydroxy-Ci -C&-alkyl-,
CrCe-alkoxy-d-Ce-alkyl-, halo-Ci -C6-alkoxy-Ci -C6-alkyl-,
R8-(CrC6-alkyl)-, R8-(CH2)n(CHOH)(CH2)m- , R8-(C C6-alkoxy)-,
R8-(CH2)n(CHOH)(CH2)p-0-, R8-(Ci -C6-alkoxy-Ci -C6-alkyl)-,
R8-(Ci -C6-alkoxy-Ci -C6-alkyl)-0-, aryl-, R8-0-, -C(=0)R8, -C(=0)0-R8, -OC(=0)-R8, -N(H)C(=0)R8, -N(R7)C(=0)R8, -N(H)C(=0)NR8R7, -N(R7)C(=0)NR8R7, -NR8R7 , -C(=0)N(H)R8, -C(=0)NR8R7, R8-S-, R8-S(=0)-, R8-S(=0)2-, -N(H)S(=0)R8, -N(R7)S(=0)R8, -S(=0)N(H)R8, -S(=0)NR8R7, -N(H)S(=0)2R8, -N(R7)S(=0)2R8, -S(=0)2N(H)R8, -S(=0)2NR8R7,
-S(=0)(=NR8)R ,-S(=0)(=NR7)R8, -N=S(=0)(R8)R7 ;
R7 represents a hydrogen atom, a Ci-C&-alkyl-, or C3-C&-cycloalkyl- group ;
R8 represents a hydrogen atom, a Ci-C&-alkyl- or C3-C&-cycloalkyl- group ; R9 represents a d-Ce-alkyl- group ;
or
R9 and R7,
together with the nitrogen atom to which they are attached,
represent a 3- to 10-membered heterocycloalkyl- group; n, m, p
represent, independently from each other, an integer of 0, 1 , 2, 3, 4, or 5 ;
q represents an integer of 1 ; and
t represents an integer of 0, 1 or 2 ; or a stereoisomer, a tautomer, an N -oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.
In another preferred embodiment, the invention relates to compounds of formula (I):
Figure imgf000060_0001
is selected from
Figure imgf000060_0002
wherein * represents the point of attachment to the nitrogen atom and ** represents the point of attachment to the R1 group; represents
Figure imgf000060_0003
wherein * indicates the point of attachment of said group with the rest of the molecule; represents a phenyl group which is substituted, one or more times, identically or differently, with a substituent selected from :
halo-, cyano-, d-C6-alkoxy-, hydroxy-d-C6-alkyl-, -NR9R7, -C(=0)NR9R7,
R9-S(=0)2-;
represents:
Figure imgf000061_0001
wherein * indicates the point of attachment of said group with the rest of the molecule; represents a CrC3-alkoxy- or a halo-Ci -C3-alkoxy-group;
R' 6a represents a
Figure imgf000061_0002
group ;
wherein * indicates the point of attachment of said group with the rest of the molecule ; wherein said group is optionally substituted, one or more times, identically or differently, with a halogen atom or a methyl- group;
R7 represents a hydrogen atom, a CrC&-alkyl-, or C3-C&-cycloalkyl- group ;
R8 represents a hydrogen atom, a CrC&-alkyl- or C3-Ce-cycloalkyl- group ; represents a Ci -C&-alkyl- group ;
R7,
together with the nitrogen atom to which they are attached,
represent a 3- to 10-membered heterocycloalkyl- group; and
R10 represents a group selected from: G-C3-alkyl-, hydroxy-Ci-C3-alkyl-,
N(H)(R8)-CrC3-alkyl-;
or a stereoisomer, a tautomer, an N -oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.
In another preferred embodiment, the invention relates to compounds formula (I):
Figure imgf000062_0001
(I)
in which :
A represents
Figure imgf000062_0002
wherein * represents the point of attachment to the nitrogen atom and ** represents the point of attachment to the R1 group; represents
Figure imgf000062_0003
wherein * indicates the point of attachment of said group with the rest of the molecule; represents a group selected from:
Figure imgf000063_0001
wherein * indicates the point of attachment of said group with the rest of the molecule; or a stereoisomer, a tautomer, an N -oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.
The present invention covers compounds of general formula (I) which are disclosed in the Example section of this text, infra.
In an embodiment of the above-mentioned embodimemts of the above- metioned aspects, the invention relates to a stereoisomer, a tautomer, an N- oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same, of any of the compounds of formula (I).
In accordance with another aspect, the present invention covers methods of preparing compounds of the present invention, said methods comprising the steps as described in the Experimental Section herein. This invention also relates to pharmaceutical compositions containing one or more compounds of the present invention. These compositions can be utilised to achieve the desired pharmacological effect by administration to a patient in need thereof. A patient, for the purpose of this invention, is a mammal, including a human, in need of treatment for the particular condition or disease. Therefore, the present invention includes pharmaceutical compositions that are comprised of a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound, or salt thereof, of the present invention. A pharmaceutically acceptable carrier is preferably a carrier that is relatively non-toxic and innocuous to a patient at concentrations consistent with effective activity of the active ingredient so that any side effects ascribable to the carrier do not vitiate the beneficial effects of the active ingredient. A pharmaceutically effective amount of compound is preferably that amount which produces a result or exerts an influence on the particular condition being treated. The compounds of the present invention can be administered with pharmaceutically-acceptable carriers well known in the art using any effective conventional dosage unit forms, including immediate, slow and timed release preparations, orally, parenterally, topically, nasally, ophthalmically, optically, sublingually, rectally, vaginally, and the like.
The compounds of this invention can be administered as the sole pharmaceutical agent or in combination with one or more other pharmaceutical agents where the combination causes no unacceptable adverse effects. The present invention relates also to such combinations. For example, the compounds of this invention can be combined with known anti-hyper- proliferative or other indication agents, and the like, as well as with admixtures and combinations thereof. Other indication agents include, but are not limited to, anti-angiogenic agents, mitotic inhibitors, alkylating agents, anti-metabolites, DNA-intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzyme inhibitors, toposisomerase inhibitors, biological response modifiers, or anti-hormones.
Preferred additional pharmaceutical agents are: 131 1-chTNT, abarelix, abiraterone, aclarubicin, aldesleukin, alemtuzumab, alitretinoin, altretamine, aminoglutethimide, amrubicin, amsacrine, anastrozole, arglabin, arsenic trioxide, asparaginase, azacitidine, basiliximab, BAY 80-6946, BAY 1000394, BAY 86-9766 (RDEA 1 19), belotecan, bendamustine, bevacizumab, bexarotene, bicalutamide, bisantrene, bleomycin, bortezomib, buserelin, busulfan, cabazitaxel, calcium folinate, calcium levofolinate, capecitabine, carboplatin, carmofur, carmustine, catumaxomab, celecoxib, celmoleukin, cetuximab, chlorambucil, chlormadinone, chlormethine, cisplatin, cladribine, clodronic acid, clofarabine, crisantaspase, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, darbepoetin alfa, dasatinib, daunorubicin, decitabine, degarelix, denileukin diftitox, denosumab, deslorelin, dibrospidium chloride, docetaxel, doxifluridine, doxorubicin, doxorubicin + estrone, eculizumab, edrecolomab, elliptinium acetate, eltrombopag, endostatin, enocitabine, epirubicin, epitiostanol, epoetin alfa, epoetin beta, eptaplatin, eribulin, erlotinib, estradiol, estramustine, etoposide, everolimus, exemestane, fadrozole, filgrastim, fludarabine, fluorouracil, flutamide, formestane, fotemustine, fulvestrant, gallium nitrate, ganirelix, gefitinib, gemcitabine, gemtuzumab, glutoxim, goserelin, histamine dihydrochloride, histrelin, hydroxycarbamide, 1-125 seeds, ibandronic acid, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib, imiquimod, improsulfan, interferon alfa, interferon beta, interferon gamma, ipilimumab, irinotecan, ixabepilone, lanreotide, lapatinib, lenalidomide, lenograstim, lentinan, letrozole, leuprorelin, levamisole, lisuride, lobaplatin, lomustine, lonidamine, masoprocol, medroxyprogesterone, megestrol, melphalan, mepitiostane, mercaptopurine, methotrexate, methoxsalen, Methyl aminolevulinate, methyltestosterone, mifamurtide, miltefosine, miriplatin, mitobronitol, mitoguazone, mitolactol, mitomycin, mitotane, mitoxantrone, nedaplatin, nelarabine, nilotinib, nilutamide, nimotuzumab, nimustine, nitracrine, ofatumumab, omeprazole, oprelvekin, oxaliplatin, p53 gene therapy, paclitaxel, palifermin, palladium-103 seed, pamidronic acid, panitumumab, pazopanib, pegaspargase, PEG-epoetin beta (methoxy PEG-epoetin beta), pegfilgrastim, peginterferon alfa-2b, pemetrexed, pentazocine, pentostatin, peplomycin, perfosfamide, picibanil, pirarubicin, plerixafor, plicamycin, poliglusam, polyestradiol phosphate, polysaccharide- K, porfimer sodium, pralatrexate, prednimustine, procarbazine, quinagolide, raloxifene, raltitrexed, ranimustine, razoxane, regorafenib, risedronic acid, rituximab, romidepsin, romiplostim, sargramostim, sipuleucel-T, sizofiran, sobuzoxane, sodium glycididazole, sorafenib, streptozocin, sunitinib, talaporfin, tamibarotene, tamoxifen, tasonermin, teceleukin, tegafur, tegafur + gimeracil + oteracil, temoporfin, temozolomide, temsirolimus, teniposide, testosterone, tetrofosmin, thalidomide, thiotepa, thymalfasin, tioguanine, tocilizumab, topotecan, toremifene, tositumomab, trabectedin, trastuzumab, treosulfan, tretinoin, trilostane, triptorelin, trofosfamide, tryptophan, ubenimex, valrubicin, vandetanib, vapreotide, vemurafenib, vinblastine, vincristine, vindesine, vinflunine, vinorelbine, vorinostat, vorozole, yttrium-90 glass microspheres, zinostatin, zinostatin stimalamer, zoledronic acid, zorubicin. Optional anti-hyper-proliferative agents which can be added to the composition include but are not limited to compounds listed on the cancer chemotherapy drug regimens in the 11th Edition of the Merck Index, (1996), which is hereby incorporated by reference, such as asparaginase, bleomycin, carboplatin, carmustine, chlorambucil, cisplatin, colaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, doxorubicin (adriamycine), epirubicin, etoposide, 5-fluorouracil, hexamethylmelamine, hydroxyurea, ifosfamide, irinotecan, leucovorin, lomustine, mechlorethamine, 6-mercaptopurine, mesna, methotrexate, mitomycin C, mitoxantrone, prednisolone, prednisone, procarbazine, raloxifen, streptozocin, tamoxifen, thioguanine, topotecan, vinblastine, vincristine, and vindesine.
Other anti-hyper-proliferative agents suitable for use with the composition of the invention include but are not limited to those compounds acknowledged to be used in the treatment of neoplastic diseases in Goodman and Gilman's The Pharmacological Basis of Therapeutics (Ninth Edition), editor Molinoff et a/. , publ. by McGraw-Hill, pages 1225-1287, (1996), which is hereby incorporated by reference, such as aminoglutethimide, L-asparaginase, azathioprine, 5- azacytidine cladribine, busulfan, diethylstilbestrol, 2',2'-difluorodeoxycytidine, docetaxel, erythrohydroxynonyl adenine, ethinyl estradiol, 5- fluorodeoxyuridine, 5-fluorodeoxyuridine monophosphate, fludarabine phosphate, fluoxymesterone, flutamide, hydroxyprogesterone caproate, idarubicin, interferon, medroxyprogesterone acetate, megestrol acetate, melphalan, mitotane, paclitaxel, pentostatin, N-phosphonoacetyl-L-aspartate (PALA), plicamycin, semustine, teniposide, testosterone propionate, thiotepa, trimethylmelamine, uridine, and vinorelbine.
Other anti-hyper-proliferative agents suitable for use with the composition of the invention include but are not limited to other anti-cancer agents such as epothilone and its derivatives, irinotecan, raloxifen and topotecan. The compounds of the invention may also be administered in combination with protein therapeutics. Such protein therapeutics suitable for the treatment of cancer or other angiogenic disorders and for use with the compositions of the invention include, but are not limited to, an interferon (e.g., interferon .alpha., .beta. , or .gamma. ) supraagonistic monoclonal antibodies, Tuebingen, TRP-1 protein vaccine, Colostrinin, anti-FAP antibody, YH-16, gemtuzumab, infliximab, cetuximab, trastuzumab, denileukin diftitox, rituximab, thymosin alpha 1 , bevacizumab, mecasermin, mecasermin rinfabate, oprelvekin, natalizumab, rhMBL, MFE-CP1 + ZD-2767-P, ABT-828, ErbB2-specific immunotoxin, SGN-35, MT-103, rinfabate, AS-1402, B43-genistein, L-19 based radioimmunotherapeutics, AC-9301 , NY-ESO-1 vaccine, IMC-1C11 , CT-322, rhCCIO, r(m)CRP, MORAb-009, aviscumine, MDX-1307, Her-2 vaccine, APC- 8024, NGR-hTNF, rhH1.3, IGN-311 , Endostatin, volociximab, PRO-1762, lexatumumab, SGN-40, pertuzumab, EMD-273063, L19-IL-2 fusion protein, PRX- 321 , CNTO-328, MDX-214, tigapotide, CAT-3888, labetuzumab, alpha-particle- emitting radioisotope-llinked lintuzumab, EM-1421 , HyperAcute vaccine, tucotuzumab celmoleukin, galiximab, HPV-16-E7, Javelin - prostate cancer, Javelin - melanoma, NY-ESO-1 vaccine, EGF vaccine, CYT-004-MelQbG10, WT1 peptide, oregovomab, ofatumumab, zalutumumab, cintredekin besudotox, WX- G250, Albuferon, aflibercept, denosumab, vaccine, CTP-37, efungumab, or 131 l-chTNT-1 /B. Monoclonal antibodies useful as the protein therapeutic include, but are not limited to, muromonab-CD3, abciximab, edrecolomab, daclizumab, gentuzumab, alemtuzumab, ibritumomab, cetuximab, bevicizumab, efalizumab, adalimumab, omalizumab, muromomab-CD3, rituximab, daclizumab, trastuzumab, palivizumab, basiliximab, and infliximab.
Generally, the use of cytotoxic and/or cytostatic agents in combination with a compound or composition of the present invention will serve to:
(1 ) yield better efficacy in reducing the growth of a tumor or even eliminate the tumor as compared to administration of either agent alone, (2) provide for the administration of lesser amounts of the administered chemotherapeutic agents,
(3) provide for a chemotherapeutic treatment that is well tolerated in the patient with fewer deleterious pharmacological complications than observed with single agent chemotherapies and certain other combined therapies, (4) provide for treating a broader spectrum of different cancer types in mammals, especially humans,
(5) provide for a higher response rate among treated patients, (6) provide for a longer survival time among treated patients compared to standard chemotherapy treatments,
(7) provide a longer time for tumor progression, and/or
(8) yield efficacy and tolerability results at least as good as those of the agents used alone, compared to known instances where other cancer agent combinations produce antagonistic effects.
In accordance with another aspect therefore, the present invention covers a compound of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, as described and defined herein, for use in the treatment or prophylaxis of a disease, as mentioned supra.
Another particular aspect of the present invention is therefore the use of a compound of general formula (I), described supra, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, for the prophylaxis or treatment of a disease. Another particular aspect of the present invention is therefore the use of a compound of general formula (I) described supra for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.
The diseases referred to in the two preceding paragraphs are diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses, or diseases which are accompanied with uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses, particularly in which the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses is mediated by Mps-1 , such as, for example, haematological tumours, solid tumours, and/or metastases thereof, e.g. leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.
The term "inappropriate" within the context of the present invention, in particular in the context of "inappropriate cellular immune responses, or inappropriate cellular inflammatory responses", as used herein, is to be understood as preferably meaning a response which is less than, or greater than normal, and which is associated with, responsible for, or results in, the pathology of said diseases.
Preferably, the use is in the treatment or prophylaxis of diseases, wherein the diseases are haemotological tumours, solid tumours and/or metastases thereof.
The present invention relates to a method for using the compounds of the present invention and compositions thereof, to treat mammalian hyper- proliferative disorders. Compounds can be utilized to inhibit, block, reduce, decrease, etc. , cell proliferation and/or cell division, and/or produce apoptosis. This method comprises administering to a mammal in need thereof, including a human, an amount of a compound of this invention, or a pharmaceutically acceptable salt, isomer, polymorph, metabolite, hydrate, solvate or ester thereof ; etc. which is effective to treat the disorder. Hyper- proliferative disorders include but are not limited, e.g., psoriasis, keloids, and other hyperplasias affecting the skin, benign prostate hyperplasia (BPH), solid tumors, such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases. Those disorders also include lymphomas, sarcomas, and leukemias.
Examples of breast cancer include, but are not limited to invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ.
Examples of cancers of the respiratory tract include, but are not limited to small-cell and non-small-cell lung carcinoma, as well as bronchial adenoma and pleuropulmonary blastoma.
Examples of brain cancers include, but are not limited to brain stem and hypophtalmic glioma, cerebellar and cerebral astrocytoma, medulloblastoma, ependymoma, as well as neuroectodermal and pineal tumor. Tumors of the male reproductive organs include, but are not limited to prostate and testicular cancer. Tumors of the female reproductive organs include, but are not limited to endometrial, cervical, ovarian, vaginal, and vulvar cancer, as well as sarcoma of the uterus.
Tumors of the digestive tract include, but are not limited to anal, colon, colorectal, esophageal, gallbladder, gastric, pancreatic, rectal, small- intestine, and salivary gland cancers.
Tumors of the urinary tract include, but are not limited to bladder, penile, kidney, renal pelvis, ureter, urethral and human papillary renal cancers.
Eye cancers include, but are not limited to intraocular melanoma and retinoblastoma. Examples of liver cancers include, but are not limited to hepatocellular carcinoma (liver cell carcinomas with or without fibrolamellar variant), cholangiocarcinoma (intrahepatic bile duct carcinoma), and mixed hepatocellular cholangiocarcinoma. Skin cancers include, but are not limited to squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, and non-melanoma skin cancer.
Head-and-neck cancers include, but are not limited to laryngeal, hypopharyngeal, nasopharyngeal, oropharyngeal cancer, lip and oral cavity cancer and squamous cell. Lymphomas include, but are not limited to AIDS- related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Burkitt lymphoma, Hodgkin's disease, and lymphoma of the central nervous system.
Sarcomas include, but are not limited to sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma.
Leukemias include, but are not limited to acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia. These disorders have been well characterized in humans, but also exist with a similar etiology in other mammals, and can be treated by administering pharmaceutical compositions of the present invention.
The term "treating" or "treatment" as stated throughout this document is used conventionally, e.g., the management or care of a subject for the purpose of combating, alleviating, reducing, relieving, improving the condition of, etc., of a disease or disorder, such as a carcinoma. The present invention also provides methods for the treatment of disorders associated with aberrant mitogen extracellular kinase activity, including, but not limited to stroke, heart failure, hepatomegaly, cardiomegaly, diabetes, Alzheimer's disease, cystic fibrosis, symptoms of xenograft rejections, septic shock or asthma.
Effective amounts of compounds of the present invention can be used to treat such disorders, including those diseases (e.g. , cancer) mentioned in the Background section above. Nonetheless, such cancers and other diseases can be treated with compounds of the present invention, regardless of the mechanism of action and/or the relationship between the kinase and the disorder.
The phrase "aberrant kinase activity" or "aberrant tyrosine kinase activity, " includes any abnormal expression or activity of the gene encoding the kinase or of the polypeptide it encodes. Examples of such aberrant activity, include, but are not limited to, over-expression of the gene or polypeptide ; gene amplification ; mutations which produce constitutively-active or hyperactive kinase activity ; gene mutations, deletions, substitutions, additions, etc.
The present invention also provides for methods of inhibiting a kinase activity, especially of mitogen extracellular kinase, comprising administering an effective amount of a compound of the present invention, including salts, polymorphs, metabolites, hydrates, solvates thereof, and diastereoisomeric forms thereof. Kinase activity can be inhibited in cells (e.g. , in vitro), or in the cells of a mammalian subject, especially a human patient in need of treatment.
EXPERIMENTAL SECTION The following Table lists the abbreviations used in this paragraph, and in the Examples section.
Figure imgf000074_0001
dichloro[1 , 1 '-
Pd(dppf)Cl2
bis(diphenylphosphino)ferrocene]palladium(ll)
CH2Cl2
dichloromethane adduct chloro[2-(dicyclohexylphosphino)-3,6-dimethoxy-2'-4'-6'-
Pd-Brett-Phos- tri-iso-propyl-1 , 1 '-biphenyl] [2-(2- pre-cat
aminoethyl)phenyl]palladium(ll )
Pd-tBu-X-Phos- chloro(2-di-teri-butylphosphino-2',4',6'-tri-isopropyl-1 , 1 '- pre-cat biphenyl)[2-(2-aminoethyl)phenyl] paUadium(ll ), chloro(2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1 , 1 '-
Pd-X-Phos-pre- biphenyl)[2-(2-aminoethyl)phenyl] paUadium(ll ) methyl- cat
tert-butylether adduct
PPh3 triphenylphosphine
P(oTol)3 tri-o-tolylphosphine
Rac racemic
Rt retention time
r.t. room temperature
TBAF Tetrabutylammoniumfluorid
N-[(1 H-benzotriazol-1 -yloxy)(dimethylamino)methylene]-
TBTU
N-methylmethanaminium tetrafluoroborate
THF tetrahydrofurane
TFA trifluoroacetic acid
X-Phos 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl
NMR peak forms are stated as they appear in the spectra, possible higher order effects have not been considered.
The schemes and procedures described below illustrate general synthetic routes to the compounds of general formula (I ) of the invention and are not intended to be limiting. It is clear to the person skilled in the art that the order of transformations as exemplified in the Schemes can be modified in various ways. The order of transformations exemplified in the Schemes is therefore not intended to be limiting. In addition, interconversion of any of the substituents R1, R2, R a, R b, R6 ,R7, R8 or R9 can be achieved before and/or after the exemplified transformations. These modifications can be such as the introduction of protecting groups, cleavage of protecting groups, reduction or oxidation of functional groups, halogenation, metallation, substitution or other reactions known to the person skilled in the art. These transformations include those which introduce a functionality which allows for further interconversion of substituents. Appropriate protecting groups and their introduction and cleavage are well-known to the person skilled in the art (see for example T.W. Greene and P.G.M. Wuts in Protective Groups in Organic Synthesis, 3rd edition, Wiley 1999). Specific examples are described in the subsequent paragraphs. A first reaction scheme is outlined infra :
Synthesis of compounds of general formula (I) of the present invention Scheme 1
Figure imgf000077_0001
wherein A, R1, and R2 are as defined for the compounds of general formula (I), supra, and Y represents a leaving group, such as a halogen atom or a trifluoromethylsulphonyloxy or nonafluorobutylsulphonyloxy group for example, and Z represents a suitable functional group via which the R1 of the R1-Z compound can be coupled, by a coupling reaction, onto the Y-bearing carbon atom of a compound (4), thereby replacing said Y with said R1 moiety. Many aryl halides of the formula R2-Y may be obtained commercially. Reagents of the general structure R1a-Z and R1-Z can for example be aryl boronic acids or aryl boronic esters. Many such reagents of the general structures R1a-Z and R1-Z are also commercially available. Reagents of the general structures R1a-Z and R1-Z can be prepared from aryl halides [see for example K. L. Billingslay, T. E. Barde, S. L Buchwald, Angew. Chem. 2007, 1 19, 5455 or T.Graening, Nachrichten aus der Chemie, Jan 2009, 57, 34] . R1a can be converted to R1 in one or several steps. Typically, R1a can be a protected phenyl-amine, especially -phenyl-NH-Boc, or a phenyl-carboxylic acid, [-phenyl-C(0)OH] or a -phenyl-carboxylic acid ester [ phenyl-C(0)0- alkyl] . For example, when R1a is a phenyl group to which an -NH2 substituent is bound, this -NH2 substituent may be allowed to react with a compound of general formula R1b-X (7a), in which R1b is -C(=0)R6 or -C(=0)NR6R7 (R6 and R7 being as defined as for compounds of general formula (I ) of the present invention as defined in the claims), and X is a suitable functional group (e.g. an -OH, -0-Ci-C&-alkyl group, or a halogen atom), via which the R1b of the R1b-X compound (7a) can be coupled, via a coupling reaction, such as an amide coupling reaction for example, onto the -NH2 substituent bound to the phenyl group R1a of compound (7), thereby replacing said X with said R1a, thus providing a compound of general formula (I) of the present invention.
Intermediates of general formula (3) can be converted to intermediates of general formula (4) by reaction with suitable aryl compounds R2-Y, preferably aryl bromides, or aryl iodides or for example aryl trifluoromethylsulphonates or aryl nonafluorobutylsulphonates in the presence of a suitable base, such as, for example NaOtBu or caesium carbonate or potassium phosphate, and a suitable catalyst/ ligand system, such as for example Pd2(dba)3/rac-BINAP, Pd2dba3/X- Phos, Pd2dba3/tBu-X-Phos, Pd2dba3/Brett-Phos, Pd-X-Phos-pre-cat/X-Phos, Pd- tBu-X-Phos-pre-cat/tBu-X-Phos, Pd-Brett-Phos-pre-cat/ Brett-Phos in a suitable solvent such as THF, toluene, xylene, DME, or NMP, or mixtures of these solvents at temperatures ranging from room temperature to the 200° C. The person skilled in the art will recognise that the appropriate choice of reaction conditions, such as temperature, choice of solvent and catalyst system is critical for preferred derivatization at the amino group of intermediates of general formula (3).
Alternatively, intermediates of general formula (3) can be converted to intermediates of general formula (4) by reaction with suitable phenyl or pyridyl compounds R2-Y, preferably phenyl chlorides, and more preferably 2- chloro-pyridines or 6-chloro-pyridines in the presence of a suitable base, such as, for example sodium hydride in a suitable solvent such as THF, DMF, DME, or NMP, preferably THF or NMP or mixtures of these solvents at temperatures ranging from room temperature to the 200° C, preferably 130 °C in a microwave vessel.
Intermediates of general formula (4) can be converted to compounds of general formula (I) by reaction with a suitable reagent, like for example a boronic acid derivative in the presence of a suitable catalyst system, like for example Pd(OAc)2 and P(oTol)3, or PdCl2(PPh3)2 and PPh3 and a suitable base, like for example aqueous potassium carbonate in a suitable solvent, like for example THF, DME, ethanol or 1 -propanol or mixtures of these solvents at temperatures ranging from room temperature to 200° C, preferably the boiling point of the used solvent.
In an alternative route for the synthesis of compounds of general formula (I), intermediates of general formula (3) can be reacted with a suitable reagent, like for example a boronic acid derivative in the presence of a suitable catalyst system, like for example Pd(OAc)2 and P(oTol)3, or PdCl2(PPh3)2 and PPh3 and a suitable base, like for example aqueous potassium carbonate in a suitable solvent, like for example THF, DME, ethanol or 1 -propanol or mixtures of these solvents at temperatures ranging from room temperature to 200° C, preferably the boiling point of the used solvent to furnish intermediates of the general formula (5). Intermediates of general formula (5) can be converted to compounds of general formula (I) by reaction with suitable phenyl or pyridyl compounds R2-Y, preferably bromides, iodides, trifluoromethylsulphonates or nonafluorobutylsulphonates in the presence of a suitable base, such as, for example NaOtBu or caesium carbonate or potassium phosphate, and a suitable catalyst/ ligand system, such as for example Pd2(dba)3/rac-BINAP, Pd2dba3/X- Phos, Pd2dba3/tBu-X-Phos, Pd2dba3/Brett-Phos, Pd-X-Phos-pre-cat/X-Phos, Pd- tBu-X-Phos-pre-cat/tBu-X-Phos, Pd-Brett-Phos-pre-cat/Brett-Phos in a suitable solvent such as THF, toluene, xylene, DME, or NMP, or mixtures of these solvents at temperatures ranging from room temperature to 200° C.
Also as depicted in Scheme 1 , is a further alternative route for the synthesis of compounds of general formula (I): Intermediates of general formula (3) can be converted to intermediates of general formula (6) by a coupling reaction as described supra for synthesis of intermediate of general formula (5), thereby replacing said Y of intermediates of general formula (3) with said R1a moiety.
Intermediates of general formula (6) can then be converted to intermediates of general formula (7) by a coupling reaction as described supra for synthesis of intermediates of general formula (4), thereby forming a bond between NH and said R2 moiety. Intermediates of general formula (7) can then be converted to compounds of general formula (I) by one or more further transformations. These can be modifications such as cleavage of protecting groups, reduction or oxidation of functional groups, halogenation, metallation, substitution or other reactions known to the person skilled in the art, for example the formation of an amide bond, the formation of a urea, or the formation of a sulfonamide, thereby converting R1a to said R1 moiety. Additionally, intermediates of general formula (6) can be converted to intermediates of general formula (5) by one or more further transformations. These can be modifications such as cleavage of protecting groups, reduction or oxidation of functional groups, halogenation, metallation, substitution or other reactions known to the person skilled in the art, for example the formation of an amide bond, the formation of a urea, or the formation of a sulphonamide, thereby converting R1a to said R1 moiety.
Intermediates of general formula (5) can then be converted to compounds of general formula (I) by a coupling reaction as described supra for synthesis of intermediates of general formula (4), thereby forming a bond between NH and said R2 moiety.
The compounds and intermediates produced according to the methods of the invention may require purification. Purification of organic compounds is well known to the person skilled in the art and there may be several ways of purifying the same compound. In some cases, no purification may be necessary. In some cases, the compounds may be purified by crystallisation. In some cases, impurities may be stirred out using a suitable solvent. In some cases, the compounds may be purified by chromatography, particularly flash chromatography, using for example pre-packed silica gel cartridges, e.g. from Separtis such as Isolute® Flash silica gel (silica gel chromatography) or Isolute® Flash NH2 silica gel (aminophase-silica-gel chromatography) in combination with a suitable chromatographic system such as a Flashmaster II (Separtis) or an Isolera system (Biotage) and eluents such as, for example, gradients of hexane/ethyl acetate or DCM/methanol. In some cases, the compounds may be purified by preparative HPLC using, for example, a Waters autopurifier equipped with a diode array detector and/or on-line electrospray ionisation mass spectrometer in combination with a suitable pre-packed reverse phase column and eluants such as, for example, gradients of water and acetonitrile which may contain additives such as trifluoroacetic acid, formic acid or aqueous ammonia.
Names of compounds were generated using ACD/Name Batch ver. 12.00 or ACD/Name Batch ver. 12.01 . Names of compounds in table format were generated using ACD/Name Batch ver. 12.00.
In the present text, in particular in the Experimental Section, for the synthesis of intermediates and of examples of the present invention, when a compound is mentioned as a salt form with the corresponding base or acid, the exact stoichiometric composition of said salt form, as obtained by the respective preparation and/or purification process, is, in most cases, unknown.
Unless specified otherwise, suffixes to chemical names or structural formulae such as "hydrochloride", "trifluoroacetate", "sodium salt", or "x HQ", "x CF3COOH", "x Na+", for example, are to be understood as not a stoichiometric specification, but solely as a salt form.
This applies analogously to cases in which synthesis intermediates or example compounds or salts thereof have been obtained, by the preparation and/or purification processes described, as solvates, such as hydrates with (if defined) unknown stoichiometric composition.
HPLC Methods: Method 1 :
Instrument: Waters Acquity UPLCMS ZQ4000; Column: Acquity UPLC BEH C18 1 .7 μιτι, 50x2.1 mm; eluent A: water + 0.05vol% formic acid, Eluent B: acetonitrile + 0.05vol% formic acid gradient: 0-1.6 min 1 -99% B, 1.6-2.0 min 99% B; flow 0.8 mL/min; temperature: 60 °C; injection: 2 μΙ_; DAD scan: 210- 400 nm; ELSD.
Method 2:
Instrument: Waters Acquity UPLCMS SQD 3001 ; Column: Acquity UPLC BEH C18 1 .7 μιτι, 50x2.1 mm; eluent A: water + 0.1vol% formic acid (95%), eluent B: acetonitrile, gradient: 0-1.6 min 1 -99% B, 1 .6-2.0 min 99% B; flow 0.8 mL/min; temperature: 60 °C; injection: 2 μί; DAD scan: 210-400 nm; ELSD. Method 3:
Instrument: Waters Acquity UPLCMS SQD; Column: Acquity UPLC BEH C18 1 .7 μιτι, 50x2.1 mm; eluent A: water + 0.05vol% formic acid (95%), eluent B: acetonitrile + 0.05vol% formic acid (95%), gradient: 0-1 .6 min 1 -99% B, 1 .6-2.0 min 99% B; flow 0.8 mL/min; temperature: 60 °C; injection: 2 μί; DAD scan: 210-400 nm; ELSD.
Method 4:
Instrument: Waters Acquity UPLC-MS SQD; Column: Acquity UPLC BEH C18 1.7 50x2.1 mm; eluent A: water + 0.1vol% formic acid (99%), eluent B: acetonitrile; gradient: 0-1 .6 min 1 -99% B, 1 .6-2.0 min 99% B; flow 0.8 mL/min; temperature: 60 °C; injection: 2 μί; DAD scan: 210-400 nm; ELSD.
Method 5:
Instrument: Waters Acquity UPLCMS SQD 3001 ; Column: Acquity UPLC BEH C18 1 .7 μιτι, 50x2.1 mm; eluent A: water + 0.2 vol.% ammonia (32%), eluent B: acetonitrile, gradient: 0-1 .6 min 1 -99% B, 1 .6-2.0 min 99% B; flow 0.8 mL/min; temperature: 60 °C; injection: 2 μί; DAD scan: 210-400 nm; ELSD.
Method 6 Instrument: Waters Acquity UPLC-MS SQD; Column: Acquity UPLC BEH C18 1.7 50x2.1 mm; eluent A: water + 0.2% vol. ammonia (32%), eluent B: acetonitrile; gradient: 0-1.6 min 1 -99% B, 1.6-2.0 min 99% B; flow 0.8 mL/min; temperature: 60 °C; injection: 2 μΐ; DAD scan: 210-400 nm; ELSD.
Method 7
Instrument: Waters Acquity UPLC-MS ZQ; column: Acquity UPLC BEH C18 1.7 50x2.1 mm; eluent A: water + 0.1% vol. formic acid (99%), eluent B: acetonitrile; gradient: 0-1.6 min 1 -99% B, 1.6-2.0 min 99% B; flow 0.8 mL/min; temperature: 60 °C; injection: 2 μΐ; DAD scan: 210-400 nm; ELSD.
Method 8:
Instrument: Waters Acquity UPLCMS SQD; Column: Acquity UPLC BEH C18 1.7 m, 50x2.1 mm; Eluent A: water + 0.2% vol. ammonia (32%), eluent B: acetonitrile; gradient: 0-1.6 min 1 -99% B, 1.6-2.0 min 99% B; flow 0.8 mL/min; temperature: 60° C; injection: 2 μΐ; DAD scan: 210-400 nm; ELSD.
Intermediates
Intermediate Example 01.01.
ethyl [(6-bromopyridazin-3-yl)carbamothioyl]carbamate
Figure imgf000084_0001
Ethoxycarbonyl isothiocyanate (9.12 g) was added to a stirred solution of 6- bromopyridazin-3-amine (11 g) in dioxane (113 mL). The mixture was stirred for 16 h at r.t. A white solid precipitated. Hexane (110 mL) was added and the white solid was collected by filtration to give 16.6 g of the title compound.
Intermediate Example 01.02. 6-bromo[1 ,2,4]triazolo[1 ,5-b]pyridazin-2-amine
Figure imgf000085_0001
Hydroxylammonium chloride (13.7 g) was suspended in methanol (70 mL), and ethanol (70 mL) and Hiinig Base (20.5 mL) were added at r.t. The mixture was heated to 60° C, ethyl [(6-bromopyridazin-3-yl)carbamothioyl]carbamate (10.0 g) was added portionwise, and the mixture was stirred at 60° C for 2 h. A solid precipitated and was collected by filtration. The solid was stirred with aqueous sodium hydroxide (100 mL, c = 1 ) for 1 h. The solid was collected by filtration and was washed with water and dried in vacuum to give 5.1 g of the title compound.
Intermediate Example 01.03.
tert-butyl [4-(2-amino[1 ,2,4]triazolo[1 ,5-b]pyridazin-6- yl)phenyl]carbamate
Figure imgf000085_0002
To a stirred solution of 6-bromo[1 ,2,4]triazolo[1 ,5-b]pyridazin-2-amine (5.0 g) in 1 -propanol (135 mL) was added 2M potassium carbonate solution (35 mL), (4-[(tert-butoxycarbonyl) amino] phenyl} boronic acid (6.1 g), triphenylphosphine (306 mg) and PdCl2(PPh3)2 (953 mg). The mixture was heated to reflux for 1 h. Further triphenylphosphine (306 mg) and PdClz(PPh3)2 (953 mg) were added and the mixture was heated to reflux for 1 h. The mixture was stirred at room temperature for 16 h, a solid precipitated and was collected by filtration. The solid was stirred with water (100 mL) for 1 h. The solid was collected by filtration and dried in vacuum to give 5.6 g of the title compound. Intermediate Example 01.04.
6-(4-aminophenyl)[1 ,2,4]triazolo[1 ,5-b]pyridazin-2-amine
Figure imgf000086_0001
To a stirred suspension of tert-butyl [4-(2-amino[1 ,2,4]triazolo[1 ,5-b]pyridazin- 6-yl)phenyl]carbamate (5.6 g) in dichloromethane (56 mL) was added TFA (13.2 ml_). The mixture was stirred at r.t. for 70 h. The mixture was concentrated in vacuum. Water was added and the solution was filtered. An aqueous solution of sodium hydroxide was added until pH 11 was reached. A solid precipitated and was collected by filtration and dried in vacuum to give 2.7 g of the title compound.
Intermediate Example 01.05.
N-[4-(2-amino[1 ,2,4]triazolo[1 ,5-b]pyridazin-6-yl)phenyl]-2-(4- fluorophenyl)acetamide
Figure imgf000086_0002
To a stirred solution of 6-(4-aminophenyl)[1 ,2,4]triazolo[1 ,5-b]pyridazin-2- amine (2.70 g) in THF (135 mL) was added Hiinig Base (2.29 mL), (4- fluorophenyl)acetic acid (2.02 g), and HATU (4.99 g). The mixture was stirred at room temperature for 24 h. Water was added and the mixture was stirred at room temperature for 1 h. The precipitated solid was collected by filtration, was washed with ethanol and hexane and was dried in vacuum to give 2.4 g of the title compound.
Intermediate Example 02.01 eth l [(5-bromopyrazin-2-yl)carbamothioyl]carbamate
Figure imgf000087_0001
Ethoxycarbonyl isothiocyanate (49.7 g) was added to a stirred solution of 5- bromopyrazin-2-amine (60.0 g) in dioxane (600 ml_). The mixture was stirred for 48 h at r.t. A white solid precipitated. The white solid was collected by filtration to give 78.5 g of the title compound.
Intermediate Example 02.02.
6-bromo[1 ,2,4]triazolo[1 ,5-a]pyrazin-2-amine
Figure imgf000087_0002
Hydroxylammonium chloride (99.1 g) was suspended in methanol (498 ml_), and ethanol (450 ml.) and Hiinig Base (150 mL) were added at r.t. The mixture was heated to 60° C, ethyl [(5-bromopyrazin-2-yl)carbamothioyl]carbamate (75 g) was added portion wise, and the mixture was stirred at 60° C for 2 h. Hexane (500 mL) was added, and a solid was collected by filtration. The solid was stirred with water (75 mL) for 1 h. The solid was collected by filtration and was washed with water and dried in vacuum to give 46.2 g of the title compound. Intermediate Example 02.03.
tert-but l [4-(2-amino[ 1 , 2,4]triazolo[ 1 , 5-a]pyrazin-6-yl)phenyl]carbamate
Figure imgf000087_0003
To a stirred solution of 6-bromo[1 ,2,4]triazolo[1 ,5-a]pyrazin-2-amine (10.0 g) in 1 -propanol (420 mL) was added 2M potassium carbonate solution (70 mL), {4-[(tert-butoxycarbonyl) amino] phenyl} boronic acid (15.6 g), triphenylphosphine (613 mg) and PdCl2(PPh3)2 (3.28 g). The mixture was heated to reflux for 2h. Water was added and the mixture was stirred at room temperature for 15 minutes. A solid precipitated and was collected by filtration and dried in vacuum to give 14.7 g of the title compound.
Intermediate Example 02.04.
6- 4-aminophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrazin-2-amine
Figure imgf000088_0001
To a stirred suspension of tert-butyl [4-(2-amino[1 ,2,4]triazolo[1 ,5-a]pyrazin-6- yl)phenyl]carbamate (14.7 g) in dichloromethane (115 mL) was added TFA (52 mL). The mixture was stirred at r.t. for 5 h. The mixture was concentrated in vacuum to approx. 40 mL. Water was added and an aqueous solution of potassium carbonate was added until pH 11 was reached. A solid precipitated and was collected by filtration and dried in vacuum to give 8.7 g of the title compound.
Intermediate Example 02.05.
N-[4-(2-amino[1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl)phenyl]-2-(4- fluoro henyl)acetamide
Figure imgf000088_0002
To a stirred solution of 6-(4-aminophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrazin-2-amine (4.00 g) in THF (270 mL) was added Hiinig Base (5.4 mL), (4-fluorophenyl)acetic acid (3.48 g), and HATU (12.1 g). The mixture was stirred at room temperature for 24 h. Water was added and the mixture was stirred at room temperature for 16 h. The precipitated solid was collected by filtration, was washed with methanol and ether and was dried in vacuum to give 5.4 g of the title compound.
Intermediate Example 02.06.
N- 4-(2-amino[ 1 , 2,4]triazolo[ 1 , 5-a]pyrazin-6-yl)phenyl]-2-phenylacetamide
Figure imgf000089_0001
To a stirred suspension of 6-(4-aminophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrazin-2- amine (300 mg) in DMF (10 mL) was added potassium carbonate (0.49 g), phenylacetic acid (199 mg), and HATU (554 mg). The mixture was stirred at room temperature for 24 h. Water was added and the mixture was stirred at room temperature for 1 h. The mixture was extracted with ethyl acetate. The organic phase was dried (sodium sulfate) and the solvent was removed in vacuum to give a solid that was recrystallized from ethanol to give 330 mg of the title compound.
Intermediate Example 02.07.
N-[4-(2-amino[1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl)phenyl]-2-(3,4- difluoro henyl)acetamide
Figure imgf000089_0002
To a stirred solution of 6-(4-aminophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrazin-2-amine (300 mg) in THF (25 mL) was added Hunig Base (0.25 mL), (3,4- difluorophenyl)acetic acid (256 mg), and HATU (555 mg). The mixture was stirred at room temperature for 16 h. Water was added and the mixture was stirred at room temperature for 1 h. The precipitated solid was collected by filtration and was washed with ethanol and ether. The solid was recrystallized from ethanol to give 500 mg of the title compound.
Intermediate Example 02.08.
tert-butyl(4-{2-[(2-cyanophenyl)amino][1,2,4]triazolo[1 ,5-a]pyrazin-6- l}phenyl)carbamate
Figure imgf000090_0001
To a stirred suspension of tert-butyl [4-(2-amino[1 ,2,4]triazolo[1 ,5-a]pyrazin-6- yl)phenyl]carbamate (2.0 g) in toluene (10 mL) and NMP (0.4 mL) was added 2- bromobenzonitrile (1.57 g), rac-BINAP (389 mg) and Pd2dba3 (281 mg) and cesium carbonate (6.1 g) and the flask was degassed twice and backfilled with argon. The mixture was heated to reflux for 16 h. Water was added and the reaction mixture was extracted with ethyl acetate. The organic phase was washed with saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum to give a solid that was triturated with dichloromethane to give 1.3 g of the title compound.
Intermediate Example 02.09.
4- 2-amino[1 ,2,4]triazolo[1,5-a]pyrazin-6-yl)-2,6-dimethylphenol
Figure imgf000090_0002
To a solution of 2,6-dimethyl-4-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- yl)phenol (777 mg) in dichloromethane was added aqueous hydrochloric acid (c=2N, 7.5 mL). The mixture was vigorously shaken for 5 minutes, the organic phase was separated and the aqueous phase was extracted with a mixture of dichloromethane and methanol (100:1 ). The combined organic phases were dried (sodium sulfate) and the solvent was removed in vacuum.
The residue (720 mg) was dissolved in 1 -propanol (35 mL) and a 2 M potassium carbonate solution (3.5 mL), 6-bromo[1 ,2,4]triazolo[1 ,5-a]pyrazin-2-amine (500 mg), triphenylphosphine (13 mg) and PdCl2(PPh3)2 (164 mg) were added. The mixture was heated to reflux for 3h, water (100 mL) was added and the mixture was extracted with a mixture of ethyl acetate and hexane (3:1 ). The organic phase was washed with water and with saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum. Silicagel chromatography gave a solid that was triturated with ethanol to give 250 mg of the title compound.
Intermediate Example 02.10.
N-[4-(2-amino[1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl)phenyl]-2- c clopropylacetamide
Figure imgf000091_0001
To a stirred solution of 6-(4-aminophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrazin-2-amine (320 mg) in THF (27 mL) was added Hunig Base (0.27 mL), cyclopropylacetic acid (156 mg), and HATU (592 mg). The mixture was stirred at room temperature for 64 h. Water was added and the mixture was stirred at room temperature for 1 h. The precipitated solid was collected by filtration and was washed with ethanol and ether to give 420 mg of the title compound.
Intermediate Example 02.11. 3- 2-amino[1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl)benzoic acid
Figure imgf000092_0001
To a stirred solution of 6-bromo[1 ,2,4]triazolo[1 ,5-a]pyrazin-2-amine (5.0 g) in 1 -propanol (350 mL) was added 2M potassium carbonate solution (35 ml_), 3- (dihydroxyboryl)benzoic acid (5.04 g), triphenylphosphine (306 mg) and PdCl2(PPh3)2 (1.64 g). The mixture was heated to reflux for 2h. The solvent was removed in vacuum. An aqueous solution of citric acid (10% w/w) was added and the mixture was extracted with ethyl acetate. The organic phase was separated, filtered and the solvent was removed in vacuum to give 5.82 g of the title compound.
Intermediate Example 02.12.
eth l 3-(2-amino[1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl)benzoate
Figure imgf000092_0002
To a stirred suspension of 3-(2-amino[1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl)benzoic acid (6.0 g) in ethanol (120 mL) was added thionyl dichloride (15.4 mL) with ice bath cooling. The mixture was heated to reflux for 48 h. Further ethanol (100 mL) and further thionyl dichloride (15.4 mL) was added with ice bath cooling and the mixture was heated to reflux for further 64 h. The mixture was cooled to room temperature and a solid was collected by filtration. The solid was dissolved in a mixture of dichloromethane and methanol (10:1 ) and was washed with an aqueous solution of sodium bicarbonate. The organic phase was separated, filtered and the solvent was removed in vacuum to give 4.31 g of the title compound. Intermediate Example 02.13.
ethyl 3-{2-[(2-cyanophenyl)amino][1 ,2,4]triazolo[1 ,5-a]pyrazin-6- l}benzoate
Figure imgf000093_0001
To a stirred suspension of ethyl 3-(2-amino[1 ,2,4]triazolo[1 ,5-a]pyrazin-6- yl)benzoate (500 mg) in toluene (15 mL) and NMP (0.3 mL) was added 2- bromobenzonitrile (662 mg), rac-BINAP (112 mg) and Pd2dba3 (81 mg) and cesium carbonate (1.76 g) and the flask was degassed twice and backfilled with argon. The mixture was heated to reflux for 3 h. Water was added and the reaction mixture was extracted with ethyl acetate. The organic phase was washed with saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum. Silicagel chromatography gave 548 mg of the title compound.
Intermediate Example 02.14.
3-{2-[(2-cyanophenyl)amino][1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl}benzoic acid
Figure imgf000093_0002
To a stirred solution of ethyl 3-{2-[(2-cyanophenyl)amino][1 ,2,4]triazolo[1 ,5- a]pyrazin-6-yl}benzoate (444 mg) in methanol (14 mL) and tetrahydrofurane (7.0 mL) was added an aqueous solution of sodium hydroxide (11.6 mL, c = 2.5 M). The mixture was stirred at room temperature for 2 h. An aqueous solution of hydrochloric acid (c = 2 N) was added until pH 3 was reached. The mixture was stirred for 10 minutes and the precipitated solid was collected by filtration to give 407 mg of the title compound.
Intermediate Example 03.01.
tert-butyl [4-(2-amino-1 ,3-benzothiazol-6-yl)phenyl]carbamate
Figure imgf000094_0001
To a stirred solution of 6-bromo-1 ,3-benzothiazol-2-amine (2.0 g) in 1 -propanol (50 mL) was added 2M potassium carbonate solution (13 mL), {4-[(tert- butoxycarbonyl)amino]phenyl}boronic acid (2.28 g), triphenylphosphine (343 mg) and PdCl2(PPh3)2 (919 mg). The mixture was heated to reflux for 3 h. The solvent was removed in vacuum, water was added and the mixture was extracted with ethyl acetate. The organic phase was washed with saturated sodium chloride solution, dried (sodium sulfate), filtered through celite and the solvent was removed in vacuum. The residue was titurated with dichloromethane to give 1.21 g of the title compound.
Intermediate Example 03.02.
6-(4-aminophenyl)-1 ,3-benzothiazol-2-amine
Figure imgf000094_0002
To a stirred solution of tert-butyl [4-(2-amino-1 ,3-benzothiazol-6- yl)phenyl]carbamate (1.2 g) in dichloromethane (6.0 mL) was added TFA (2.7 mL). The mixture was stirred at room temperature for 3 h. A saturated solution of potassium carbonate was added until pH 9 was reached. The mixture was extracted with dichloromethane. The solution was dried (sodium sulfate) and the solvent was removed in vacuum. Aminophase-silica-gel chromatography gave a solid that was triturated with dichloromethane to give 662 mg of the title compound.
Intermediate Example 04.01.
methyl 4-bromo-3-methoxybenzoate
Figure imgf000095_0001
To a stirred solution of methyl 4-bromo-3-hydroxybenzoate (10.0 g) in DMF (50 mL) was added potassium carbonate (17.9 g) and iodomethane (9.2 mg). The mixture was stirred at room temperature for 2 h. Ethyl acetate was added and the mixture was washed with water. The organic phase was washed with saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum to give 10 g of the title compound, that was used without further purification.
1H-NMR (400MHz, DMSO-d6): δ [ppm] = 3.82 (s, 3H), 3.87 (s, 3H), 7.41 (dd, 1 H), 7.47 (d, 1 H), 7.67 (d, 1 H).
Intermediate Example 04.02.
4-bromo-3-methoxybenzoic acid
Figure imgf000095_0002
stirred solution of methyl 4-bromo-3-methoxybenzoate (11.2 g) in THF mL), methanol (45 mL) and water (45 mL) was added a 1 M solution of lithium hydroxide in water (140 ml_). The mixture was stirred at room temperature for 1 h. The solvent was removed in vacuum. Water was added and 1 N hydrochloric acid was added with ice bath cooling until pH 4 was reached. The precipitated solid was collected by filtration, washed with water and dried in vacuum to give 10.1 g of the title compound, that was used without further purification.
1H-N R (300MHz, DMSO-d6): δ [ppm] = 3.87 (s, 3H), 7.42 (dd, 1 H), 7.50 (d, 1 H), 7.68 (d, 1 H), 13.21 (br. s., 1 H). Intermediate Example 04.03.
(4-bromo-3-methoxyphenyl)(morpholin-4-yl)methanone
Figure imgf000096_0001
To a stirred solution of 4-bromo-3-methoxybenzoic acid (3.0 g) in dichloromethane (32 ml_) and DMF (1.0 ml_) was added oxalyl chloride (1.78 g) at OT. The mixture was stirred at room temperature for 1 h. The solvent was removed in vacuum. The residue was dissolved in THF (62 mL) and Hiinig Base (6.6 mL) and morpholine (1.66 g) were added. The mixture was stirred at room temperature for 1 h. A half -saturated solution of sodium bicarbonate was added and the mixture was extracted with ethyl acetate. The organic phase was washed with saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum. Silica gel chromatography gave 3.76 g of the title compound.
1H-NMR (400MHz, CHLOROFORM-d): δ [ppm]
6.83 (dd, 1 H), 6.98 (d, 1 H), 7.56 (d, 1 H).
Intermediate Example 04.04. azetidin-1-yl(4-bromo-3-methoxyphenyl)methanone
Figure imgf000097_0001
To a stirred solution of 4-bromo-3-methoxybenzoic acid (400 mg) in DMF (4.0 mL) was added potassium carbonate (720 mg), azetidine (148 mg) and TBTU (890 mg). The mixture was stirred at room temperature for 60 h. Water was added, the mixture was stirred for 15 minutes and the solvent was removed in vaccum. Water was added and the mixture was extracted with ethyl acetate. The organic phase was washed with saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum. Silica gel chromatography gave 370 mg of the title compound.
1H-NMR (400MHz, DMSO-d6): δ [ppm]= 2.15 - 2.27 (m, 2H), 3.85 (s, 3H), 4.00 (t, 2H), 4.26 (t, 2H), 7.07 (dd, 1 H), 7.21 (d, 1 H), 7.61 (d, 1 H).
Intermediate Example 04.05.
(4-Bromo-3-methoxyphenyl)(3-fluoroazetidin-1 -yl)methanone
Figure imgf000097_0002
To a stirred solution of 4-bromo-3-methoxybenzoic acid (1.4 g) in DMF (15 mL) was added potassium carbonate (2.51 g), 3-fluoroazetidine hydrochloride (1.01 g) and HATU (3.69 g). The mixture was stirred at room temperature for 18 h. Water was added, the mixture was stirred for 15 minutes and the solvent was removed in vacuum. Water was added and the mixture was extracted with ethyl acetate. The organic phase was washed with water, saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum, to give 1.25 g of the title compound.
1H-NMR (400 MHz, DMSO-d6): δ [ppm] = 3.90 (s, 3H), 3.99 - 4.16 (m, 1 H), 4.31 - 4.65 (m, 3H), 5.36 (tt, 0.5H), 5.50 (tt, 0.5H), 7.14 (dd, 1 H), 7.26 (d, 1 H), 7.66 (d, 1 H).
Intermediate Example 05.01.
2-(4-bromo-3-methoxyphenyl)propan-2-ol
Figure imgf000098_0001
To a stirred solution of methyl 4-bromo-3-methoxybenzoate (5.3 g) in THF (250 mL) was added methyl magnesium bromide (21.5 mL; c = 3.0 M) at room temperature and the mixture was heated to reflux for 1 h. A half-saturated aqueous solution of ammonium chloride was added and the mixture was extracted with ethyl acetate. The organic phase was washed with saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum. Silicagel chromatography gave 3.09 g of the title compound.
Intermediate Example 06.01.
1 -bromo-2-methoxy-4-(methylsulfanyl)benzene
Figure imgf000098_0002
To a stirred solution of 1 -bromo-4-fluoro-2-methoxybenzene (4.0 mg) in DMF (40 mL) was added sodium methanethiolate (2.76 g). The mixture was stirred at room temperature for 30 minutes and at 85 °C for 2 h. Water was added and the mixture was extracted with ethyl acetate. The organic phase was washed with saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum. Silica gel chromatography gave 280 mg of the title compound.
1H-NMR (400MHz, DMSO-d6): δ [ppm] = 2.46 (s, 3H), 3.82 (s, 3H), 6.74 (dd, 1 H), 6.91 (d, 1 H), 7.44 (d, 1 H).
1 -bromo-2-methoxy-4-(methylsulfanyl)benzene
Figure imgf000099_0001
To a stirred solution of 1 -bromo-4-fluoro-2-methoxybenzene (10.0 g) in DMF (100 mL) was added sodium methanethiolate (4.44 g). The mixture was stirred at 65°C for 2 h. The mixture was cooled to 0°C and methyl iodide (4.55 mL) was added. The mixture was stirred at room temperature for 1 h and further sodium methanethiolate (4.44 g) was added. The mixture was stirred at 65 °C for 1 h. The mixture was cooled to 0°C and methyl iodide (4.55 mL) was added. The mixture was stirred at room temperature for 1 h. Water was added and the mixture was extracted with ethyl acetate. The organic phase was washed with saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum. Silica gel chromatography gave 6.2 g of the title compound as a 2:1 mixture with the starting material. The mixture was used for the next step without purification.
Intermediate Example 06.02.
1 -bromo-2-methoxy-4-(methylsulfonyl)benzene
Figure imgf000100_0001
To a stirred solution of 1 -bromo-2-methoxy-4-(methylsulfanyl)benzene (265 mg) in chloroform (10 mL) was added 3-chlorobenzenecarboperoxoic acid (mCPBA) (890 mg). The mixture was stirred at room temperature for 1 h. A half-saturated solution of sodium bicarbonate was added and the mixture was extracted with dichloromethane. The organic phase was washed with saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum. Silica gel chromatography gave 252 mg of the title compound.
1H-NMR (300MHz, DMSO-d6): δ [ppm] = 3.22 (s, 3H), 3.93 (s, 3H), 7.39 (dd, 1 H), 7.50 (d, 1 H), 7.84 (d, 1 H).
Intermediate Example 07.01.
1 -(4-Bromo-3-methoxyphenyl)piperazine
Figure imgf000100_0002
1 -(3-Methoxyphenyl)piperazine dihydrochloride (1 1 .97 g, 45.1 mmol) and sodium acetate (4.07 g, 49.7 mmol) were added to a mixture of water (77 mL) and glacial acetic acid (360 mL) at 5 °C. Bromine (7.93 g, 49.7 mmol) was added slowly and the mixture was stirred at 0 °C for 1 h. Subsequently, the solvents were removed in vacuo. This residue was dissolved in ethyl acetate and washed with 1 N sodium hydroxide solution. The organic layer was dried (sodium sulphate) and the solvent was evaporated. HPLC separation gave 4.39 g of the title compound. 1H-NMR (400MHz, DMSO-d6): δ [ppm] = 2.79 - 2.83 (4H), 3.03 - 3.08 (4H), 3.33 (1 H), 3.81 (3H), 6.42 (1 H), 6.59 (1 H), 7.30 (1 H).
Intermediate Example 07.02.
1 -(4-Bromo-3-methoxyphenyl)-4-methylpiperazine
Figure imgf000101_0001
To a stirred solution of 1 -(4-Bromo-3-methoxyphenyl)piperazine (1 .0 g, 3.69 mmol) in methanol (60 mL) were added acetic acid (0.42 mL) and after 5 min sodium cyanoborohydride (463 mg, 7.38 mmol). After additional 5 min formaldehyde solution (33 % in water; 0.59 mL, 7.38 mmol) was added. The reaction mixture was stirred at 60 °C for 16 h. Subsequently, the solvents were removed in vacuo. This residue was dissolved in ethyl acetate and washed with 1 N sodium hydroxide solution. The organic layer was dried (sodium sulphate) and the solvent was evaporated. Crystallization from pentanes/ tert-butyl methyl ether gave 961 mg (91 %) of the title compound.
1H-NMR (400MHz, DMSO-d6): δ [ppm] = 2.21 (3H), 2.41 - 2.46 (4H), 3.12 - 3.17 (4H), 3.81 (3H), 6.44 (1 H), 6.61 (1 H), 7.30 (1 H).
Intermediate Example 08.01.
Rac-methyl 2-(4-fluorophenyl)propanoate
Figure imgf000101_0002
To a stirred solution of diisopropylamine (13.0 g) in tetrahydrofurane (160 mL) was added a solution of n-butyllithium in hexane (51.4 mL; c= 2.5 M) at -78 °C. The solution was stirred at 0 °C for 15 minutes. The solution was cooled to -78 °C and a solution of methyl (4-fluorophenyl)acetate (18.0 g), dissolved in tetrahydrofurane (40 mL) was added. The solution was stirred at -78 °C for 30 minutes. Methyl iodide (10.0 mL) was added at -78 °C, and the solution was allowed to warm up to 0 °C within 1 h. Water was added and the reaction mixture was extracted with ethyl acetate. The organic phase was dried (sodium sulfate) and the solvent was removed in vacuum. Silicagel chromatography gave 18.9 g of the title compound.
1H-NMR (400MHz, DMSO-d6): δ [ppm] = 1.34 (d, 3H), 3.55 (s, 3H), 3.79 (q, 1 H), 7.08 - 7.15 (m, 2H), 7.25 - 7.32 (m, 2H).
Intermediate Example 08.02.
Rac-2-(4-fluorophenyl)propanoic acid
Figure imgf000102_0001
To a stirred solution of rac-methyl 2-(4-fluorophenyl)propanoate (18.9 g) in ethanol (200 mL) was added a solution of potassium hydroxide (35 g), dissolved in water (200 mL). The mixture was stirred at 0 °C for 4 h. Hydrochloric acid (c = 4.0 M) was added until pH 5 was reached and the reaction mixture was extracted with ethyl acetate. The organic phase was separated and the solvent was removed in vacuum to give 15.64 g of the title product. The crude product was used without further purification.
1H-NMR (300MHz, DMSO-d6): δ [ppm] = 1.31 (d, 3H), 3.66 (q, 1 H), 7.05 - 7.15 (m, 2H), 7.24 - 7.33 (m, 2H), 12.30 (s, 1 H). Intermediate Example 08.03.
(2/?)-2-(4-fluorophenyl)propanoic acid
Figure imgf000103_0001
To a stirred solution of Rac-2-(4-fluorophenyl)propanoic acid (23.6 g) in refluxing ethyl acetate (250mL) was added a solution of (1S)-1 - phenylethanamine (17.35 g) in ethyl acetate. The mixture was allowed to cool down to room temperature within 1 h. A white solid was collected by filtration, was washed with ethyl acetate and dried in vacuum to give 27.5 g of a solid. The solid was recrystallized from 400 mL refluxing ethyl acetate. The mixture was allowed to cool down to room temperature. A white solid was collected by filtration, was washed with ethyl acetate and dried in vacuum to give 18.3 g of a solid. The solid was twice recrystallized from refluxing ethyl acetate (350 mL; 300 mL). A white solid was collected by filtration, was washed with ethyl acetate and dried in vacuum to give 10.51 g of a solid. The solid was dissolved in water, hydrochloric acid (c = 2.0 M) was added until pH 5 was reached and the reaction mixture was extracted with dichloromethane. The organic phase was dried (sodium sulfate) and the solvent was removed in vacuum to give 5.6 g of the title product. The crude product was used without further purification.
1H-NMR (300MHz, DMSO-d6): δ [ppm] = 1.31 (d, 3H), 3.66 (q, 1 H), 7.05 - 7.16 (m, 2H), 7.24 - 7.33 (m, 2H), 12.28 (br. s., 1 H).
[a]D 20 : -79.3° (in DMSO)
Column: Chiralcel OJ-H 150x4.6; Flow: 1.00 mL/min; Solvent: A: Hexane, B: 2- propanol with 0.1 % formic acid; Solvent mixture: 80% A + 20% B. Run Time: 30 min. Retention Time: 3.41 min; UV 254 nm; Enantiomeric Ratio: 99.8% : 0.2%. Intermediate Example 08.04.
(2R)-2-(4-fluorophenyl)-N-[4-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- yl)phenyl]propanamide
Figure imgf000104_0001
To a stirred solution of 4-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)aniline (1.0 g) in DMF (45 mL) and dichloromethane (90 mL) was added sodium bicarbonate (766 mg), (2R)-2-(4-fluorophenyl)propanoic acid (844 mg) and HATU (2.6 g). The mixture was stirred at room temperature for 4 h. Water was added, and the mixture was stirred for 30 minutes. A half-saturated solution of sodium bicarbonate was added and the mixture was extracted with ethyl acetate. The organic phase was washed with saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum. Silica- gel chromatography gave 1.53 g of the title compound.
1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 1.23 (12H), 1.37 (3H), 3.74-3.87 (1 H), 7.06-7.16 (2H), 7.31 -7.42 (2H), 7.51 -7.61 (4H), 10.12 (1 H).
Intermediate Example 08.05.
(4-{[(2R)-2-(4-fluorophenyl)propanoyl]amino}phenyl)boronic acid
Figure imgf000104_0002
To a stirred solution of (4-aminophenyl)boronic acid hydrochloride (2.00 g) in DMF (42 mL) was added sodium bicarbonate (2.9 g), (2R)-2-(4- fluorophenyl)propanoic acid (2.04 g) and HATU (6.58 g). The mixture was stirred at room temperature for 72 h. Water (140 mL) was added, and the mixture was stirred for 2 h. The white precipitate was collected by filtration and was washed with water and was dried in vacuum to give 2.86 g of the title compound.
1H-NMR (300 MHz, DMSO-d6), δ [ppm] = 1.39 (3H), 3.84 (1 H), 7.08-7.21 (2H), 7.35-7.44 (2H), 7.52 (2H), 7.69 (2H), 7.88 (2H), 10.07 (1 H).
Intermediate Example 09.01.
(2R)-N-[4-(2-amino[1 ,2,4]triazolo[1 ,5-a]pyridin-7-yl)phenyl]-2-(4- fluorophenyl)propanamide
Figure imgf000105_0001
To a stirred solution of 7-bromo[1 ,2,4]triazolo[1 ,5-a]pyridin-2-amine (100 mg; CAS-RN [882521 -63-3]; commercially available from Allichem LLC, USA; Baltimore, MD; preparation described WO2010/020363A1 ) in 1 -propanol (3 mL) was added potassium carbonate solution (0.7 mL, c = 2 M), (4-{[(2R)-2-(4- fluorophenyl)propanoyl]amino}phenyl)boronic acid (202 mg), triphenylphosphine (12 mg) and PdCl2(PPh3)2 (33 mg). The mixture was heated to reflux for 16 h. Further triphenylphosphine (12 mg) and PdCl2(PPh3)2 (33 mg) were added and the mixture was heated to reflux for further 4 h. The reaction mixture was filtered through an aminophase-silica-gel column and the solvent was removed in vacuum. Silicagel chromatography gave 150 mg of the title compound. 1H-NMR (400 MHz, DMSO-d6), δ [ppm]= 1.42 (3H), 3.86 (1 H), 5.97 (2H), 7.08- 7.25 (3H), 7.35-7.49 (2H), 7.58 (1 H), 7.63-7.83 (4H), 8.53 (1 H), 10.21 (1 H).
Intermediate Example 09.02.
ethyl [(4-chloropyridin-2-yl)carbamothioyl]carbamate
H H
O S
Ethoxycarbonyl isothiocyanate (11.1 g) was added to a stirred solution of 2- amino-4-chloropyridine (10.1 g) in dioxane (100 mL). The mixture was stirred for 2h at r.t. A white solid precipitated. Hexane (25 mL) was added and the white solid was collected by filtration to give 8.0 g of the title compound. The solution was concentrated in vacuum and the residue was recrystallized from ethyl acetate to give further 8.5 g of the title compound.
Intermediate Example 09.03.
7-chloro[ 1 , 2,4]triazolo[ 1 , 5-a]pyridin-2-amine
Figure imgf000106_0001
Hydroxylammonium chloride (13.9 g) was suspended in methanol (70 mL), and ethanol (65 mL) and Hiinig Base (21.1 mL) were added at r.t. The mixture was heated to 60° C, ethyl [(4-chloropyridin-2-yl)carbamothioyl]carbamate (9.0 g) was added portionwise, and the mixture was stirred at 60 °C for 2h. The solvent was removed in vacuum and water (150 mL) was added. A solid was collected by filtration and was washed with ethanol and dried in vacuum. Silicagel chromatography gave 4.2 g of the title compound.
1H-NMR (300 MHz, DMSO-d6), δ [ppm] = 6.14 (2H), 6.92 (1 H), 7.50 (1 H), 8.55 (1 H).
Intermediate Example 09.04.
7-chloro-N-[2-methoxy-4-(methylsulfonyl)phenyl][1 ,2,4]triazolo[1 ,5- a]pyridin-2-amine
Figure imgf000107_0001
Starting from 7-chloro[1 ,2,4]triazolo[1 ,5-a]pyridin-2-amine (300 mg) and 1 - bromo-2-methoxy-4-(methylsulfonyl)benzene (543 mg), Intermediate Example 09.04. was prepared analogously to the procedure for the preparation of Intermediate Example 09.05. Yield: 236 mg of the title compound.
1H-NMR (300 MHz, DMSO-d6), δ [ppm] = 3.18 (3H), 3.97 (3H), 7.17 (1 H), 7.44 (1 H), 7.53 (1 H), 7.86 (1 H), 8.43 (1 H), 8.75 (1 H), 8.87 (1 H).
Intermediate Example 09.05.
{4-[(7-chloro[1 ,2,4]triazolo[1 ,5-a]pyridin-2-yl)amino]-3-methoxyphenyl}(3- fluoroazetidin-1 -yl)methanone
Figure imgf000108_0001
To a stirred suspension of 7-chloro[1 ,2,4]triazolo[1 ,5-a]pyridin-2-amine
(190 mg) in toluene (7 mL) and NMP (0.7 mL) was added (4-Bromo-3- methoxyphenyl)(3-fluoroazetidin-1 -yl)methanone (373 mg), chloro(2- dicyclohexylphosphino-2^4\6'-tri-iso-propyl-1,r-biphenyl)[2-(2-aminoethyl) phenyl] palladium(ll) methyl-tert-butylether adduct (28 mg), X-Phos (16 mg) and powdered potassium phosphate monohydrate (0.60 g) and the flask was degassed twice and backfilled with argon. The mixture was heated to reflux for 16 h.
A half-saturated solution of potassium carbonate was added and the mixture was extracted with a mixture of dichloromethane and methanol. The organic phase was dried (sodium sulfate) and the solvent was removed in vacuum. The mixture was filtered and concentrated in vacuum. Silicagel chromatography gave 120 mg of the title compound.
1H-NMR (300 MHz, DMSO-d6), δ [ppm] = 3.91 (3H), 3.94-4.80 (4H), 5.26-5.59 (1 H), 7.15 (1 H), 7.23-7.33 (2H), 7.82 (1 H), 8.21 -8.36 (1 H), 8.46 (1 H), 8.85 (1 H).
Intermediate Example 09.06.
7-chloro-N-[4-(methylsulfonyl)-2-(2,2,2- trifluoroethoxy)phenyl][1 ,2,4]triazolo[1 ,5-a]pyridin-2-amine
Figure imgf000109_0001
Starting from 7-chloro[1 ,2,4]triazolo[1 ,5-a]pyridin-2-amine (100 mg) and 1 -bromo-4-(methylsulfonyl)-2-(2,2,2-trifluoroethoxy)benzene (227 mg), Intermediate Example 09.06. was prepared analogously to the procedure for the preparation of Intermediate Example 09.05. Yield: 50 mg of the title compound.
1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 3.19 (3H), 5.00 (2H), 7.18 (1 H), 7.58- 7.71 (2H), 7.86 (1 H), 8.44 (1 H), 8.70 (1 H), 8.81 -8.92 (1 H).
Intermediate Example 09.07.
{4-[(7-chloro[1 ,2,4]triazolo[1 ,5-a]pyridin-2-yl)amino]-3-(2,2,2- trifluoroethoxy)phenyl}(3-fluoroazetidin-1 -yl)methanone
Figure imgf000109_0002
Starting from 7-chloro[1 ,2,4]triazolo[1 ,5-a]pyridin-2-amine (250 mg) and [4-bromo-3-(2,2,2-trifluoroethoxy)phenyl](3-fluoroazetidin-1 -yl)methanone (607 mg), Intermediate Example 09.07. was prepared analogously to the procedure for the preparation of Intermediate Example 09.05. Yield: 198 mg of the title compound. 1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 3.93-4.72 (4H), 4.93 (2H), 5.32-5.55 (1 H), 7.16 (1 H), 7.36-7.43 (2H), 7.83 (1 H), 8.27-8.33 (1 H), 8.41 (1 H), 8.81 -8.90 (1 H).
Intermediate Example 09.08.
azetidin-1 -yl{4-[(7-chloro[1 ,2,4]triazolo[1 ,5-a]pyridin-2-yl)amino]-3- methoxyphenyljmethanone
Figure imgf000110_0001
Starting from 7-chloro[1 ,2,4]triazolo[1 ,5-a]pyridin-2-amine (190 mg) and azetidin-1 -yl(4-bromo-3-methoxyphenyl)methanone (350 mg), Intermediate Example 09.08. was prepared analogously to the procedure for the preparation of Intermediate Example 09.05. Yield: 130 mg of the title compound. 1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 2.27 (2H), 3.88-3.94 (3H), 3.97-4.47 (4H), 7.15 (1 H), 7.23-7.31 (2H), 7.83 (1 H), 8.28 (1 H), 8.42 (1 H), 8.79-8.93 (1 H). Intermediate Example 10.01.
6-chloro-N-[2-methoxy-4-(methylsulfonyl)phenyl]imidazo[1 ,2-b]pyridazin- 2-amine
Figure imgf000111_0001
To a stirred suspension of 6-chloroimidazo[1 ,2-b]pyridazin-2-amine (250 mg; CAS-RN [887625-09-4]; commercially available from Zylexa Pharma Ltd.; United Kingdom) in toluene (10 mL) and NMP (1.0 mL) was added 1 -bromo-2- methoxy-4-(methylsulfonyl)benzene (590 mg), chloro(2-dicyclohexylphosphino- 2',4',6'-tri-iso-propyl-1 ,1'-biphenyl)[2-(2-aminoethyl) phenyl] palladium(ll) methyl-tert-butylether adduct (123 mg), X-Phos (71 mg) and powdered potassium phosphate monohydrate (1.57 g) and the flask was degassed twice and backfilled with argon. The mixture was heated to reflux for 16 h. The mixture was filtered and concentrated in vacuum. Silicagel chromatography followed by aminophase silicagel chromatography gave 120 mg of the title compound.
1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 3.15 (3H), 3.99 (3H), 7.26 (1 H), 7.40 (1 H), 7.46 (1 H), 8.01 (1 H), 8.05 (1 H), 8.53 (1 H), 8.92 (1 H). Intermediate Example 1 1.01.
2-chloro-3-methoxy-5-(methylsulfonyl)pyridine
Figure imgf000112_0001
To a solution of sodium sulphite (448 mg) and sodium bicarbonate (313 mg) in water (2.4 ml) was added 6-chloro-5-methoxypyridine-3-sulfonyl chloride (430 mg; CAS-RN [75720-93-3]; commercially available from Ablock Pharmatech, Inc., USA) and ethanol (1 .2 ml_). The mixture was heated to 50T for 45 minutes and concentrated to dryness. The residue was suspended in DMF (3.6 ml_), iodomethane (1261 mg) was added and the mixture was stirred at room temperature for 1 hour. The mixture was diluted with water whereby the desired product precipitated. The solid was separated by suction filtration and dried in vacuo to give 265 mg of the title compound.
1H-NMR (400 MHz, CDCU), δ [ppm] = 3.16 (3H), 4.04 (3H), 7.66 (1 H), 8.55 (1 H).
Intermediate Example 1 1.02.
6-bromo-N-[3-methoxy-5-(methylsulfonyl)pyridin-2-yl]imidazo[1 ,2- a]pyridin-2-amine
Figure imgf000112_0002
To a stirred suspension of 6-bromoimidazo[1 ,2-a]pyridin-2-amine hydrochloride (144 mg; CAS-RN [947248-52-4]; commercially available from Apollo Scientific Ltd.; United Kingdom) in THF (10 mL) at 0°C was added sodium hydride (101 mg; 55%) and the mixture was stirred for 30 minutes. 2-chloro-3- methoxy-5-(methylsulfonyl)pyridine (150 mg) was added and the suspension was heated at 130°C for 1 hour in a closed microwave vessel in a microwave oven. After cooling, the mixture was diluted with water and extracted with ethyl acetate (3x). The combined organic phases were washed with an aqueous solution of sodium chloride, dried (MgS04), filtered and concentrated. Silicagel chromatography gave 75 mg of the title compound.
1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 3.24 (3H), 3.98 (3H), 7.32 (1 H), 7.40 (1 H), 7.55 (1 H), 8.29 (1 H), 8.40 (1 H), 8.93 (1 H), 9.07 (1 H).
Intermediate Example 1 2.01
5-bromo-6-methoxy-2,3-dihydro-1 -benzothioph
Figure imgf000113_0001
Int12.01 was prepared as described by David W. Robertson et al. in European Journal of Medicinal Chemistry, 1986, 21 , p223-229.
Int12.01 can also be prepared in a similar way as described below:
Intermediate Example 12.01. a
1 -[(2,2-dimethoxyethyl)sulfanyl]-3-methoxybenzene
Figure imgf000114_0001
To a stirred solution of 3-methoxybenzenethiol (5.14 g) in acetonitrile (31 mL) was added potassium carbonate (6.08 g) and the mixture was stirred for 2 h at r.t.. 2-bromo-1 ,1 -dimethoxyethane (7.67 g) was added and the mixture was stirred for at r.t. for 70 h. Water was added and the mixture was extracted with a mixture of ethyl acetate and hexane (1 : 1 ). The organic phase was dried (sodium sulfate) and the solvent was removed in vacuum. Silicagel chromatography gave 8.0 g of the title compound.
1H-NM (300 MHz, CHLOROFORM-d), δ [ppm] = 3.15 (2H), 3.40 (6H), 3.82 (3H), 4.56 (1 H), 6.76 (1 H), 6.92-7.01 (2H), 7.19-7.26 (1 H).
Intermediate Example 12.01.b
6-methoxy-1 -benzothiophene
Figure imgf000114_0002
To a stirred solution of 1 -[(2,2-dimethoxyethyl)sulfanyl]-3-methoxybenzene (1.0 g) in chlorobenzene (40 mL) was added polyphosphoric acid (1.0 g; CAS- RN: [8017-16-1]; >83% phosphate (as P205) from Sigma-Aldrich; Order No. 04101 ) and the mixture was heated to 80°C for 1 h. The mixture was cooled to OT with an ice-bath and an aqueous solution of sodium hydroxide was added with ice bath cooling until pH7 was reached. The mixture was extracted with dichloromethane, the organic phase was dried (sodium sulfate) and the solvent was removed in vacuum. Silicagel chromatography gave 407 mg of the title compound, containing approx. 20% of a second isomer. This mixture was used for the next step without further purification. 1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 3.81 (3H), 6.99 (1 H), 7.31 -7.35 (1 H), 7.51 (1 H), 7.56 (1 H), 7.74 (1 H). The product contains approx. 20% of a second isomer. Intermediate Example 12.01. C
6-methox -1 -benzothiophene 1 , 1 -dioxide
Figure imgf000115_0001
To a stirred solution of 6-methoxy-1 -benzothiophene (700 mg) in chloroform (11 mL) at 0°C was added 3-chlorobenzenecarboperoxoic acid (1.99 g) and the mixture was stirred for 2 h at r.t.. An aqueous solution of disodium sulfurothioate was added, the mixture was stirred for 30 minutes and was consecutively extracted with ethyl acetate and with dichloromethane. Both organic phases were washed with a half saturated sodium bicarbonate solution and with saturated sodium chloride solution. The organic phases were combined, dried (sodium sulfate) and the solvent was removed in vacuum. Silicagel chromatography gave 612 mg of the title compound, containing approx. 20% of a second isomer. This mixture was used for the next step without further purification.
1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 3.86 (3H), 7.15-7.22 (2H), 7.45 (1 H), 7.49 (1 H), 7.54 (1 H).
Intermediate Example 12.01.d
6-methoxy-2,3-dihydro-1 -benzothiophene 1 , 1 -dioxide
Figure imgf000115_0002
To a stirred solution of 6-methoxy-1 -benzothiophene 1 ,1 -dioxide (605 mg) in ethanol (10 mL) and dichloromethane (10 mL) was added palladium on carbon (10 % w/w palladium) (147 mg) and the mixture was stirred at r.t. in a hydrogen atmosphere for 16 h. The mixture was filtered, and concentrated in vacuum. Silicagel chromatography gave a solid that was recrystallized from ethanol to give 248 mg of the title compound, as a single isomer.
1H-NMR (300 MHz, DMSO-d6), δ [ppm] = 3.20-3.29 (2H), 3.53-3.63 (2H), 3.82 (3H), 7.18-7.25 (2H), 7.42 (1 H).
Intermediate Example 12.01.e
6-methox -2,3-dihydro-1 -benzothiophene
Figure imgf000116_0001
To a stirred solution of 6-methoxy-2,3-dihydro-1 -benzothiophene 1 ,1 -dioxide (224 mg) in diethyl ether (80 ml_) was added lithium aluminumhydride (386 mg) and the mixture was heated to reflux for 4 h. Water was added, and aqueous hydrochloric acid was added until a clear solution had formed. The mixture was extracted with diethyl ether, the solution was dried (sodium sulfate) and the solvent was removed in vacuum. Silicagel chromatography gave 136 mg of the title compound.
1H-NMR (300 MHz, DMSO-d6), δ [ppm] = 3.08-3.17 (2H), 3.28-3.37 (2H), 3.69 (3H), 6.55 (1 H), 6.81 (1 H), 7.11 (1 H).
Intermediate Example 12.01
5-bromo-6-methoxy-2,3-dihydro-1-benzothiophene
Figure imgf000117_0001
To a stirred solution of 6-methoxy-2,3-dihydro-1 -benzothiophene (136 mg) in trichloromethane (9.5 mL) was added a freshly prepared solution of bromine in trichloromethane (0.44 mL; c = 10 % w/w) at OT and the solution was stirred at 0°C for 1 h. An aqueous solution of disodium sulfurothioate was added, and the mixture was extracted with dichloromethane. The organic phase was dried (sodium sulfate) and the solvent was removed in vacuum. Silicagel chromatography gave 170 mg of the title compound.
1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 3.13-3.19 (2H), 3.34-3.40 (2H), 3.78 (3H), 7.03 (1 H), 7.33-7.45 (1 H).
Intermediate Example 12.02
5-bromo-1 ,1 -dioxido-2,3-dihydro-1 -benzothiophen-6-yl methyl ether
Figure imgf000117_0002
To a stirred solution of 5-bromo-6-methoxy-2,3-dihydro-1 -benzothiophene (200 mg) in chloroform (15 mL) was added 3-chlorobenzenecarboperoxoic acid (380 mg) and the mixture was stirred for 1 h at r.t.. An aqueous solution of disodium sulfurothioate was added, the mixture was stirred for 30 minutes and was extracted with dichloromethane. The organic phase was washed with a half saturated potassium carbonate solution and with saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum. Silicagel chromatography gave 130 mg of the title compound.
1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 3.26 (2H), 3.59 (2H), 3.93 (3H), 7.40 (1 H), 7.82 (1 H).
Intermediate Example 1 3.01
1 -bromo-4-f luoro-2-(2, 2, 2-trif luoroethoxy )benzene
Figure imgf000118_0001
To a stirred solution of 2-bromo-5-fluorophenol (1.5 g) in acetonitrile (0.5 mL) and DMF (8.5 mL) in a microwave tube was added potassium carbonate (2.1 g) and 2,2,2-trifluoroethyl trifluoromethanesulfonate (2.37 g). The mixture was heated to 150°C in a microwave oven for 30 minutes. In a second microwave tube the same reaction was repeated. Both mixtures were combined. The solvent was removed in vacuum, ethyl acetate and hexane (1 :1 ) was added and the mixture was washed with water. The organic phase was washed with saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum. Silica gel chromatography gave 4.0 g of the title compound.
1H-NMR (300MHz, CHLOROFORM-d): δ [ppm]= 4.39 (q, 2H), 6.62 - 6.78 (m, 2H), 7.53 (dd, 1 H).
Intermediate Example 1 3.02
1 -bromo-4-(methylsulfanyl)-2-(2,2,2-trifluoroethoxy)benzene
Figure imgf000119_0001
To a stirred solution of 1 -bromo-4-fluoro-2-(2,2,2-trifluoroethoxy)benzene (4.0 g) in DMF (15 mL) was added sodium methanethiolate (1.0 g). The mixture was stirred for 2 h at 60 °C. The mixture was cooled to room temperature. Water was added and the mixture was extracted with ethyl acetate. The organic phase was washed with saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum to give 3.8 g of the crude title compound, that was used for the next step without purification.
1H-NMR (300MHz, CHLOROFORM-d): δ [ppm]= 2.48 (s, 3H), 4.39 (q, 2H), 6.78 - 6.88 (m, 2H), 7.46 (d, 1 H).
Intermediate Example 1 3.03
1 -bromo-4-(methylsulfonyl)-2-(2,2,2-trifluoroethoxy)benzene
Figure imgf000119_0002
To a stirred solution of 1 -bromo-4-(methylsulfanyl)-2-(2,2,2- trifluoroethoxy)benzene (3.8 g) in chloroform (100 mL) was added 3- chlorobenzenecarboperoxoic acid (mCPBA) (8.48 g). The mixture was stirred at room temperature for 16 h. With ice bath cooling, a half-saturated solution of sodium bicarbonate and and a 0.2 M solution of sodium thiosulfate was added, the mixture was stirred for 30 minutes and the mixture was extracted with dichloromethane. The organic phase was washed with a 0.2 M solution of sodium thiosulfate and a saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum. Silica gel chromatography gave a solid that was triturated with ether to give 2.1 g of the title compound. H-NMR (400MHz, CHLOROFORM-d): δ [ppm]= 3.06 (s, 3H), 4.50 (q, 2H), 7.45 (d, 1 H), 7.52 (dd, 1 H), 7.81 (d, 1 H).
Intermediate Example 14.01
methyl 4-bromo-3-(2, 2, 2-trif luoroethoxy )benzoate
Figure imgf000120_0001
To a stirred solution of methyl 4-bromo-3-hydroxybenzoate (2.5 g) in acetonitrile (0.5 mL) and DMF (10 mL) in a microwave tube was added potassium carbonate (2.93 g) and 2,2,2-trifluoroethyl trifluoromethane- sulfonate (2.79 g). The mixture was heated to 150°C in a microwave oven for 30 minutes. The solvent was removed in vacuum, ethyl acetate was added and the mixture was washed with water. The organic phase was washed with saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum. Recrystallization of the residue from ethanol gave 1.2 g of the title compound. The mother liquor was concentrated in vacuum and purified by aminophase-silica-gel chromatography followed by recrystallized from methanol and water to give further 0.64 g of the title compound.
1H-NMR (300MHz, CHLOROFORM-d): δ [ppm]= 3.93 (s, 3H), 4.47 (q, 2H), 7.56 (d, 1 H), 7.58 - 7.70 (m, 2H).
Intermediate Example 14.02
4-bromo-3-(2, 2, 2-trif luoroethoxy )benzoic acid
Figure imgf000121_0001
To a stirred solution of methyl 4-bromo-3-(2,2,2-trifluoroethoxy)benzoate (1.83 g) in THF (30 ml_), methanol (10 mL) and water (10 mL) was added a 1 M solution of lithium hydroxide in water (18 mL). The mixture was stirred at room temperature for 1 h. Water was added and 2 N hydrochloric acid was added until pH 4 was reached. The precipitated solid was collected by filtration, was washed with water. The solid was suspended with toluene and concentrated in vacuum. Trituration of the residue with hexane gave 1.6 g of the title compound.
1H-NMR (300MHz, DMSO-d6): δ [ppm]= 4.95 (q, 2H), 7.51 (dd, 1 H), 7.65 (d, 1 H), 7.74 (d, 1 H), 13.29 (br. s., 1 H).
Intermediate Example 14.03
4-bromo-3-(2, 2, 2-trif luoroethoxy )benzamide
Figure imgf000121_0002
To a stirred suspension of 4-bromo-3-(2,2,2-trifluoroethoxy)benzoic acid (0.50 g) in THF (20 mL) was added DMF (0.2 mL) and oxalyl choride (0.30 mL). The mixture was stirred at room temperature for 0.5 h. With ice bath cooling, ammonia gas was bubbled through the reaction mixture. A white solid precipitated. The mixture was stirred for further 15 minutes. Ethyl acetate was added and the mixture was washed with water and with a saturated solution of sodium chloride. The organic phase was dried (sodium sulfate) and the solvent was removed in vacuum to give a white solid. The solid was triturated with toluene and washed with toluene and hexanes to give 0.27 g of the title compound.
1H-NMR (300MHz, DMSO-d6): δ [ppm]= 4.88 (q, 2H), 7.45 (dd, 1 H), 7.50 (br. s., 1 H), 7.64 (d, 1 H), 7.69 (d, 1 H), 8.00 (br. s., 1 H).
Intermediate Example 14.04
4-bromo-3-(2,2,2-trifluoroethoxy)phenyl](3-fluoroazetidin-1 -yl)methanone
Figure imgf000122_0001
Starting from 4-bromo-3-(2,2,2-trifluoroethoxy)benzoic acid and 3- fluoroazetidine hydrochloride, Intermediate Example 14.04 was prepared analogously to the procedure for the preparation of Intermediate Example 04.05.
EXAMPLES
Example 1.1.
2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(morpholin-4- ylcarbonyl)phenyl]amino}[1 ,2,4]triazolo[1 ,5-b]pyridazin-6- yl)phenyl]acetamide
Figure imgf000123_0001
To a stirred suspension of N-[4-(2-amino[1 ,2,4]triazolo[1 ,5-b]pyridazin-6- yl)phenyl]-2-(4-fluorophenyl)acetamide (100 mg) in toluene (2.5 mL) and NMP (1.3 mL) was added (4-bromo-3-methoxyphenyl)(morpholin-4-yl)methanone (124 mg), chloro(2-dicyclohexylphosphino-2',4',6'-tri-iso-propyl-1 ,1'- biphenyl)[2-(2-aminoethyl)phenyl] palladium(ll) methyl-tert-butylether adduct (22.8 mg) and X-Phos (13.4 mg) and the flask was degassed twice and backfilled with argon. The mixture was stirred for 5 minutes at room temperature. Powdered potassium phosphate (293 mg) was added and the flask was degassed twice and backfilled with argon. The mixture was heated to reflux for 3 h. The reaction mixture was filtered through an aminophase-silica- gel column and the solvent was removed in vacuum. Aminophase-silica-gel chromatography gave 79 mg of the title compound.
1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 3.50 (4H), 3.58 (4H), 3.66 (2H), 3.89 (3H), 7.03-7.08 (2H), 7.09-7.18 (2H), 7.31 -7.39 (2H), 7.76 (2H), 8.03 (2H), 8.07- 8.12 (1 H), 8.15-8.21 (1 H), 8.26 (1 H), 8.46 (1 H), 10.38 (1 H).
Example 1.2.
2-(4-fluorophenyl)-N-[4-(2-{[4-(2-hydroxypropan-2-yl)-2- methoxyphenyl]amino}[1 ,2,4]triazolo[1 ,5-b]pyridazin-6- yl)phenyl]acetamide
Figure imgf000124_0001
To a stirred suspension of N-[4-(2-amino[1 ,2,4]triazolo[1 ,5-b]pyridazin-6- yl)phenyl]-2-(4-fluorophenyl)acetamide (100 mg) in toluene (2.5 mL) and NMP (1.3 mL) was added 2-(4-bromo-3-methoxyphenyl)propan-2-ol (101 mg), chloro(2-dicyclohexylphosphino-2',4',6'-tri-iso-propyl-1 ,1'-biphenyl)[2-(2- aminoethyl)phenyl] palladium(ll) methyl-tert-butylether adduct (22.8 mg) and X-Phos (13.4 mg) and the flask was degassed twice and backfilled with argon. The mixture was stirred for 5 minutes at room temperature. Powdered potassium phosphate (293 mg) was added and the flask was degassed twice and backfilled with argon. The mixture was heated to reflux for 3 h. The reaction mixture was filtered through an aminophase-silica-gel column and the solvent was removed in vacuum. Aminophase-silica-gel chromatography gave 90 mg of the title compound.
1H-NMR (300 MHz, DMSO-d6), δ [ppm] = 1.41 (6H), 3.66 (2H), 3.84 (3H), 4.93 (1 H), 7.01 (1 H), 7.07-7.18 (3H), 7.29-7.40 (2H), 7.75 (2H), 7.96-8.09 (4H), 8.09- 8.17 (2H), 10.39 (1 H).
Example 1.3.
2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-
(methylsulfonyl)phenyl]amino}[1 ,2,4]triazolo[1 ,5-b]pyridazin-6- yl)phenyl]acetamide
Figure imgf000125_0001
To a stirred suspension of N-[4-(2-amino[1 ,2,4]triazolo[1 ,5-b]pyridazin-6- yl)phenyl]-2-(4-fluorophenyl)acetamide (100 mg) in toluene (2.5 mL) and NMP (1.3 mL) was added 1 -bromo-2-methoxy-4-(methylsulfonyl)benzene (110 mg), chloro(2-dicyclohexylphosphino-2',4',6'-tn-iso-propyl-1 ,1'-biphenyl)[2-(2- aminoethyl)phenyl] palladium(ll) methyl-tert-butylether adduct (22.8 mg) and X-Phos (13.4 mg) and the flask was degassed twice and backfilled with argon. The mixture was stirred for 5 minutes at room temperature. Powdered potassium phosphate (293 mg) was added and the flask was degassed twice and backfilled with argon. The mixture was heated to reflux for 3 h. The reaction mixture was filtered through an aminophase-silica-gel column and the solvent was removed in vacuum. Aminophase-silica-gel chromatography gave 90 mg of the title compound.
1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 3.17 (3H), 3.66 (2H), 3.96 (3H), 7.08- 7.17 (2H), 7.31 -7.39 (2H), 7.44 (1 H), 7.55 (1 H), 7.76 (2H), 8.04 (2H), 8.13 (1 H), 8.19-8.27 (1 H), 8.46 (1 H), 8.85 (1 H), 10.40 (1 H).
Example 2.1.
N-(4-{2-[(2-cyanophenyl)amino][1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl}phenyl)- 2- 4-fluorophenyl)acetamide
Figure imgf000125_0002
To a stirred suspension of N-[4-(2-amino[1 ,2,4]triazolo[1 ,5-a]pyrazin-6- yl)phenyl]-2-(4-fluorophenyl)acetamide (4.00 g) in toluene (100 mL) and NMP (8.0 mL) was added 2-bromobenzonitrile (4.10 g), (R)-BINAP (1.37 g) and Pd2dba3 (1.01 g) and cesium carbonate (17.98 g) and the flask was degassed twice and backfilled with argon. The mixture was heated to reflux for 3 h. Water was added and the reaction mixture was extracted with ethyl acetate. The organic phase was washed with saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum. Silicagel chromatography gave a solid that was triturated with dichloromethane and afterwards with hot ethyl acetate to give 1.88 g of the crude title compound as a solid. The solid was dissolved in DMF (50 mL). Ethyl acetate (300 mL) was added and the organic phase was washed with a half-saturated sodium chloride solution for three times. The compound precipitated in the organic phase and was collected by filtration. The solid was washed with dichloromethane and hexane and dried in vacuum to give 1.65 g of the title compound.
1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 3.65 (2H), 7.09-7.16 (2H), 7.20 (1 H), 7.31 -7.38 (2H), 7.62-7.72 (3H), 7.76 (1 H), 7.94 (1 H), 8.01 -8.08 (2H), 9.10 (1 H), 9.43 (1 H), 9.90 (1 H), 10.33 (1 H). Example 2.2.
N-(4-{2-[(2-cyano-3-fluorophenyl)amino][1 ,2,4]triazolo[1 ,5-a]pyrazin-6- l}phenyl)-2-(4-fluorophenyl)acetamide
Figure imgf000126_0001
To a stirred suspension of N-[4-(2-amino[1 ,2,4]triazolo[1 ,5-a]pyrazin-6- yl)phenyl]-2-(4-fluorophenyl)acetamide (200 mg) in toluene (2 mL) and NMP (0.2 mL) was added 2-bromo-6-fluorobenzonitrile (227 mg), (rac)-BINAP (35 mg) and Pd2dba3 (25 mg) and cesium carbonate (551 mg) and the flask was degassed twice and backfilled with argon. The mixture was heated to reflux for 4 h. A mixture of ethyl acetate and methanol (100:1 ; 250 mL) was added and the mixture was filtered through celite. The organic phase was washed with saturated sodium bicarbonate solution, with saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum. Repeated silicagel chromatography gave a solid that was triturated with warm ethanol to give 31 mg of the title compound.
1H-NMR (300 MHz, DMSO-d6), δ [ppm] = 3.64 (2H), 7.08-7.18 (3H), 7.30-7.39 (2H), 7.65-7.75 (3H), 7.80-7.87 (1 H), 8.05 (2H), 9.15 (1 H), 9.46 (1 H), 10.23 (1 H), 10.31 (1 H).
Example 2.3.
N-(4-{2-[(2-cyanophenyl)amino][1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl}phenyl)- 2- henylacetamide
Figure imgf000127_0001
To a stirred solution of 2-{[6-(4-aminophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrazin-2- yl]amino}benzonitrile (70 mg) in DMF (2.1 mL) was added potassium carbonate (118 mg), phenylacetic acid (43.7 mg) and TBTU (206 mg). The mixture was stirred at room temperature for 64 h. Water was added, the mixture was stirred for 15 minutes and the mixture was extracted with dichloromethane and methanol (100:1 ). The organic phase was washed with saturated sodium bicarbonate solution dried (sodium sulfate) and the solvent was removed in vacuum. Repeated silicagel chromatography followed by preparative reverse phase HPLC gave a solid that was triturated with warm ethanol to give 11 mg of the title compound. 1H-NMR (300 MHz, DMSO-d6), δ [ppm] = 3.64 (2H), 7.16-7.25 (2H), 7.26-7.35 (4H), 7.62-7.73 (3H), 7.76 (1 H), 7.94 (1 H), 8.04 (2H), 9.11 (1 H), 9.43 (1 H), 9.90 (1 H), 10.31 (1 H). Example 2.4.
2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(4-methylpiperazin-1 - l)phenyl]amino}[1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl)phenyl]acetamide
Figure imgf000128_0001
To a stirred suspension of N-[4-(2-amino[1 ,2,4]triazolo[1 ,5-a]pyrazin-6- yl)phenyl]-2-(4-fluorophenyl)acetamide (150 mg) in toluene (7.0 mL) and NMP (3.4 mL) was added 1 -(4-Bromo-3-methoxyphenyl)-4-methylpiperazine (236 mg), chloro(2-dicyclohexylphosphino-2',4',6'-tri-iso-propyl-1 ,1'-biphenyl)[2-(2- aminoethyl)phenyl] palladium(ll) methyl-tert-butylether adduct (34.2 mg) and X-Phos (20.1 mg) and the flask was degassed twice and backfilled with argon. The mixture was stirred for 5 minutes at room temperature. Sodium 2- methylpropan-2-olate (199 mg) was added and the flask was degassed twice and backfilled with argon. The mixture was heated to reflux for 2 h. Water was added and the reaction mixture was extracted with ethyl acetate and methanol (10:1 ). The organic phase was washed with saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum. Repeated aminophase-silica-gel chromatography gave a solid that was triturated with dichloromethane to give 28 mg of the title compound.
1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 2.19 (3H), 2.40-2.45 (4H), 3.02-3.12 (4H), 3.64 (2H), 3.79 (3H), 6.48 (1 H), 6.62 (1 H), 7.08-7.17 (2H), 7.30-7.38 (2H), 7.68 (2H), 7.72-7.77 (1 H), 8.02 (2H), 8.20 (1 H), 8.93-9.02 (1 H), 9.35 (1 H), 10.30 (1 H).
Example 2.5.
N-(4-{2-[(2-cyano-3-fluorophenyl)amino][1 ,2,4]triazolo[1 ,5-a]pyra l}phenyl)-2-phenylacetamide
Figure imgf000129_0001
To a stirred suspension of N-[4-(2-amino[1 ,2,4]triazolo[1 ,5-a]pyrazin-6- yl)phenyl]-2-phenylacetamide (330 mg) in toluene (3.5 mL) and NMP (0.35 mL) was added 2-bromo-6-fluorobenzonitrile (395 mg), (rac)-BINAP (61 mg) and Pd2dba3 (44 mg) and cesium carbonate (956 mg) and the flask was degassed twice and backfilled with argon. The mixture was heated to reflux for 4 h. A mixture of ethyl acetate and methanol (100:1 ; 250 mL) was added and the mixture was filtered through celite. The organic phase was washed with saturated sodium bicarbonate solution, with saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum. Silicagel chromatography followed by repeated aminophase-silica-gel chromatography gave a solid that was dissolved in DMF/THF/methanol and was precipitated by adding this solution to excess water. The precipitate was collected by filtration, was washed with water, ethanol and ether and was dried in vacuum to give 52 mg of the title compound.
1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 3.64 (2H), 7.13 (1 H), 7.19-7.25 (1 H), 7.26-7.35 (4H), 7.65-7.75 (3H), 7.84 (1 H), 8.05 (2H), 9.15 (1 H), 9.47 (1 H), 10.24 (1 H), 10.32 (1 H).
Example 2.6. N-(4-{2-[(2 yanophenyl)amino][1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl}ph
2- 3,4-difluorophenyl)acetamide
Figure imgf000130_0001
To a stirred suspension of N-[4-(2-amino[1 ,2,4]triazolo[1 ,5-a]pyrazin-6- yl)phenyl]-2-(3,4-difluorophenyl)acetamide (270 mg) in toluene (4.0 mL) and NMP (0.4 mL) was added 2-bromobenzonitrile (196 mg), (rac)-BINAP (45.1 mg) and Pd2dba3 (32.5 mg) and cesium carbonate (708 mg) and the flask was degassed twice and backfilled with argon. The mixture was heated to reflux for 4 h. Ethyl acetate and methanol (100:1 ) was added and the mixture was filtered through a silica-gel column and the solvent was removed in vacuum. Aminophase-silica-gel chromatography gave a solid that was triturated with ethanol to give a solid. The solid was dissolved in DMF and THF (1 :1 ) and was precipitated by adding this solution to excess water. The precipitate was collected by filtration, was washed with water, ethanol and ether and was dried in vacuum to give a solid that was recrystallized from ethanol to give 17 mg of the title compound.
1H-N R (400 MHz, DMSO-d6), δ [ppm] = 3.68 (2H), 7.11 -7.25 (2H), 7.31 -7.42 (2H), 7.61 -7.72 (3H), 7.76 (1 H), 7.94 (1 H), 8.05 (2H), 9.11 (1 H), 9.43 (1 H), 9.89 (1 H), 10.31 (1 H).
Example 2.7.
N-(4-{2-[(2-cyano-3-fluorophenyl)amino][1 ,2,4]triazolo[1 ,5-a]pyrazin-6- yl}phenyl)-2-(3,4-difluorophenyl)acetamide
Figure imgf000131_0001
To a stirred suspension of N-[4-(2-amino[1 ,2,4]triazolo[1 ,5-a]pyrazin-6- yl)phenyl]-2-(3,4-difluorophenyl)acetamide (270 mg) in toluene (4.0 mL) and NMP (0.4 mL) was added 2-bromo-6-fluorobenzonitrile (220 mg), (rac)-BINAP (45.1 mg) and Pd2dba3 (32.5 mg) and cesium carbonate (708 mg) and the flask was degassed twice and backfilled with argon. The mixture was heated to reflux for 4 h. Ethyl acetate and methanol (100:1 ) was added and the mixture was filtered through a silica-gel column and the solvent was removed in vacuum. Aminophase-silica-gel chromatography gave a solid that was triturated with ethanol to give a solid. The solid was dissolved in DMF and THF (1 :1 ) and was precipitated by adding this solution to excess water. The precipitate was collected by filtration, was washed with water, ethanol and ether and was dried in vacuum to give 80 mg of the title compound.
1H-NMR (300 MHz, DMSO-d6), δ [ppm] = 3.67 (2H), 7.06-7.19 (2H), 7.29-7.43 (2H), 7.63-7.76 (3H), 7.78-7.88 (1 H), 8.06 (2H), 9.15 (1 H), 9.46 (1 H), 10.22 (1 H), 10.32 (1 H).
Example 2.8.
2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4- (methylsulfonyl)phenyl]amino}[1 ,2,4]triazolo[1 ,5-a]pyrazin-6- yl)phenyl]acetamide
Figure imgf000132_0001
To a stirred suspension of N-[4-(2-amino[1 ,2,4]triazolo[1 ,5-a]pyrazin-6- yl)phenyl]-2-(4-fluorophenyl)acetamide (100 mg) in toluene (3.0 mL) and NMP (1.5 mL) was added 1 -bromo-2-methoxy-4-(methylsulfonyl)benzene (146 mg), chloro(2-dicyclohexylphosphino-2',4',6'-tri-iso-propyl-1 ,1'-biphenyl)[2-(2- aminoethyl)phenyl] palladium(ll) methyl-tert-butylether adduct (22.8 mg) and X-Phos (13.4 mg) and the flask was degassed twice and backfilled with argon. The mixture was stirred for 5 minutes at room temperature. Powdered potassium phosphate (293 mg) was added and the flask was degassed twice and backfilled with argon. The mixture was heated to reflux for 2 h. The reaction mixture was filtered through an aminophase-silica-gel column and the solvent was removed in vacuum. Aminophase-silica-gel chromatography gave 88 mg of the title compound.
1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 3.17 (3H), 3.65 (2H), 3.95 (3H), 7.06- 7.19 (2H), 7.35 (2H), 7.44 (1 H), 7.53 (1 H), 7.70 (2H), 8.07 (2H), 8.46 (1 H), 9.06 (1 H), 9.17 (1 H), 9.47 (1 H), 10.32 (1 H).
Example 3.1.
2-{[6-(4-hydroxy-3,5-dimethylphenyl)[1 ,2,4]triazolo[1 ,5-a]pyrazin-2- yl]amino}benzonitrile
Figure imgf000132_0002
To a stirred suspension of 4-(2-amino[1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl)-2,6- dimethylphenol (90 mg) in toluene (3.0 mL) and NMP (0.3 mL) was added 2- bromobenzonitrile (97.2 mg), (rac)-BINAP (22.4 mg) and Pd2dba3 (16.1 mg) and cesium carbonate (352 mg) and the flask was degassed twice and backfilled with argon. The mixture was heated to reflux for 5 h. Ethyl acetate and methanol (100:1 ) was added and the mixture was filtered through celite. The organic phase was washed with saturated sodium bicarbonate solution, with saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum. Silicagel chromatography gave a solid that was triturated with warm ethanol to give 80 mg of the title compound.
1H-NMR (300 MHz, DMSO-d6), δ [ppm] = 2.14-2.25 (6H), 7.19 (1 H), 7.61 -7.71 (3H), 7.75 (1 H), 7.94 (1 H), 8.52 (1 H), 9.06 (1 H), 9.30 (1 H), 9.86 (1 H).
Example 3.2.
N-(4-{2-[(2-cyanophenyl)amino][1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl}phenyl)-
2-c clopropylacetamide
Figure imgf000133_0001
To a stirred suspension of N-[4-(2-amino[1 ,2,4]triazolo[1 ,5-a]pyrazin-6- yl)phenyl]-2-cyclopropylacetamide (140 mg) in toluene (1.65 mL) and NMP (0.165 mL) was added 2-bromobenzonitrile (125 mg), (rac)-BINAP (28.8 mg) and Pd2dba3 (20.8 mg) and cesium carbonate (453 mg) and the flask was degassed twice and backfilled with argon. The mixture was heated to reflux for 4 h. Ethyl acetate and methanol (100:1 ) was added and the mixture was filtered through a silica-gel column and the solvent was removed in vacuum. Aminophase-silica-gel chromatography gave a solid that was triturated with ethanol to give a solid. The solid was dissolved in DMF and THF (1 :1 ), filtered and was precipitated by adding this solution to excess water. The precipitate was collected by filtration, was washed with water, ethanol and ether and was dried in vacuum to give 87 mg of the title compound.
1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 0.13-0.22 (2H), 0.41-0.51 (2H), 0.98- 1.11 (1H), 2.21 (2H), 7.21 (1H), 7.63-7.72 (3H), 7.76 (1H), 7.94 (1H), 7.99-8.08 (2H), 9.11 (1H), 9.44 (1H), 9.91 (1H), 9.95 (1H).
Example 3.3.
3-{2-[(2-cyanophenyl)amino][1,2,4]triazolo[1,5-a]pyrazin
c clopropylbenzamide
Figure imgf000134_0001
To a stirred suspension of 3-{2-[(2-cyanophenyl)amino][1,2,4]triazolo[1,5- a]pyrazin-6-yl}benzoic acid (88 mg) in THF (3.0 mL) was added Hiinig Base (46 μΙ_), cyclopropanamine (19 μΙ_), and HATU (103 mg). The mixture was stirred at room temperature for 16 h. Water was added and the mixture was stirred at room temperature for 15 minutes. The solvent was removed in vacuum and the residue was triturated with methanol to give 56 mg of the title compound. 1H-NMR (300 MHz, DMSO-d6), δ [ppm] = 0.53-0.61 (2H), 0.65-0.74 (2H), 2.85 (1H), 7.22 (1H), 7.55 (1H), 7.67 (1H), 7.77 (1H), 7.83 (1H), 7.94 (1H), 8.22 (1H), 8.45-8.59 (2H), 9.17 (1H), 9.56 (1H), 9.96 (1H).
Example 3.4.
3-{2-[(2-cyanophenyl)amino][1,2,4]triazolo[1,5-a]pyrazin-6-yl}-N- ethylbenzamide
Figure imgf000135_0001
To a stirred suspension of 3-{2-[(2-cyanophenyl)amino][1 ,2,4]triazolo[1 ,5- a]pyrazin-6-yl}benzoic acid (133 mg) in THF (5.0 mL) was added HUnig Base (70 μΙ_), ethanamine (205 μΙ_; solution in THF, c = 2M), and HATU (156 mg). The mixture was stirred at room temperature for 64 h. Water was added and the mixture was stirred at room temperature for 1 h. The precipitated solid was collected by filtration, was washed with ethanol and ether and was dried in vacuum to give 130 mg of the title compound.
1H-NMR (300 MHz, DMSO-d6, detected signals), δ [ppm] = 1.13 (3H), 7.22 (1 H), 7.56 (1 H), 7.67 (1 H), 7.77 (1 H), 7.85 (1 H), 7.94 (1 H), 8.22 (1 H), 8.49-8.61 (2H), 9.17 (1 H), 9.57 (1 H), 9.97 (1 H).
Example 3.5.
3-{2-[(2-cyanophenyl)amino][ 1 , 2,4]triazolo[ 1 , 5-a]pyrazin-6-yl}-N- c clopentylbenzamide
Figure imgf000135_0002
To a stirred suspension of 3-{2-[(2-cyanophenyl)amino][1 ,2,4]triazolo[1 ,5- a]pyrazin-6-yl}benzoic acid (133 mg) in THF (5.0 mL) was added HUnig Base (70 μΙ_), cyclopentanamine (40 μΙ_), and HATU (156 mg). The mixture was stirred at room temperature for 64 h. Water was added and the mixture was stirred at room temperature for 1 h. The precipitated solid was collected by filtration, was washed with ethanol and ether and was dried in vacuum to give 140 mg of the title compound.
1H-NMR (300 MHz, DMSO-d6), δ [ppm] = 1.40-1.61 (4H), 1.62-1.77 (2H), 1.81 - 1.99 (2H), 4.13-4.33 (1 H), 7.22 (1 H), 7.55 (1 H), 7.67 (1 H), 7.77 (1 H), 7.85 (1 H), 7.94 (1 H), 8.17-8.26 (1 H), 8.37 (1 H), 8.50 (1 H), 9.18 (1 H), 9.59 (1 H), 9.96 (1 H).
Example 3.6.
N-(4-{2-[(2-cyano-3-fluorophenyl)amino][1 ,2,4]triazolo[1 ,5-a]pyrazin-6- l}phenyl)-2-cyclopropylacetamide
Figure imgf000136_0001
To a stirred suspension of N-[4-(2-amino[1 ,2,4]triazolo[1 ,5-a]pyrazin-6- yl)phenyl]-2-cyclopropylacetamide (280 mg) in toluene (3.3 mL) and NMP (0.33 mL) was added 2-bromo-6-fluorobenzonitrile (280 mg), (rac)-BINAP (57.7 mg) and Pd2dba3 (41.6 mg) and cesium carbonate (906 mg) and the flask was degassed twice and backfilled with argon. The mixture was heated to reflux for 4 h. Ethyl acetate and methanol (100:1 ) was added and the mixture was filtered through celite and through a silica-gel column and the solvent was removed in vacuum. The residue was triturated with ethanol to give a solid. The solid was dissolved in DMF and THF (1 :1 ) and was precipitated by adding this solution to excess water. The precipitate was collected by filtration, was washed with water, ethanol and ether and was dried in vacuum to give a solid that was recrystallized from ethanol to give 258 mg of the title compound. 1H-NMR (300 MHz, DMSO-d6), δ [ppm] = 0.10-0.24 (2H), 0.38-0.52 (2H), 0.94- 1.13 (1 H), 2.20 (2H), 7.07-7.19 (1 H), 7.63-7.77 (3H), 7.80-7.88 (1 H), 8.05 (2H), 9.15 (1 H), 9.46 (1 H), 9.95 (1 H), 10.23 (1 H). Example 3.7.
2- 6-(4-aminophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrazin-2-yl]amino}benzonitrile
Figure imgf000137_0001
To a stirred suspension of tert-butyl(4-{2-[(2-cyanophenyl)amino][1 ,2,4] triazolo[1 ,5-a]pyrazin-6-yl}phenyl)carbamate (1.3 g) in dichloromethane (65 mL) was added 1 ,3 dimethoxybenzene (3.89 mL) and glacial acetic acid (43 mL). The mixture was stirred at room temperature until a clear solution had formed. The solution was cooled to 0°C and borontrifluoride diethyletherat (1.54 mL) was added. The mixture was stirred at r.t. for 2 h. An aqueous solution of potassium carbonate was added until pH 11 was reached and the mixture was extracted with ethyl acetate. The organic phase was washed with saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum. Silicagel chromatography gave 120 mg of the title compound.
1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 5.40 (2H), 6.61 (2H), 7.19 (1 H), 7.66 (1 H), 7.72-7.82 (3H), 7.94 (1 H), 9.03 (1 H), 9.21 (1 H), 9.81 (1 H).
Example 3.8.
4-{2-[(2-methoxyphenyl)amino][1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl}-2,6- dimethylphenol
Figure imgf000137_0002
To a stirred suspension of 4-(2-amino[1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl)-2,6- dimethylphenol (160 mg) in toluene (5.3 mL) and NMP (0.53 mL) was added 1 - bromo-2-methoxybenzene (0.16 mL), (rac)-BINAP (39.8 mg) and Pd2dba3 (28.7 mg) and cesium carbonate (612 mg) and the flask was degassed twice and backfilled with argon. The mixture was heated to reflux for 5 h. Ethyl acetate and methanol (100:1 ) was added and the mixture was filtered through celite. The organic phase was washed with saturated sodium bicarbonate solution, with saturated sodium chloride solution, was dried (sodium sulfate) and the solvent was removed in vacuum. Silicagel chromatography gave a solid that was triturated with a mixture of diisopropyl ether and ethanol to give 9 mg of the title compound.
1H-NMR (300 MHz, DMSO-d6), δ [ppm] = 2.21 (6H), 3.84 (3H), 6.88-7.08 (3H), 7.69 (2H), 8.08-8.22 (1 H), 8.36 (1 H), 8.51 (1 H), 9.03 (1 H), 9.29 (1 H). Example 3.9.
3-{2-[(2-cyanophenyl)amino][1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl}-N- c clohexylbenzamide
Figure imgf000138_0001
To a stirred suspension of 3-{2-[(2-cyanophenyl)amino][1 ,2,4]triazolo[1 ,5- a]pyrazin-6-yl}benzoic acid (133 mg) in THF (5.0 mL) was added Hiinig Base (70 pL), cyclohexanamine (41 pL), and HATU (156 mg). The mixture was stirred at room temperature for 64 h. Water was added and the mixture was stirred at room temperature for 1 h. The precipitated solid was collected by filtration, was washed with ethanol and ether and was dried in vacuum to give 140 mg of a solid that was triturated with dichloromethane to give 109 mg the title compound.
1H-NMR (400 MHz, METHANOLS), δ [ppm] = 1.85-1.99 (1 H), 2.02-2.19 (4H), 2.41 (1 H), 2.53 (2H), 2.65 (2H), 4.49-4.67 (1 H), 8.03 (1 H), 8.37 (1 H), 8.48 (1 H), 8.58 (1 H), 8.64-8.69 (1 H), 8.75 (1 H), 9.00-9.06 (1 H), 9.10 (1 H), 9.26-9.36 (1 H), 9.99 (1 H), 10.40 (1 H), 10.78 (1 H).
Example 4.1.
2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(morpholin-4- ylcarbonyl)phenyl]amino}-1 ,3-benzothiazol-6-yl)phenyl]acetamide
Figure imgf000139_0001
To a stirred suspension of N-[4-(2-amino-1 ,3-benzothiazol-6-yl)phenyl]-2-(4- fluorophenyl)acetamide (100 mg) in toluene (2.4 mL) and NMP (1.3 mL) was added (4-bromo-3-methoxyphenyl)(morpholin-4-yl)methanone (119 mg), chloro(2-dicyclohexylphosphino-2',4',6'-tri-iso-propyl-1 ,1'-biphenyl)[2-(2- aminoethyl)phenyl] palladium(ll) methyl-tert-butylether adduct (21.9 mg) and X-Phos (12.9 mg) and the flask was degassed twice and backfilled with argon. The mixture was stirred for 5 minutes at room temperature. Powdered potassium phosphate (281 mg) was added and the flask was degassed twice and backfilled with argon. The mixture was heated to reflux for 3 h. Further chloro(2-dicyclohexylphosphino-2',4',6'-tri-iso-propyl-1 ,1'-biphenyl)[2-(2- aminoethyl)phenyl] palladium(ll) methyl-tert-butylether adduct (11 mg) and X- Phos (6.5 mg) were added and the flask was degassed twice and backfilled with argon. The mixture was heated to reflux for further 2 h. The reaction mixture was filtered through an aminophase-silica-gel column and the solvent was removed in vacuum. Aminophase-silica-gel chromatography followed by preparative reverse phase HPLC gave a solid that was triturated with dichloromethane to give 7 mg of the title compound.
1H-NMR (300 MHz, DMSO-d6), δ [ppm] = 3.44-3.66 (10H), 3.89 (3H), 7.00-7.19 (4H), 7.34 (2H), 7.51 -7.72 (6H), 8.07 (1 H), 8.62 (1 H), 10.03 (1 H), 10.20 (1 H).
Example 4.2.
2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amino}- 1 , 3-benzothiazol-6-y l)pheny l]acetamide
Figure imgf000140_0001
To a stirred suspension of N-[4-(2-amino-1 ,3-benzothiazol-6-yl)phenyl]-2-(4- fluorophenyl)acetamide (100 mg) in toluene (2.4 mL) and NMP (1.3 mL) was added 1 -bromo-2-methoxy-4-(methylsulfonyl)benzene (105 mg), chloro(2- dicyclohexyl-phosphino-2',4',6'-tri-iso-propyl-1 ,1'-biphenyl)[2-(2- aminoethyl)phenyl] palladium(ll) methyl-tert-butylether adduct (21.9 mg) and X-Phos (12.9 mg) and the flask was degassed twice and backfilled with argon. The mixture was stirred for 5 minutes at room temperature. Powdered potassium phosphate (281 mg) was added and the flask was degassed twice and backfilled with argon. The mixture was heated to reflux for 3 h. The reaction mixture was filtered through an aminophase-silica-gel column and the solvent was removed in vacuum. Aminophase-silica-gel chromatography followed by preparative reverse phase HPLC gave a solid that was triturated with dichloromethane to give 25 mg of the title compound. 1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 3.18 (3H), 3.63 (2H), 3.98 (3H), 7.09- 7.17 (2H), 7.29-7.39 (2H), 7.46 (1 H), 7.55 (1 H), 7.57-7.70 (6H), 8.12 (1 H), 8.88 (1 H), 10.24 (1 H), 10.33 (1 H).
Example 4.3.
N-[4-(2-amino-1 ,3-benzothiazol-6-yl)phenyl]-2-(4-fluorophenyl)acetamide
Figure imgf000141_0001
To a stirred solution of 6-(4-aminophenyl)-1 ,3-benzothiazol-2-amine (645 mg) in THF (33 mL) was added Hiinig base (0.50 ml_), (4-fluorophenyl)acetic acid (454 mg) and HATU (1.12 g) and the mixture was stirred at room temperature for 16 h. Water was added, the mixture was stirred for 1 h and the mixture was extracted with ethyl acetate. The organic phase was washed with saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum. The residue was triturated with dichloromethane to give 970 mg of the title compound.
1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 3.62 (2H), 7.08-7.16 (2H), 7.29-7.37 (3H), 7.45 (1 H), 7.48 (2H), 7.53-7.59 (2H), 7.60-7.64 (2H), 7.90 (1 H), 10.20 (1 H).
Example 5.1.
(2R)-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4- (methylsulfonyl)phenyl]amino}[ 1 , 2,4]triazolo[ 1 , 5-a]pyridin-7- yl)phenyl]propanamide
Figure imgf000142_0001
To a stirred suspension of (2R)-N-[4-(2-amino[1 ,2,4]triazolo[1 ,5-a]pyridin-7- yl)phenyl]-2-(4-fluorophenyl)propanamide (100 mg) in toluene (4 mL) and NMP (0.2 mL) was added 1 -bromo-2-methoxy-4-(methylsulfonyl)benzene (106 mg), chloro(2-dicyclohexylphosphino-2',4',6'-tri-iso-propyl-1 ,1'-biphenyl)[2-(2- aminoethyl)phenyl] palladium(ll) methyl-tert-butylether adduct (22 mg), X- Phos (13 mg) and powdered potassium phosphate monohydrate (283 mg) and the flask was degassed twice and backfilled with argon. The mixture was heated to reflux for 16 h. The mixture was filtered and concentrated in vacuum. Silicagel chromatography followed by preparative reverse phase HPLC gave 10 mg of the title compound.
1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 1.44 (3H), 3.20 (3H), 3.88 (1 H), 4.00 (3H), 7.12-7.24 (2H), 7.40-7.50 (4H), 7.56 (1 H), 7.75 (2H), 7.86 (2H), 7.92 (1 H), 8.52 (1 H), 8.63 (1 H), 8.86 (1 H), 10.28 (1 H).
LC-MS (Method 2): Rt = 1.28 min; MS (ESIpos) m/z = 560 [M+H]+.
Example 5.2.
(2R)-N-{4-[2-({4-[(3-fluoroazetidin-1 -yl)carbonyl]-2- methoxyphenyl}amino)[ 1 , 2,4]triazolo[ 1 , 5-a]pyridin-7-yl]phenyl}-2-(4- fluorophenyl)propanamide
Figure imgf000143_0001
To a stirred suspension of {4-[(7-chloro[1 ,2,4]triazolo[1 ,5-a]pyridin-2- yl)amino]-3-methoxyphenyl}(3-fluoroazetidin-1 -yl)methanone (110 mg) in toluene (4.0 mL) and NMP (0.4 mL) was added (4-{[(2R)-2-(4- fluorophenyl)propanoyl]amino}phenyl)boronic acid (126 mg), powdered potassium phosphate monohydrate (248 mg), dicyclohexyl(2',6'- dimethoxybiphenyl-2-yl)phosphine (24 mg) and Pd(OAc)2 (6.6 mg) and the flask was degassed twice and backfilled with argon. The mixture was heated to reflux for 2 h. The reaction mixture was filtered and the solvent was removed in vacuum. Aminophase silicagel chromatography gave a solid that was triturated with ether to give 150 mg of the title compound.
1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 1.44 (3H), 3.82-3.98 (4H), 3.98-4.77 (4H), 5.31 -5.59 (1 H), 7.18 (2H), 7.24-7.35 (2H), 7.37-7.50 (3H), 7.75 (2H), 7.80- 7.95 (3H), 8.29-8.48 (2H), 8.83 (1 H), 10.27 (1 H).
LC-MS (Method 2): Rt = 1.27 min; MS (ESIpos) m/z = 583 [M+H]+.
Example 5.3.
(2R)-N-{4-[2-({4-[(3-fluoroazetidin-1 -yl)carbonyl]-2-(2,2,2- trifluoroethoxy)phenyl}amino)[1 ,2,4]triazolo[1 ,5-a]pyridin-7-yl]phenyl}-2-
(4-fluorophenyl)propanamide
Figure imgf000144_0001
Starting from {4-[(7-chloro[1 ,2,4]triazolo[1 ,5-a]pyridin-2-yl)amino]-3-(2,2,2- trifluoroethoxy)phenyl}(3-fluoroazetidin-1 -yl)methanone (70 mg) and (4-{[(2R)- 2-(4-fluorophenyl)propanoyl]amino}phenyl)boronic acid (61 mg), Example 5.3. was prepared analogously to the procedure for the preparation of Example 5.2. Yield: 73 mg of the title compound.
1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 1.44 (3H), 3.89 (1 H), 3.96-4.76 (4H), 4.96 (2H), 5.34-5.59 (1 H), 7.13-7.22 (2H), 7.39-7.48 (5H), 7.75 (2H), 7.81 -7.87 (2H), 7.89 (1 H), 8.28 (1 H), 8.38-8.44 (1 H), 8.84 (1 H), 10.28 (1 H).
LC-MS (Method 2): Rt = 1.35 min; MS (ESIpos) m/z = 651 [M+H]+.
Example 5.4.
(2R)-2-(4-fluorophenyl)-N-(4-{2-[(6-methoxy-1 ,1 -dioxido-2,3-dihydro-1 - benzothiophen-5-yl)amino][1 ,2,4]triazolo[1 ,5-a]pyridin-7- yl}phenyl)propanamide
Figure imgf000145_0001
The compound of Example 5.4. can be prepared in analogy to the methods described herein.
Example 5.5.
(2R)-2-(4-fluorophenyl)-N-[4-(2-{[4-(methylsulfonyl)-2-(2,2,2- trifluoroethoxy)phenyl]amino}[1 ,2,4]triazolo[1 ,5-a]pyridin-7- yl)phenyl]propanamide
Figure imgf000145_0002
Starting from 7-chloro-N-[4-(methylsulfonyl)-2-(2,2,2- trifluoroethoxy)phenyl][1 ,2,4]triazolo[1 ,5-a]pyridin-2-amine (50 mg) and (4- {[(2R)-2-(4-fluorophenyl)propanoyl]amino}phenyl)boronic acid (51 mg), Example 5.5. was prepared analogously to the procedure for the preparation of Example 5.2. Yield: 20 mg of the title compound.
1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 1.42 (3H), 3.19 (3H), 3.87 (1 H), 5.02 (2H), 7.12-7.20 (2H), 7.39-7.46 (3H), 7.62-7.67 (2H), 7.74 (2H), 7.81 -7.88 (2H), 7.91 (1 H), 8.53 (1 H), 8.60 (1 H), 8.85 (1 H), 10.27 (1 H). LC-MS (Method 2): Rt = 1.35 min; MS (ESIpos) m/z = 628 [M+H]+.
Example 5.6.
(2R)-N-[4-(2-{[4-(azetidin-1 -ylcarbonyl)-2- methoxyphenyl]amino}[ 1 , 2,4]triazolo[ 1 , 5-a]pyridin-7-yl)phenyl]-2-(4- fluorophenyl)propanamide
Figure imgf000146_0001
Starting from azetidin-1 -yl{4-[(7-chloro[1 ,2,4]triazolo[1 ,5-a]pyridin-2- yl)amino]-3-methoxyphenyl}methanone (120 mg) and (4-{[(2R)-2-(4- fluorophenyl)propanoyl]amino}phenyl)boronic acid (144 mg), Example 5.6. was prepared analogously to the procedure for the preparation of Example 5.2. Yield: 30 mg of the title compound. 1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 1.42 (3H), 2.25 (2H), 3.82-3.94 (4H), 4.03 (2H), 4.36 (2H), 7.12-7.20 (2H), 7.22-7.29 (2H), 7.35-7.46 (3H), 7.73 (2H), 7.80-7.89 (3H), 8.29 (1 H), 8.33 (1 H), 8.81 (1 H), 10.26 (1 H).
LC-MS (Method 2): Rt = 1.27 min; MS (ESIpos) m/z = 565 [M+H]+.
Example 6.1. (2R)-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-
(methylsulfonyl)phenyl]amino}imidazo[1 ,2-b]pyridazin-6- yl)phenyl]propanamide
Figure imgf000147_0001
To a stirred suspension of 6-chloro-N-[2-methoxy-4- (methylsulfonyl)phenyl]imidazo[1 ,2-b]pyridazin-2-amine (100 mg) in toluene (4.0 mL) and NMP (0.4 mL) was added (4-{[(2R)-2-(4- fluorophenyl)propanoyl]amino}phenyl)boronic acid (122 mg), powdered potassium phosphate monohydrate (240 mg), dicyclohexyl(2',6'- dimethoxybiphenyl-2-yl)phosphine (23 mg) and Pd(OAc)2 (6.4 mg) and the flask was degassed twice and backfilled with argon. The mixture was heated to reflux for 2 h. The reaction mixture was filtered and the solvent was removed in vacuum. Silicagel chromatography followed by aminophase silicagel chromatography and by preparative reverse phase HPLC gave a solid that was triturated with warm ethanol to give 35 mg of the title compound.
1H-NMR (400 MHz, DMSO-d6), δ [ppm] = 1.44 (3H), 3.17 (3H), 3.89 (1 H), 4.01 (3H), 7.12-7.24 (2H), 7.38-7.53 (4H), 7.70 (1 H), 7.77 (2H), 7.97-8.08 (4H), 8.57 (1 H), 8.84 (1 H), 10.31 (1 H).
LC-MS (Method 2): Rt = 1.28 min; MS (ESIpos) m/z = 560 [M+H]+.
Example 7.1.
(2R)-2-(4-fluorophenyl)-N-[4-(2-{[3-methoxy-5-(methylsulfonyl)pyridin yl]amino}imidazo[ 1 , 2-a]pyridin-6-yl)phenyl]propanamide
Figure imgf000148_0001
A stirred suspension of 6-bromo-N-[3-methoxy-5-(methylsulfonyl)pyridin-2- yl]imidazo[1 ,2-a]pyridin-2-amine (70 mg), (4-{[2-(4- fluorophenyl)propanoyl]amino}phenyl)boronic acid (56 mg) and [1 ,Γ- bis(diphenylphosphino)ferrocene]dichloropalladium(ll) (14 mg) in 1 ,2- dimethoxyethane (1.29 mL) and an aqueous solution of potassium carbonate (2M, 0.26 mL) was stirred at 90° C under argon overnight. After cooling, the mixture was diluted with water and extracted with ethyl acetate (3x). The combined organic phases were dried (MgSC ), filtered and concentrated. The residue was purified by preparative reverse phase HPLC to give 20 mg of the title compound.
1H-NM (400 MHz, DMSO-d6), δ [ppm] = 1.43 (3H), 3.26 (3H), 3.87 (1 H), 4.01 (3H), 7.13-7.20 (2H), 7.42-7.46 (2H), 7.47-7.50 (1 H), 7.53-7.57 (2H), 7.64 (2H), 7.69-7.72 (2H), 8.32 (1 H), 8.42 (1 H), 8.92 (1 H), 8.99 (1 H), 10.18 (1 H).
Further, the compounds of formula (I) of the present invention can be converted to any salt as described herein, by any method which is known to the person skilled in the art. Similarly, any salt of a compound of formula (I) of the present invention can be converted into the free compound, by any method which is known to the person skilled in the art. Biological assay: Proliferation Assay
Cultivated tumor cells (MCF7, hormone dependent human mammary carcinoma cells, ATCC HTB22; NCI-H460, human non-small cell lung carcinoma cells, ATCC HTB-177; DU 145, hormone-independent human prostate carcinoma cells, ATCC HTB-81 ; HeLa-MaTu, human cervical carcinoma cells, EPO-GmbH, Berlin; HeLa- MaTu-ADR, multidrug-resistant human cervical carcinoma cells, EPO-GmbH, Berlin; HeLa human cervical tumor cells, ATCC CCL-2; B16F10 mouse melanoma cells, ATCC CRL-6475) were plated at a density of 5000 cells/ well (MCF7, DU145, HeLa-MaTu-ADR), 3000 cells/well (NCI-H460, HeLa-MaTu, HeLa), or 1000 cells/ well (B16F10) in a 96-well multititer plate in 200 μΐ of their respective growth medium supplemented 10% fetal calf serum. After 24 hours, the cells of one plate (zero-point plate) were stained with crystal violet (see below), while the medium of the other plates was replaced by fresh culture medium (200 μΐ), to which the test substances were added in various concentrations (0 μΜ, as well as in the range of 0.01 -30 μΜ; the final concentration of the solvent dimethyl sulfoxide was 0.5%). The cells were incubated for 4 days in the presence of test substances. Cell proliferation was determined by staining the cells with crystal violet: the cells were fixed by adding 20 μΐ/measuring point of an 11% glutaric aldehyde solution for 15 minutes at room temperature. After three washing cycles of the fixed cells with water, the plates were dried at room temperature. The cells were stained by adding 100 μΐ/measuring point of a 0.1% crystal violet solution (pH 3.0). After three washing cycles of the stained cells with water, the plates were dried at room temperature. The dye was dissolved by adding 100 μΐ/measuring point of a 10% acetic acid solution. The extinction was determined by photometry at a wavelength of 595 nm. The change of cell number, in percent, was calculated by normalization of the measured values to the extinction values of the zero-point plate (=0%) and the extinction of the untreated (0 μιη) cells (=100%). The IC50 values were determined by means of a 4 parameter fit using the company's own software. The compounds of the present invention are characterized by the following IC50 values, determined in a HeLa cell proliferation assay (as described above):
Figure imgf000150_0001
Mps-1 kinase assay
The human kinase Mps-1 phosphorylates a biotinylated substrate peptide. Detection of the phosphorylated product is achieved by time-resolved fluorescence resonance energy transfer (TR-FRET) from Europium-labelled anti- phospho-Serine/Threonine antibody as donor to streptavidin labelled with cross-linked allophycocyanin (SA-XLent) as acceptor. Compounds are tested for their inhibition of the kinase activity.
N-terminally GST-tagged human full length recombinant Mps-1 kinase (purchased from Invitrogen, Karslruhe, Germany, cat. no PV4071 ) was used. As substrate for the kinase reaction a biotinylated peptide of the amino-acid sequence PWDPDDADITEILG (C-terminus in amide form, purchased from Biosynthan GmbH, Berlin) was used.
For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μΐ of a solution of Mps-1 in assay buffer [0.1 mM sodium-ortho-vanadate, 10 mM MgCl2, 2 mM DTT, 25 mM Hepes pH 7.7, 0.05% BSA, 0.001 % Pluronic F-127] were added and the mixture was incubated for 1 5 min at 22° C to allow pre-binding of the test compounds to Mps-1 before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μΐ of a solution of 16.7 adenosine-tri-phosphate (ATP, 16.7 μΜ => final cone, in the 5 μΐ assay volume is 10 μΜ) and peptide substrate (1 .67 μΜ => final cone, in the 5 μΐ assay volume is 1 μΜ) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22° C. The concentration of Mps-1 in the assay was adjusted to the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical enzyme concentrations were in the range of about 1 nM (final cone, in the 5 μΐ assay volume). The reaction was stopped by the addition of 3 μΐ of a solution of HTRF detection reagents (100 mM Hepes pH 7.4, 0.1 % BSA, 40 mM EDTA, 140 nM Streptavidin-XLent [# 61 GSTXLB, Fa. Cis Biointernational, Marcoule, France] , 1 .5 nM anti-phospho(Ser/Thr)-Europium-antibody [#AD0180, PerkinElmer L.AS, Rodgau-Jiigesheim, Germany] .
The resulting mixture was incubated 1 h at 22° C to allow the binding of the phosphorylated peptide to the anti-phospho(Ser/Thr)-Europium-antibody. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the Europium-labelled anti-phospho(Ser/Thr) antibody to the Streptavidin-XLent. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm was measured in a Viewlux TR-FRET reader (PerkinElmer L.AS, Rodgau-Jiigesheim, Germany). The "blank-corrected normalized ratio" (a Viewlux specific readout, similar to the traditional ratio of the emissions at 665 nm and at 622 nm, in which blank and Eu-donor crosstalk are subtracted from the 665 nm signal before the ratio is calculated) was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor = 0 % inhibition, all other assay components but no enzyme = 100 % inhibition). Test compounds were tested on the same microtiter plate at 10 different concentrations in the range of 20 μΜ to 1 nM (20 μΜ, 6.7 μΜ, 2.2 μΜ, 0.74 μΜ, 0.25 μΜ, 82 nM, 27 nM, 9.2 nM, 3.1 nM and 1 nM, dilution series prepared before the assay at the level of the 100fold cone, stock solutions by serial 1 :3 dilutions) in duplicate values for each concentration and IC50 values were calculated by a 4 parameter fit using an inhouse software.
Figure imgf000152_0001
4.3 8.6 nM
5.1 < 1 nM
5.2 < 1 nM
5.3 < 1 nM
5.5 < 1 nM
5.6 < 1 nM
6.1 < 1 nM
7.1 < 1 nM
Spindle Assembly Checkpoint Assay
The spindle assembly checkpoint assures the proper segregation of chromosomes during mitosis. Upon entry into mitosis, chromosomes begin to condensate which is accompanied by the phosphorylation of histone H3 on serine 10. Dephosphorylation of histone H3 on serine 10 begins in anaphase and ends at early telophase. Accordingly, phosphorylation of histone H3 on serine 10 can be utilized as a marker of cells in mitosis. Nocodazole is a microtubule destabilizing substance. Thus, nocodazole interferes with microtubule dynamics and mobilises the spindle assembly checkpoint. The cells arrest in mitosis at G2/M transition and exhibit phosphorylated histone H3 on serine 10. An inhibition of the spindle assembly checkpoint by Mps-1 inhibitors overrides the mitotic blockage in the presence of nocodazole, and the cells complete mitosis prematurely. This alteration is detected by the decrease of cells with phosphorylation of histone H3 on serine 10. This decline is used as a marker to determine the capability of compounds of the present invention to induce a mitotic breakthrough. Cultivated cells of the human cervical tumor cell line HeLa (ATCC CCL-2) were plated at a density of 2500 cells/well in a 384-well microtiter plate in 20 μΐ Dulbeco's Medium (w/o phenol red, w/o sodium pyruvate, w 1000 mg/mL glucose, w pyridoxine) supplemented with 1 % (v/v) glutamine, 1 % (v/v) penicillin, 1 % (v/v) streptomycin and 10% (v/v) fetal calf serum. After incubation overnight at 37°C, 10 μΐ/well nocodazole at a final concentration of 0.1 Mg/mL were added to cells. After 24 h incubation, cells were arrested at G2/M phase of the cell cycle progression. Test compounds solubilised in dimethyl sulfoxide (DMSO) were added at various concentrations (0 μΜ, as well as in the range of 0.005 μΜ - 10 μΜ; the final concentration of the solvent DMSO was 0.5% (v/v)). Cells were incubated for 4 h at 37 °C in the presence of test compounds. Thereafter, cells were fixed in 4% (v/v) paraformaldehyde in phosphate buffered saline (PBS) at 4°C overnight then permeabilised in 0.1% (v/v) Triton X™ 100 in PBS at room temperature for 20 min and blocked in 0.5% (v/v) bovine serum albumin (BSA) in PBS at room temperature for 15 min. After washing with PBS, 20 μΐ/well antibody solution (anti-phospho-histone H3 clone 3H10, FITC; Upstate, Cat# 16-222; 1 :200 dilution) was added to cells, which were incubated for 2 h at room temperature. Afterwards, cells were washed with PBS and 20 μΐ/well HOECHST 33342 dye solution (5 μg/mL) was added to cells and cells were incubated 12 min at room temperature in the dark. Cells were washed twice with PBS then covered with PBS and stored at 4°C until analysis. Images were acquired with a Perkin Elmer OPERA™ High-Content Analysis reader. Images were analyzed with image analysis software MetaXpress™ from Molecular devices utilizing the Cell Cycle application module. In this assay both labels HOECHST 33342 and phosphorylated Histone H3 on serine 10 were measured. HOECHST 33342 labels DNA and is used to count cell number. The staining of phosphorylated Histone H3 on serine 10 determines the number of mitotic cells. Inhibition of Mps-1 decreases the number of mitotic cells in the presence of nocodazole indicating an
inappropriate mitotic progression. The raw assay data were further analysed by four parameter logistic regression analysis to determine the IC50 value for each tested compound.
Thus the compounds of the present invention effectively inhibit Mps-1 kinase and are therefore suitable for the treatment or prophylaxis of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses, particularly in which the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses is mediated by Mps-1 , more particularly in which the diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses are haemotological tumours, solid tumours and/or metastases thereof, e.g. leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.

Claims

1. A compound of general formula (I) :
Figure imgf000156_0001
which :
is selected from:
Figure imgf000156_0002
wherein * represents the point of attachment to the nitrogen atom and ** represents the point of attachment to the R1 group; represents a phenyl- group
- which is substituted, one or more times, identically or differently, with a substituent selected from :
-OH, -N(H)C(=0)R6, -N(R7)C(=0)R6, -N(H)C(=0)NR6R7,
-N(R7)C(=0)NR6R7, -NH2, -NR6R7, -C(=0)N(H)R6, -C(=0)NR6R7;
and
- which is optionally substituted, one or more times, identically or differently, with a CrCe-alkyl- group ; represents a hydrogen atom or a group selected from phenyl-, pyridyl-; said group being substituted, one or more times, identically or differently, with a substituent selected from :
halo-, hydroxy-, cyano-, nitro-, CrC6-alkyl-,
halo-CrCe-alkyl-, CrC6-alkoxy-, halo-G -Ce-alkoxy-,
hydroxy-CrCe-alkyl-, CrCe-alkoxy-Ci -Ce-alkyl-,
halo-CrCe-alkoxy-CrCe-alkyl-,
R9-, R9- (CrC6-alkyl)-, R9- (CH2)n(CHOH ) (CH2)m- , R9-(d-C6-alkoxy)-,
R9- (CH2)n(CHOH ) (CH2)p-0-, R9- (Ci -C6-alkoxy-Ci -C6-alkyl)-,
R9- (Ci -C6-alkoxy-Ci -C6-alkyl)-0-, -0- (CH2)n-C(=0)NR9R7, R -0-, -C(=0)R9, -C(=0)0-R9, -OC(=0)-R9, -N(H )C(=0)R9, -N(R7)C(=0)R9, -N(H )C(=0)NR9R7, -N(R7)C(=0)NR9R7, -NR9R7, -C(=0)N(H)R9, -C(=0)NR9R7, R9-S-, R9-S(=0)-, R9-S(=0)2-, -N(H)S(=0)R9, -N(R7)S(=0)R9, -S(=0)N(H)R9, -S(=0)NR9R7, - N(H)S(=0)2R9, -N(R7)S(=0)2R9, -S(=0)2N(H)R9, -S(=0)2NR9R7, - S(=0)(=NR9)R7, -S(=0)(=NR7)R9 or -N=S(=0)(R9)R7 ;
R2 re resents a group selected from:
Figure imgf000157_0001
wherein * indicates the point of attachment of said group with the rest of the molecule; represents a 4- to 6-membered heterocyclic ring; which is optionally substituted, one or more times, identically or differently, with halo-, -CN , -OH, nitro-, CrC6-alkyl-, halo-Ci -C&-alkyl-, Ci -C&-alkoxy-,
halo-G -Ce-alkoxy-, hydroxy-Ci -C&-alkyl-,
CrCe-alkoxy-d-Ce-alkyl-, halo-Ci -C6-alkoxy-Ci -C&-alkyl-, R8-(CrC6-alkoxy)-, R8-0-, -NR8R7, R8-S-, R8-S(=0)-, R8-S(=0)2-,
(C3-C6-cycloalkyl)-(CH2)n-0-; represents a 4- to 6-membered heterocyclic ring; which is optionally substituted, one or more times, identically or differently, with halo-, -CN, -OH, nitro-, Ci-C&-alkyl-, halo-Ci-C&-alkyl-, Ci-C&-alkoxy-, halo-d-Ce-alkoxy-, hydroxy-G-Ce-alkyl-,
d-Ce-alkoxy-CrCe-alkyl-, halo-Ci-C6-alkoxy-Ci-C6-alkyl-,
R8-(CrC6-alkoxy)-, R8-0-, -NR8R7, R8-S-, R8-S(=0)-, R8-S(=0)2-,
(C3-C6-cycloalkyl)-(CH2)n-0-; each Ra
independently represents a group selected from:
halo-, cyano, nitro-, d-Ce-alkyl-, halo-Ci-C6-alkyl-, G-Ce-alkoxy-, halo-d-Ce-alkoxy-, hydroxy-Ci-C&-alkyl-, CrCe-alkoxy-d-Ce-alkyl-, halo-Ci-C6-alkoxy-Ci-C6-alkyl-, R8-(Ci-C6-alkoxy)-, R8-0-, -NR8R7, R8-S-, R8-S(=0)-, R8-S(=0)2-, (C3-C6-cycloalkyl)-(CH2)n-0-; represents a group selected from :
Ci-C&-alkyl-, C3-C&-cycloalkyl-, 3- to 10-membered heterocycloalkyl-, aryl-, heteroaryl-, -(CH2)q-(C3-C6-cycloalkyl),-(CH2)q-heteroaryl,
-(CH2)q-(3- to 10-membered heterocycloalkyl), -(CH2)q-aryl ;
said group being optionally substituted, one or more times, identically or differently, with a substituent selected from :
halo-, hydroxy-, cyano-, nitro-, Ci-C&-alkyl-, halo-Ci-C&-alkyl-,
Ci-C&-alkoxy-, halo-Ci-C&-alkoxy-, hydroxy-Ci-C&-alkyl-,
CrCe-alkoxy-CrCe-alkyl-, halo-Ci-Ce-alkoxy-Ci-Ce-alkyl-,
R8-(CrC6-alkyl)-, R8-(CH2)n(CHOH)(CH2)m-, R8-(CrC6-alkoxy)-,
R8-(CH2)n(CHOH)(CH2)p-0-, R8-(CrC6-alkoxy-CrC6-alkyl)-,
R8-(Ci-C6-alkoxy-Ci-C6-alkyl)-0-, aryl-, R8-0-, -C(=0)R8, -C(=0)0-R8, -OC(=0)-R8, -N(H)C(=0)R8, -N(R7)C(=0)R8, -N(H)C(=0)NR8R7,
-N(R7)C(=0)NR8R7, -NR8R7 , -C(=0)N(H)R8, -C(=0)NR8R7, R8-S-, R8-S(=0)-, R8-S(=0)2-, -N(H)S(=0)R8, -N(R7)S(=0)R8, -S(=0)N(H)R8, -S(=0)NR8R7, -N(H)S(=0)2R8, -N(R7)S(=0)2R8, -S(=0)2N(H)R8, -S(=0)2NR8R7,
-S(=0)(=NR8)R7, -S(=0)(=NR7)R8, -N=S(=0)(R8)R7 ;
R7 represents a hydrogen atom, a G -Ce-alkyl-, or C3-Ce-cycloalkyl- group ; or
R6 and R7,
together with the nitrogen atom to which they are attached,
represent a 3- to 10-membered heterocycloalkyl- group ; R8 represents a hydrogen atom, a Ci -C&-alkyl- or C3-C&-cycloalkyl- group ;
R9 represents a G -Ce-alkyl- or C3-C&-cycloalkyl- group ;
or
R9 and R7,
together with the nitrogen atom to which they are attached,
represent a 3- to 10-membered heterocycloalkyl- group,
which is optionally substituted with halogen; n, m, p
represent, independently from each other, an integer of 0, 1 , 2, 3, 4, or q represents an integer of 0, 1 , 2 or 3 ; and
t represents an integer of 0, 1 or 2 ; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.
2. The compound according to claim 1 , wherein :
R1 represents a phenyl group
- which is substituted, one or more times, identically or differently, with a substituent selected from:
-OH , -N (H )C(=0)R6, -N Hz, -C(=0)N (H )R6; and
- which is optionally substituted, one or more times, identically or differently, with a substituent selected from:
Ci -C6-alkyl-; and
R6 represents a group selected from:
-CH2- (C3-C6-cycloalkyl), -CH2-aryl;
wherein said group is optionally substituted, one or more times, identically or differently, with a substituent selected from:
halo-, CrC&-alkyl-, halo-Ci -C&-alkyl-, halo-d-Ce-alkoxy-.
The compound according to claim 1 or 2, wherein
represents
Figure imgf000160_0001
wherein * indicates the point of attachment of said group with the rest of the molecule;
R10 represents a group selected from: CrC3-alkyl-, hydroxy-CrC3-alkyl-, N(H)(R8)-CrC3-alkyl-; and
R6a represents a
Figure imgf000161_0001
wherein * indicates the point of attachment of said group with the rest of the molecule ;
wherein said group is optionally substituted, one or more times, identically or differently, with a halogen atom or a methyl- group.
4. The compound according to any one of claims 1 to 3, wherein :
Rz re resents
Figure imgf000161_0002
wherein * indicates the point of attachment of said group with the rest of the molecule;
R a represents a group selected from: Ci-C4-alkoxy-, halo-Ci-C4-alkoxy-, CrC4-alkyl ;
R5b represents a group selected from: -C(=0)N(H)R9, -C(=0)NR9R7,
-NR9R7, R9-S(=0)2- ;
Q1 represents CH or N;
Q2 represents CH or N;
with the proviso that Q1 represents CH if Q2 represents N, and Q2 represents CH if Q represents N.
5. The compound according to any one of claims 1 to 3, wherein :
R2 represents
Figure imgf000162_0001
wherein * indicates the point of attachment of said group with the rest of the molecule;
B represents a 5- to 6-membered heterocyclic ring; which is optionally, one or more times, identically or differently, substituted with G -C3- alkyl-, halo-Ci -C3-alkyl-;
t = 1 ;
R5a represents a group selected from:
halo- , CrC&-alkyl-, G -Ce-alkoxy-, halo-G -Ce-alkoxy- ,
CrCe-alkoxy-d-Ce-alkyl-,
(C3-C6-cycloalkyl)- (CH2)n-0-; and
n = 0 or 1 .
6. The compound according to any one of claims 1 to 5, wherein :
R6 -(CH2)q- (C3-C6-cycloalkyl) or-(CH2)q-aryl ;
said group being optionally substituted, one or more times, identically or differently, with halo- or CrC3-alkyl- ;
and
q = 0 or 1 .
7. The compound according to any one of claims 1 to 6, wherein :
R7 represents a hydrogen atom or a G -Ce-alkyl- group; preferably a methyl- group; and
R8 represents a Ci -C&-alkyl- group.
8. The compound according to claims 1 to 6, wherein
R9 and R7, together with the nitrogen atom to which they are attached,
represent a group selected from:
Figure imgf000163_0001
wherein * indicates the point of attachment of said group with the rest of the molecule.
9. The compound according to any one of claims 1 to 6, wherein :
R9 represents a Ci -C&-alkyl- group.
10. The compound according to any one of claims 1 to 9, wherein :
A is selected from:
Figure imgf000163_0002
wherein * represents the point of attachment to the nitrogen atom and ** represents the point of attachment to the R1 group.
1 1 . The compound according to any one of claims 1 to 9, wherein A represents
Figure imgf000164_0001
wherein * represents the point of attachment to the nitrogen atom and ** represents the point of attachment to the R1 group.
1 2. The compound according to claim 1 , which is selected from the group consisting of:
2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(morpholin-4- ylcarbonyl)phenyl]amino}[1 ,2,4]triazolo[1 ,5-b]pyridazin-6- yl)phenyl]acetamide,
2-(4-fluorophenyl)-N-[4-(2-{[4-(2-hydroxypropan-2-yl)-2- methoxyphenyl]amino}[1 ,2,4]triazolo[1 , 5-b]pyridazin-6-yl)phenyl]acetamide,
2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4- (methylsulfonyl)phenyl]amino}[1 ,2,4]triazolo[1 ,5-b]pyridazin-6- yl)phenyl]acetamide,
N-(4-{2-[(2-cyanophenyl)amino] [1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl}phenyl)-2-(4- fluorophenyl)acetamide,
N-(4-{2-[(2-cyano-3-fluorophenyl)amino] [1 ,2,4]triazolo[1 ,5-a]pyrazin-6- yl}phenyl)-2-(4-fluorophenyl)acetamide, N-(4-{2-[(2-cyanophenyl)amino][1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl}phenyl)-2- phenylacetamide,
2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(4-methylpiperazin-1 - yl)phenyl]amino}[1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl)phenyl]acetamide,
N-(4-{2-[(2-cyano-3-fluorophenyl)amino] [1 ,2,4]triazolo[1 ,5-a]pyrazin-6- yl}phenyl)-2-phenylacetamide, N-(4-{2-[(2-cyanophenyl)amino][1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl}phenyl)-2- (3,4-difluorophenyl)acetamide,
N-(4-{2-[(2-cyano-3-fluorophenyl)amino][1 ,2,4]triazolo[1 ,5-a]pyrazin-6- yl}phenyl)-2-(3,4-difluorophenyl)acetamide, 2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-
(methylsulfonyl)phenyl]amino}[1 ,2,4]triazolo[1 ,5-a]pyrazin-6- yl)phenyl]acetamide,
2- {[6-(4-hydroxy-3,5-dimethylphenyl)[1 ,2,4]triazolo[1 ,5-a]pyrazin-2- yl]amino}benzonitrile, N-(4-{2-[(2-cyanophenyl)amino][1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl}phenyl)-2- cyclopropylacetamide,
3- {2-[(2-cyanophenyl)amino][1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl}-N- cyclopropylbenzamide,
3-{2-[(2-cyanophenyl)amino][1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl}-N- ethylbenzamide,
3- {2-[(2-cyanophenyl)amino][1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl}-N- cyclopentylbenzamide,
N-(4-{2-[(2-cyano-3-fluorophenyl)amino][1 ,2,4]triazolo[1 ,5-a]pyrazin-6- yl}phenyl)-2-cyclopropylacetamide, 2-{[6-(4-aminophenyl)[1 ,2,4]triazolo[1 ,5-a]pyrazin-2-yl]amino}benzonitrile,
4- {2-[(2-methoxyphenyl)amino] [1 ,2,4]triazolo[1 , 5-a]pyrazin-6-yl}-2,6- dimethylphenol,
3-{2-[(2-cyanophenyl)amino][1 ,2,4]triazolo[1 ,5-a]pyrazin-6-yl}-N- cyclohexylbenzamide, 2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(morpholin-4- ylcarbonyl)phenyl]amino}-1 ,3-benzothiazol-6-yl)phenyl]acetamide, 2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amino}-1 ,3- benzothiazol-6-yl)phenyl]acetamide,
N-[4-(2-amino-1 ,3-benzothiazol-6-yl)phenyl]-2-(4-fluorophenyl)acetamide,
(2R)-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4- (methylsulfonyl)phenyl]amino}[1 ,2,4]triazolo[1 , 5-a]pyridin-7- yl)phenyl]propanamide,
(2R)-N-{4-[2-({4-[(3-fluoroazetidin-1 -yl)carbonyl]-2- methoxyphenyl}amino)[1 ,2,4]triazolo[1 , 5-a]pyridin-7-yl]phenyl}-2-(4- fluorophenyl)propanamide, (2R)-N-{4-[2-({4-[(3-fluoroazetidin-1 -yl)carbonyl]-2-(2,2,2- trifluoroethoxy)phenyl}amino)[1 ,2,4]triazolo[1 , 5-a]pyridin-7-yl]phenyl}-2-(4- fluorophenyl)propanamide,
(2R)-2-(4-fluorophenyl)-N-(4-{2-[(6-methoxy-1 , 1 -dioxido-2,3-dihydro-1 - benzothiophen-5-yl)amino][1 ,2,4]triazolo[1 , 5-a]pyridin-7- yl}phenyl)propanamide,
(2R)-2-(4-fluorophenyl)-N-[4-(2-{[4-(methylsulfonyl)-2-(2,2,2- trifluoroethoxy)phenyl]amino}[1 ,2,4]triazolo[1 , 5-a]pyridin-7- yl)phenyl]propanamide,
(2R)-N-[4-(2-{[4-(azetidin-1 -ylcarbonyl)-2- methoxyphenyl]amino}[1 ,2,4]triazolo[1 , 5-a]pyridin-7-yl)phenyl]-2-(4- fluorophenyl)propanamide,
(2R)-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4- (methylsulfonyl)phenyl]amino}imidazo[1 ,2-b]pyridazin-6- yl)phenyl]propanamide and (2R)-2-(4-fluorophenyl)-N-[4-(2-{[3-methoxy-5-(methylsulfonyl)pyridin-2- yl]amino}imidazo[1 ,2-a]pyridin-6-yl)phenyl]propanamide, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.
13. A compound of general formula (I), or a stereoisomer, a tautomer, an N- oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 12, for use in the treatment or prophylaxis of a disease.
14. A pharmaceutical composition comprising a compound of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 12, and a pharmaceutically acceptable diluent or carrier. 15. A pharmaceutical combination comprising :
- one or more compounds of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 12 ;
and
- one or more agents selected from : a taxane, such as Docetaxel, Paclitaxel, or Taxol; an epothilone, such as Ixabepilone, Patupilone, or Sagopilone; Mitoxantrone; Predinisolone; Dexamethasone; Estramustin; Vinblastin; Vincristin; Doxorubicin; Adriamycin; Idarubicin; Daunorubicin; Bleomycin; Etoposide; Cyclophosphamide; Ifosfamide; Procarbazine; Melphalan; 5- Fluorouracil; Capecitabine; Fludarabine; Cytarabine; Ara-C; 2-Chloro-2 - deoxyadenosine; Thioguanine; an anti-androgen, such as Flutamide, Cyproterone acetate, or Bicalutamide; Bortezomib; a platinum derivative, such as Cisplatin, or Carboplatin; Chlorambucil; Methotrexate; and Rituximab.
16. Use of a compound of general formula (I), or a stereoisomer, a tautomer, an N -oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 12, for the prophylaxis or treatment of a disease.
17. Use of a compound of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 12, for the preparation of a medicament for the prophylaxis or treatment of a disease.
18. Use according to claim 16 or 17, wherein said disease is a disease of uncontrolled cell growth, proliferation and/or survival, an inappropriate cellular immune response, or an inappropriate cellular inflammatory response, particularly in which the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is mediated by Mps-1 , more particularly in which the disease of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is a haemotological tumour, a solid tumour and/or metastases thereof, e.g. leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.
PCT/EP2014/061530 2013-06-10 2014-06-04 Novel compounds for the treatment of cancer WO2014198594A1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
TN2015000542A TN2015000542A1 (en) 2013-06-10 2014-06-04 Novel compounds for the treatment of cancer
JP2016518921A JP2016521737A (en) 2013-06-10 2014-06-04 Novel compounds for treating cancer
SG11201509351UA SG11201509351UA (en) 2013-06-10 2014-06-04 Novel compounds for the treatment of cancer
KR1020157034736A KR20160019426A (en) 2013-06-10 2014-06-04 Novel compounds for the treatment of cancer
AU2014280395A AU2014280395A1 (en) 2013-06-10 2014-06-04 Novel compounds for the treatment of cancer
EA201501175A EA201501175A1 (en) 2013-06-10 2014-06-04 NEW CONNECTIONS FOR THE TREATMENT OF MALIGNANT NOW-FORMATION
MA38655A MA38655A1 (en) 2013-06-10 2014-06-04 New compounds for the treatment of cancer
BR112015030774A BR112015030774A2 (en) 2013-06-10 2014-06-04 new compounds for cancer treatment
MX2015017011A MX2015017011A (en) 2013-06-10 2014-06-04 Novel compounds for the treatment of cancer.
CN201480032697.9A CN105246891A (en) 2013-06-10 2014-06-04 Novel compounds for the treatment of cancer
US14/896,450 US20160207928A1 (en) 2013-06-10 2014-06-04 Novel compounds for the treatment of cancer
EP14728921.9A EP3008061A1 (en) 2013-06-10 2014-06-04 Novel compounds for the treatment of cancer
CA2914668A CA2914668A1 (en) 2013-06-10 2014-06-04 Novel compounds for the treatment of cancer
AP2015008905A AP2015008905A0 (en) 2013-12-20 2014-06-04 Novel compounds for the treatment of cancer
IL242546A IL242546A0 (en) 2013-06-10 2015-11-11 Novel compounds for the treatment of cancer
PH12015502747A PH12015502747A1 (en) 2013-06-10 2015-12-09 Novel compounds for the treatment of cancer
CR20150653A CR20150653A (en) 2013-06-10 2015-12-10 NEW COMPOUNDS FOR CANCER TREATMENT
CUP2015000175A CU20150175A7 (en) 2013-06-10 2015-12-10 INHIBITING COMPOUNDS OF MPS-1 QUINASA, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL COMBINATIONS CONTAINING THEM
HK16107837.4A HK1219737A1 (en) 2013-06-10 2016-07-06 Novel compounds for the treatment of cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13171171 2013-06-10
EP13171171.5 2013-06-10
EP13198899.0 2013-12-20
EP13198899 2013-12-20

Publications (1)

Publication Number Publication Date
WO2014198594A1 true WO2014198594A1 (en) 2014-12-18

Family

ID=50897594

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/061530 WO2014198594A1 (en) 2013-06-10 2014-06-04 Novel compounds for the treatment of cancer

Country Status (25)

Country Link
US (1) US20160207928A1 (en)
EP (1) EP3008061A1 (en)
JP (1) JP2016521737A (en)
KR (1) KR20160019426A (en)
CN (1) CN105246891A (en)
AU (1) AU2014280395A1 (en)
BR (1) BR112015030774A2 (en)
CA (1) CA2914668A1 (en)
CL (1) CL2015003584A1 (en)
CR (1) CR20150653A (en)
CU (1) CU20150175A7 (en)
DO (1) DOP2015000298A (en)
EA (1) EA201501175A1 (en)
HK (1) HK1219737A1 (en)
IL (1) IL242546A0 (en)
MX (1) MX2015017011A (en)
NI (1) NI201500175A (en)
PE (1) PE20160747A1 (en)
PH (1) PH12015502747A1 (en)
SG (1) SG11201509351UA (en)
SV (1) SV2015005126A (en)
TN (1) TN2015000542A1 (en)
TW (1) TW201529560A (en)
UY (1) UY35602A (en)
WO (1) WO2014198594A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10913738B2 (en) 2017-02-13 2021-02-09 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
US11440913B2 (en) 2017-10-30 2022-09-13 Bristol-Myers Squibb Company Aminoimidazopyridazines as kinase inhibitors
US11767322B2 (en) 2020-10-19 2023-09-26 Bristol-Myers Squibb Company Triazolopyridinyl compounds as kinase inhibitors
US11976052B2 (en) 2019-01-11 2024-05-07 Naegis Pharmaceuticals Inc. Leukotriene synthesis inhibitors

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA38654B1 (en) * 2013-06-11 2018-11-30 Bayer Pharma AG Derivatives of the prodrug type of substituted triazolopyridines
CN109045036B (en) * 2018-07-19 2020-10-02 中山大学 Application of [1,2,4] triazolo [4,3-B ] pyridazine derivative in preparation of antitumor drugs
CN111393405B (en) * 2019-01-02 2022-11-25 中国科学院上海药物研究所 Fluorine-containing substituted benzothiophene compounds, and pharmaceutical composition and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010007100A1 (en) * 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
EP2277881A1 (en) * 2008-04-18 2011-01-26 Shionogi&Co., Ltd. Heterocyclic compound having inhibitory activity on p13k
WO2011161159A1 (en) * 2010-06-22 2011-12-29 Fovea Pharmaceuticals Heterocyclic compounds, their preparation and their therapeutic application
WO2012080230A1 (en) * 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012136531A1 (en) * 2011-04-06 2012-10-11 Bayer Pharma Aktiengesellschaft Substituted imidazopyridines and intermediates thereof
WO2012143329A1 (en) * 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Triazolopyridines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009133127A1 (en) * 2008-04-30 2009-11-05 Merck Serono S.A. Fused bicyclic compounds and use thereof as pi3k inhibitors
WO2010011964A2 (en) * 2008-07-24 2010-01-28 Siemens Medical Solutions Usa, Inc. Imaging agents useful for identifying ad pathology
TWI453207B (en) * 2008-09-08 2014-09-21 Signal Pharm Llc Aminotriazolopyridines, compositions thereof, and methods of treatment therewith
WO2011110575A1 (en) * 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
WO2012160029A1 (en) * 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
CA2866450C (en) * 2012-03-07 2020-02-18 Merck Patent Gmbh Triazolopyrazine derivatives

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2277881A1 (en) * 2008-04-18 2011-01-26 Shionogi&Co., Ltd. Heterocyclic compound having inhibitory activity on p13k
WO2010007100A1 (en) * 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
WO2011161159A1 (en) * 2010-06-22 2011-12-29 Fovea Pharmaceuticals Heterocyclic compounds, their preparation and their therapeutic application
WO2012080230A1 (en) * 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012136531A1 (en) * 2011-04-06 2012-10-11 Bayer Pharma Aktiengesellschaft Substituted imidazopyridines and intermediates thereof
WO2012143329A1 (en) * 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Triazolopyridines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROBERT URICH ET AL: "De Novo Design of Protein Kinase Inhibitors by in Silico Identification of Hinge Region-Binding Fragments", ACS CHEMICAL BIOLOGY, vol. 8, no. 5, 17 May 2013 (2013-05-17), pages 1044 - 1052, XP055144440, ISSN: 1554-8929, DOI: 10.1021/cb300729y *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10913738B2 (en) 2017-02-13 2021-02-09 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
US11440913B2 (en) 2017-10-30 2022-09-13 Bristol-Myers Squibb Company Aminoimidazopyridazines as kinase inhibitors
US11976052B2 (en) 2019-01-11 2024-05-07 Naegis Pharmaceuticals Inc. Leukotriene synthesis inhibitors
US11767322B2 (en) 2020-10-19 2023-09-26 Bristol-Myers Squibb Company Triazolopyridinyl compounds as kinase inhibitors
US12110290B2 (en) 2020-10-19 2024-10-08 Bristol-Myers Squibb Company Triazolopyridinyl compounds as kinase inhibitors

Also Published As

Publication number Publication date
KR20160019426A (en) 2016-02-19
UY35602A (en) 2015-01-30
JP2016521737A (en) 2016-07-25
MX2015017011A (en) 2016-04-25
TN2015000542A1 (en) 2017-04-06
CL2015003584A1 (en) 2016-06-24
EA201501175A1 (en) 2016-10-31
CN105246891A (en) 2016-01-13
TW201529560A (en) 2015-08-01
PH12015502747A1 (en) 2016-03-14
HK1219737A1 (en) 2017-04-13
CU20150175A7 (en) 2016-05-30
NI201500175A (en) 2016-01-06
IL242546A0 (en) 2016-02-01
DOP2015000298A (en) 2016-03-15
CR20150653A (en) 2016-03-04
BR112015030774A2 (en) 2017-07-25
AU2014280395A1 (en) 2015-12-17
EP3008061A1 (en) 2016-04-20
US20160207928A1 (en) 2016-07-21
CA2914668A1 (en) 2014-12-18
SV2015005126A (en) 2017-01-30
PE20160747A1 (en) 2016-08-25
SG11201509351UA (en) 2015-12-30

Similar Documents

Publication Publication Date Title
EP2897957B1 (en) Substituted pyrrolopyrimidinylamino-benzothiazolones as mknk kinase inhibitors
AU2012350751B2 (en) Substituted triazolopyridines and their use as TTK inhibitors
EP2834245B1 (en) Amino-substituted imidazopyridazines
EP2858993B1 (en) Amino-substituted imidazopyridazines
EP2714692B1 (en) Substituted aminoimidazopyridazines
EP3008061A1 (en) Novel compounds for the treatment of cancer
WO2015078799A1 (en) Glucose transport inhibitors
EP3172204A1 (en) Amino-substituted isoxazoles
US20170107229A1 (en) Substituted tetrahydropyridothienopyrimidines
TW201326170A (en) Substituted triazolopyridines
EP2977376A1 (en) Amino-substituted isoxazoles
EP2977377A1 (en) Amino-substituted isoxazoles
NZ625815B2 (en) Substituted triazolopyridines and their use as ttk inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14728921

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2014728921

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 242546

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2914668

Country of ref document: CA

Ref document number: 20157034736

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14896450

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2016518921

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 38655

Country of ref document: MA

Ref document number: 12015502747

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 15293288

Country of ref document: CO

Ref document number: 002596-2015

Country of ref document: PE

Ref document number: CR2015-000653

Country of ref document: CR

Ref document number: MX/A/2015/017011

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2014280395

Country of ref document: AU

Date of ref document: 20140604

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015030774

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 201501175

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: A201600084

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: IDP00201600054

Country of ref document: ID

ENP Entry into the national phase

Ref document number: 112015030774

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20151209